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 The process of transcription, which is a vital step in the cellular response to 
physiological and environmental stimuli, is highly regulated at multiple levels.  Many 
proteins are involved in orchestrating transcriptional responses, including proteins that 
modulate the physiological template for transcription, chromatin.  One such protein is 
the highly abundant nuclear enzyme Poly(ADP-ribose) Polymerase-1 , or PARP-1.  
Although PARP-1 has classically been studied with relation to its role in the detection 
and repair of DNA damage, recent work has uncovered physiological functions of 
PARP-1 in regulating transcription.  PARP-1 has been shown to have a range of 
functions in transcriptional regulating, including acting as a co-activator and as a 
modulator of chromatin structure.  Although there are increasing numbers of studies 
revealing roles for PARP-1 in many processes, the molecular mechanisms of PARP-1 
action in most pathways is largely unknown.  In this study, I have investigated 
transcriptional regulation by PARP-1 in vivo, using both genomic and gene-specific 
analyses in breast cancer cells and human cardiomyocytes.   
 Using chromatin immunoprecipitation coupled with DNA microarrays (ChIP-
chip), I show that PARP-1 binds to active promoters in MCF-7 breast cancer cells, and 
that at genes that are positively-regulated by PARP-1, it acts to exclude the binding of 
linker histone H1.  Further analysis revealed that exclusion of H1 from promoters 
allows for a favorable chromatin structure which in turn permits the binding of RNA 
Polymerase II at target genes.  This open chromatin conformation also requires 
methylated histones, which PARP-1 maintains by PARylating and preventing 
recruitment of the demethylase KDM5B, a pathway which is also utilized by signal-
dependent transcription.   
 Besides breast cancer, PARP-1 plays a prominent role in other pathologies, one 
of which is the progression of cardiovascular disease (CVD).  I use a human 
cardiomyocyte cell line to show that TNFα can drastically increase the binding of the 
transcription factor NFB to chromatin, and that this causes changes in the gene 
expression profile of these cells.  PARP-1 is known to cooperate with NFB at target 
genes.  I show that in human cardiomyocytes, PARP-1 is required for NFB up-
regulated genes, but not for down-regulated genes, confirming its role as an activator 
of NFB-dependent transcription.  Interestingly, I see that the majority of NFB 
binding in the presence of TNFα is not to canonical NFB binding sites, suggesting 
the the majority of the NFB response is intricately dependent on other transcription 
factors, and I show that one of these factors, ATF2, is vital for recruiting NFB to 
promoters and regulating transcription.  It will be interesting to further investigate how 
PARP-1 and ATF2 may be collaborating at target genes.  Together, these data 
demonstrate a conserved binding pattern of PARP-1 on chromatin across cell types, 
and establish novel connections between PARP-1, signaling pathways, chromatin and 
gene expression.   
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CHAPTER 1 
 
 
 
 
PARP-1: Molecular Actions,  
Physiological Outcomes, and Clinical Targets* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* This chapter was written by R. Krishnakumar and W. L. Kraus, and will be 
published as a review article in Molecular Cell 
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1.1 Summary 
 
The abundant nuclear enzyme PARP-1, a multifunctional regulator of 
chromatin structure, transcription, and genomic integrity, plays key roles in a wide 
variety of molecular processes in the nucleus.  Recent studies have begun to connect 
the molecular functions of PARP-1 to specific physiological and pathological 
outcomes, many of which can be altered by an expanding array of chemical inhibitors 
of PARP enzymatic activity.   
 
1.2 Introduction 
 
Nuclear processes involving access to or modification of the genome, such as 
transcription and DNA repair, require a host of structural and regulatory proteins.  
Poly(ADP-ribose) polymerase-1 (PARP-1), a ubiquitous and abundant nuclear protein 
and the founding member of the PARP family, has a number of distinct biochemical 
activities that make it well suited for both structural and regulatory roles across the 
genome (Hassa and Hottiger, 2008; Kim et al., 2005; Schreiber et al., 2006).  As 
discussed below, PARP-1 can bind to various DNA structures and nucleosomes, and it 
possesses an NAD+-dependent catalytic activity that synthesizes a negatively charged 
polymer on target proteins called poly(ADP-ribose) or PAR.  Although historically 
studied in the context of DNA damage detection and repair, PARP-1 has more 
recently been linked to the regulation of chromatin structure and transcription, DNA 
methylation and imprinting, insulator activity, and chromosome organization.  In this 
review, I provide an overview of PARP-1's structure and activities, as well as an in 
depth review of papers published in the past few years that have provided new insights 
into the molecular functions of PARP-1 in the nucleus.  In addition, I highlight 
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emerging information about the roles of PARP-1 in physiological and pathological 
outcomes, its interplay with nuclear NAD+ metabolic enzymes, and the chemical 
biology of PAR. 
 
1.3 PARP-1 and the PARP family 
 
Poly(ADP-ribosyl)ation reactions and PARP-like genes have been identified in 
a wide variety of single and multicellular eukaryotes, from fungi to mammals (but 
surprisingly not the yeasts S. cerevisae and S. pombe), as well as eubacteria, 
archaebacteria, and double stranded DNA viruses (Hassa et al., 2006; Otto et al., 
2005).  In mammalian cells, the bulk of the PAR production is catalyzed by PARP-1, 
although recent studies have begun to characterize the structure and function of related 
PARP proteins. 
 
1.3.1 PARP-1 structure and biochemical activities 
PARP-1 is a highly conserved protein of ~116 kDal (D'Amours et al., 1999).  Like 
many other chromatin- and transcription- related proteins, it has a modular structure 
comprising multiple independently folded domains.  The major functional units of 
PARP-1 are an amino terminal DNA binding domain (DBD), a central 
automodification domain (AMD), and a carboxyl-terminal catalytic domain (CD) 
(Hakme et al., 2008; Schreiber et al., 2006) (Fig. 1.1A, top).  The DBD contains two 
Cys-Cys-His-Cys zinc fingers (FI/Zn1 and FII/Zn2) that mediate binding to DNA, a 
newly discovered third zinc binding domain (Zn3) that mediates inter-domain contacts 
important for DNA-dependent enzyme activation (Langelier et al., 2008), a nuclear 
localization signal (NLS), and a caspase-3 (C3) cleavage site (Hakme et al., 2008; 
Schreiber et al., 2006).  The AMD contains a BRCT (BRCA1 C-terminus) fold, which 
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mediates protein-protein interactions (e.g., with DNA repair enzymes).  The CD, 
which is the most conserved domain across the PARP superfamily, contains a PARP 
signature motif, which binds NAD+, as well as a "WGR" motif, which is named after 
the most conserved amino acid sequence in the motif (Trp, Gly, Arg) and has an 
unknown function.  The structures of all of these domains and motifs from have now 
been determined, providing new insights about the structure and function of PARP-1 
(Fig. 1.1B).  Together, the structural and functional domains of PARP-1 confer the 
activities required for the broad range of functions of PARP-1 in the nucleus. 1.3.2  
 
Other PARP family members 
 Although much of the focus has been on PARP-1, studies over the past 
decade have identified a family of as many as 17 proteins that share homology to the 
catalytic domain of PARP-1 (Ame et al., 2004; Hakme et al., 2008; Hassa and 
Hottiger, 2008; Schreiber et al., 2006).  Recently, a new unified nomenclature 
referring to this family of proteins as (ADP-ribosyl) transferases (ARTs) has been 
proposed to recognize that fact that: (1) PARPs catalyze a transferase reaction, not a 
template-dependent polymerization reaction and (2) not all family members have 
PARP activity; some are likely to function as mono(ADP-ribosyl) transferases 
(mARTs) (Hottiger et al., 2010).  In addition to the PARP-like domain, the PARP 
family members are “functionalized” with a wide variety of other structural and 
functional domains (e.g., DNA-binding domains, RNA-binding domains, subcellular 
localization signals, macrodomains, BRCT motifs, ankyrin repeats, zinc fingers) that 
dictate their overall biological activities.  A recent structural analysis has classified 
members of the PARP family into three groups based on their catalytic domains: (1) 
PARPs 1-5, which are bona fide PARPs containing a conserved glutamate (Glu 988 in 
PARP-1) that defines the PARP catalytic activity, (2) PARPs 6-8, 10-12, and 14-16,  
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Figure 1.1.  Structural and functional organization of PARP-1 and PARP-2.   
(A) Schematic representation of human PARP-1 and PARP-2 with the functional 
domains noted in the text. 
(B) Structures of the six structural and functional domains in human PARP-1.  FI 
(PDB 2DMJ), FII (PDB 2CS2), ZnIII (PDB 2RIQ), BRCT (PDB 2COK), WGR 
(PDB: 2CR9), catalytic domain (PDB 1UK1; structure shown in complex with a 
quinazoline inhibitor).   
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which are confirmed or putative mARTs, and (3) PARPs 9 and 13, which lack key 
NAD+-binding residues and the catalytic glutamate, and are likely inactive (Kleine et 
al., 2008) (Fig. 1.2).   
PARP family members localize to various cellular compartments, including the 
nucleus, cytoplasm, mitochondria, and vault particles, although the subcellular 
localization and function of many of the PARPs are unknown (Ame et al., 2004; Hassa 
and Hottiger, 2008).  The primary nuclear PARPs are PARP-1, PARP-2 (the closest 
paralog to PARP-1), PARP-3, and tankyrase 1 and 2 (PARP-5a and -5b) (Ame et al., 
2004; Hakme et al., 2008; Hassa and Hottiger, 2008; Schreiber et al., 2006).  Also 
found in the nucleus, although not exclusively, are v-PARP (PARP-4), PARP-6, 
PARP-8, PARP-9, the Bal proteins Bal 1-3 (PARP-13, -14, -15), and PARP-10.  The 
known functions of the PARP family members span a wide range of cellular 
processes, including DNA repair, transcription, cellular signaling, cell cycle 
regulation, and mitosis (Ame et al., 2004; Hakme et al., 2008; Hassa and Hottiger, 
2008; Schreiber et al., 2006).  This diverse array of processes plays key roles in a wide 
variety of biological outcomes, including differentiation, development, stress 
responses, inflammation, and cancer.  Although the focus of this review is on PARP-1, 
I draw parallels to other PARP family members when applicable. 
 
1.4 Molecular Biology and Biochemistry of PARP-1 
 
1.4.1 DNA binding, chromatin binding, and genomic localization 
 Studies over the past few decades have shown that PARP-1 associates 
with chromatin in specific patterns that relate to its function (Kraus, 2008; Kraus and 
Lis, 2003; Tulin et al., 2003).  This association is driven by interactions with DNA, 
nucleosomes, or other chromatin-associated proteins, which are not mutually 
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Figure 1.2.  The PARP catalytic domain is highly conserved across the PARP 
family. 
(A) Alignment of the catalytic domain structures from mammalian PARP-1 (PDB 
1UK1), PARP-2, and PARP-3.  
(A) Alignment of the catalytic domain structures from mammalian PARPs 1, 2, 3, 5a, 
5b, 10, 12, 14, 15 (PDB 1A26, 1GSO, 3FHB, 2RF5, 3KR7, 3HKV, 2PQF, 3GOY, 
3GEY, respectively). 
In (A) and (B), NAD+ has been modeled in based on a structure of diptheria toxin 
(PDB 1TOX).   
[Figure courtesy of Bryan Gibson] 
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exclusive.  PARP-1 binds to a variety of DNA structures, including single- and 
double-strand breaks, crossovers, cruciforms, and supercoils, as well as some specific 
double-stranded DNA sequences (Kraus, 2008; Kraus and Lis, 2003).  PARP-1 also 
binds to nucleosomes in a specific manner, interacting with both DNA and histones at 
or near the dyad axis where the DNA enters and exits the nucleosome (Kim et al., 
2004).  Finally, PARP-1 can interact with a wide variety of chromatin-associated 
proteins, including components of the transcription machinery, sequence-specific 
DNA-binding transcription factors, chromatin modifying enzymes, and histone 
variants (e.g., macroH2A; see below) (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 
2003; Tulin et al., 2003).  Interactions with these proteins allows for indirect 
association of PARP-1 with chromatin.  By binding to chromatin, PARP-1 can alter 
the structure of nucleosomes or the composition of chromatin (Kim et al., 2004; 
Kraus, 2008; Kraus and Lis, 2003; Tulin et al., 2003; Wacker et al., 2007).  This may 
occur through target protein modification by PARP-1’s enzymatic activity, as well as 
competition for binding sites on nucleosomes.  For example, PARP-1 may displace the 
linker histone H1 from nucleosomes by PARylating it or for competing for 
overlapping binding sites on the nucleosomes (Ju et al., 2006; Kim et al., 2004; 
Krishnakumar et al., 2008). 
 Recent genomic localization studies have provided new insights about PARP-1 
function, showing that PARP-1 binds at the promoters of most actively transcribed 
genes (Krishnakumar et al., 2008).  The binding of PARP-1 at promoters correlates 
with the binding of Pol II, gene expression, and the presence of histone H3 lysine 4 
trimethylation (H3K4me3), a histone modification that marks active promoters (Fig. 
1.3).  PARP-1 also binds to chromatin outside of promoter regions, including 
enhancers (Krishnakumar et al., 2008).  In response to genotoxic stress, PARP-1 
relocalizes to sites of DNA damage (i.e., nicks, breaks) (El-Khamisy et al., 2003; 
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Huber et al., 2004; Malanga and Althaus, 2005; Petermann et al., 2005; Pleschke et al., 
2000).  Whether this DNA damage-induced relocalization results in a global 
redistribution of PARP-1 away from promoters, as was shown recently for the NAD+-
dependent chromatin regulator SIRT1 (Oberdoerffer et al., 2008), remains to be 
determined.  This is an attractive model that fits well with the global reduction in 
transcription observed in response to DNA damage. 
 
1.4.2 Catalytic activity, binding partners, and targets  
PAR is a large, negatively charged polymer that functions as a post-translational 
modification, as well as a free polymer.   Most of the PAR in the cell is produced by 
the catalytic activity of PARP-1, which catalyzes the polymerization of ADP-ribose 
units from donor NAD+ molecules on target proteins (D'Amours et al., 1999) (Fig. 
1.4).  The ADP-ribose units are linked to each other via glycosidic ribose-ribose 1’ → 
2’ bonds, and the resulting PAR polymers may be linear or branched (D'Amours et al., 
1999).  The modification most likely occurs on glutamate, aspartate, or lysine 
residues, although historically the evidence for covalent modification of specific 
residues has been weak (D'Amours et al., 1999; Hassa and Hottiger, 2008).  In fact, 
some have even argued for strong non-covalent binding of free PAR polymers, rather 
than covalent modification (Hassa and Hottiger, 2008).  Recent studies, however, have 
begun to make progress on defining specific sites of PAR attachment on target 
proteins (Altmeyer et al., 2009; Haenni et al., 2008; Kanai et al., 2007) (see below).  
PARP-1 catalytic activity is regulated through allosteric mechanisms involving 
a range of binding partners, including damaged DNA, histones, nucleosomes, and an 
assortment of nuclear proteins (D'Amours et al., 1999; Kraus and Lis, 2003; Tulin et 
al., 2003).  PARP-1 catalytic activity is also regulated by post-translational 
modifications; autoPARylation of PARP-1 inhibits its catalytic activity, while 
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Figure 1.3.  The chromatin landscape at the promoters of highly expressed genes.   
Schematic of average genomic ChIP and nucleosome mapping data across the 
promoters of the most highly expressed genes (top quartile) in cells.  The graphs are 
based on data from the literature: PARP- 1 and H1 (Krishnakumar et al., 2008), 
H3K4me3 (Barski et al., 2007), H3K9ac (Wang et al., 2008b), and nucleosome 
positioning (Schones et al., 2008).   
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phosphorylation by Erk1/2 enhances its catalytic activity (Kauppinen et al., 
2006).  PARP-1 catalytic activity may also be regulated by nicotinamide 
mononucleotide adenylyltransferase-1 (NMNAT-1), a nuclear NAD+ synthase that 
interacts with PARP-1 and can produce NAD+ locally for use by nuclear enzymes that 
require NAD+, such as PARP-1 and SIRT1 (Kim et al., 2004; Zhang et al., 2009; 
Zhang and Kraus, 2009).  Regulated catalysis, such as that exhibited by PARP-1, may 
be a more common mode of action for chromatin-modifying enzymes than has 
generally been considered, and there are likely to be some general principles that can 
be learned from the study of PARP-1’s catalytic activity. PARP-1, which has many 
protein binding partners in the nucleus, has been identified as a component of a wide 
variety of protein complexes, including those that (1) repair DNA damage (e.g., 
condensin I/XRCC1), (2) regulate transcription (e.g., Mediator; TLE corepressor), (3) 
function as insulators (e.g., CTCF), and (4) methylate DNA (e.g., DNMT-1) (Fig. 1.5) 
(Caiafa et al., 2009; Caiafa and Zlatanova, 2009; El-Khamisy et al., 2003; Guastafierro 
et al., 2008; Hassa et al., 2005; Heale et al., 2006; Ju et al., 2004; Malanga and 
Althaus, 2005; Pavri et al., 2005; Pleschke et al., 2000; Zampieri et al., 2009).  Many 
of these binding partners have been reported to be PARylated as targets of PARP-1 
catalytic activity (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 2003).  Covalent 
attachment of PAR is thought to alter the activity of target proteins through both steric 
and charge effects, ultimately preventing protein-protein interactions, protein-nucleic 
acid interactions, enzymatic activity, or subcellular localization (Hassa and Hottiger, 
2008; Schreiber et al., 2006). 
Known or suspected targets of PARP-1 catalytic activity include histones, 
transcription factors, nuclear enzymes, and nuclear structural proteins.  For example, 
PARP-1 can PARylate histones, especially H1, H2A and H2B, which may play a role 
in the regulation of chromatin structure, although the extent of histone 
14 
 
 
 
 
 
 
 
 
 
 
Figure 1.4.  Biosynthesis of NAD+ and PAR.   
Chemical structures of NAD+, PAR, and metabolites.  The enzymes that catalyze the 
synthesis of NAD+ in the mammalian salvage pathway are shown.  The enzymatic 
actions of PARP, PARG, (ADP-ribosyl) protein hydrolase, and (ADP-ribosyl) protein 
lyase are also indicated. 
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modification and its relevance to nuclear processes remains to be clarified  (D'Amours 
et al., 1999; Kim et al., 2005; Kraus, 2008; Kraus and Lis, 2003).  PARP-1 also 
PARylates a number of DNA repair proteins, including p53 (Kanai et al., 2007; 
Mendoza-Alvarez and Alvarez-Gonzalez, 2001), which is not surprising given PARP-
1’s well characterized role in DNA repair.  Although the functional significance of 
p53 PARylation has been elusive, a recent study suggests that PARylation of p53 on 
specific sites (likely Glu 255, Asp 256 and Glu 268) can prevent p53 export from the 
nucleus by blocking its interaction with the nuclear export receptor Crm1 (Kanai et al., 
2007).  PARP-1 has also been reported to PARylate and alter the function of numerous 
other transcription factors, including CTCF, AP-1, YY1 and NF-κB (Kraus, 2008), as 
well as nuclear enzymes, such as Aurora B kinase (Monaco et al., 2005), thereby 
inhibiting their function.  Finally, PARP-1-dependent PARylation of target proteins is 
required for the normal function of centromeres, centrosomes, and the mitotic spindle 
(Kim et al., 2005).  As these examples suggest, the PARylation of target proteins by 
PARP-1 plays a central role in determining the cellular functions of PARP-1. 
 
1.4.3 Post-translational modifications of PARP-1 
 Like other nuclear proteins that play key roles in regulatory processes, 
PARP-1 is subject to a variety of covalent post-translational modifications as 
endpoints of cellular signaling pathways.  These include PARylation, acetylation, 
phosphorylation, ubiquitylation, and SUMOylation (Fig. 1.6); the latter two were 
more recently discovered and are less well characterized (Cohen-Armon et al., 2007; 
Hassa et al., 2005; Kauppinen et al., 2006; Martin et al., 2009; Messner et al., 2009; 
Wang et al., 2008a)  
• PARylation.  PARP-1 is PARylated by itself, PARP-2, and possibly other 
PARPs.  Automodification of PARP-1 (i.e., autoPARylation) may occur as an 
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Figure 1.5.  Interactions and functions of PARP-1 in the nucleus. 
 PARP-1 interacts with and PARylates proteins involved in DNA repair, 
Transcription, DNA methylation, and the regulation of chromatin structure and histone 
modification to control physiological and pathological outcomes. 
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extensive addition of ADP-ribose in chains >200 units in length or as a more modest 
addition of a single unit or chains up to 20 units in length (i.e., mono- or 
oligoPARylation, respectively) (D'Amours et al., 1999; Mendoza-Alvarez and 
Alvarez-Gonzalez, 1999).  Whether this occurs primarily in cis or in trans (i.e., intra- 
or inter-molecularly, respectively) has been debated in the literature, but is typically 
considered intermolecular (Altmeyer et al., 2009; Alvarez-Gonzalez and Mendoza-
Alvarez, 1995; Mendoza-Alvarez and Alvarez-Gonzalez, 1993, 1999).  Extensive 
autoPARylation of PARP-1 (e.g., in response to DNA damage) inhibits its DNA 
binding and catalytic activities (D'Amours et al., 1999).  Biochemical and cell-based 
assays have shown that activation and autoPARylation of PARP-1 results in its release 
from chromatin (Kim et al., 2004; Petesch and Lis, 2008; Tulin and Spradling, 2003; 
Wacker et al., 2007).  The effect of less extensive autoPARylation of PARP-1 is not 
clear; modestly modified PARP-1 may have altered activities, but retain its association 
with chromatin.   
Initial reports suggested that PARylation of PARP-1 occurred on as many as 
28 glutamate residues, primarily in the AMD and DBD (D'Amours et al., 1999; 
Schreiber et al., 2006).  In contrast, a recent study has shown that the glutamate 
residues in the AMD are not required for PARylation of PARP-1 (Altmeyer et al., 
2009).  Rather, based on amino acid substitutions (i.e., Lys to Arg), the authors 
conclude that at least three lysines residues in the AMD (Lys 498, 521, and 524) are 
sites of automodification on PARP-1 (Altmeyer et al., 2009).  A similar approach was 
used to identify lysines 36 and 37 of PARP-2 as sites of auto-mono(ADP-ribosyl)ation 
(Haenni et al., 2008).  Although these results could significantly change the 
expectations of the field both in terms of PARP-1 autoregulation, as well as sites of 
modification on other PARP target proteins, they should be interpreted with caution.  
Mutation of specific residues in PARP-1 or PARP-2 could reduce automodification 
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Figure 1.6.  Covalent post-translational modifications of PARP-1.   
Schematic representation of PARP-1 modifications: PARylation, phosphorylation, 
acetylation, SUMOylation, ubiquitylation, as described in the text. 
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without necessarily being sites for covalent attachment of PAR.  Furthermore, 
PARylation seems to be promiscuous; deletion or mutation of one site may allow for 
modification of another site.  The identification of adducts on targets residues by mass 
spectrometry will be required to conclusively address this issue.   
 • Phosphorylation and acetylation.  PARP-1 is phosphorylated by ERK1/2 at 
Ser 372 and Thr 373, and JNK1 at undetermined sites (Kauppinen et al., 2006; Zhang 
et al., 2007).  The former is required for maximal PARP-1 activation after DNA 
damage (Kauppinen et al., 2006), whereas the latter promotes sustained PARP-1 
activation during H2O2-induced non-apoptotic cell death (Zhang et al., 2007).  PARP-
1 is acetylated by the acetyltransferases p300/CBP and PCAF (Hassa et al., 2003; 
Hassa et al., 2005; Rajamohan et al., 2009).  The acetylation of PARP-1 is reversed by 
a number of deacetylases, including Sirt1 (Hassa et al., 2005; Rajamohan et al., 2009).  
Acetylation of PARP-1 was first identified in the context of NF-κB-dependent 
transcription, where it plays a critical role in regulating NF-κB target genes in immune 
cells (Hassa et al., 2003; Hassa et al., 2005).  In cardiomyocytes, PARP1 is acetylated 
as an endpoint of stress responses, resulting in the DNA damage-independent 
activation of PARP-1 (Rajamohan et al., 2009).  PARP-2 is also acetylated at Lys 36 
and 37 in the NLS, which are the same sites that are mono(ADP-ribosyl)ated.  
Acetylation of PARP-2 reduces its DNA binding and enzymatic activities, and 
presumably the extent of mono(ADP-ribosyl)ation (Haenni et al., 2008).   
• SUMOylation and ubiquitylation.  Recent studies have shown that PARP-1 
is SUMOylated and ubiquitylated, modulating its role as a regulator of chromatin 
structure and transcription (Martin et al., 2009; Messner et al., 2009).  PARP-1 
interacts with and is SUMOylated by PIASy, a SUMO E3 ligase (Martin et al., 2009; 
Stilmann et al., 2009).  In Drosophila, dPARP (a homolog of mammalian PARP-1) is 
SUMOylated in response to heat shock, which is required for the full activation of the 
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Hsp70 gene (Martin et al., 2009).  PIASy is recruited and released at the Hsp70 locus 
during the heat shock response with kinetics that mirror those of both PARP-1 and the 
SUMO-conjugating enzyme Ubc9 (Martin et al., 2009).  Interestingly, the SUMO-
targeted ubiquitin ligase RNF4 polyubiquitylates dPARP and presumably causes its 
clearance from the Hsp70 promoter via degradation (Martin et al., 2009).  These 
results fit well with the fact that dPARP regulates the chromatin structure at the 
Drosophila Hsp70 locus upon heat shock (Petesch and Lis, 2008; Tulin and Spradling, 
2003).  In mammalian cells, SUMOylation and p300/CBP-dependent acetylation at 
Lys 486 of PARP-1 are mutually exclusive (Messner et al., 2009).  Since acetylation 
of PARP-1 is required for activated transcription at some target promoters (Hassa et 
al., 2003; Hassa et al., 2005), SUMOylation of PARP-1 might modulate the 
transcriptional outcome in this PARP-1-dependent pathway.  Similar to what is 
observed in Drosophila, polyubiquitylation of PARP-1, likely in the DBD, promotes 
the degradation of PARP-1, thereby regulating its overall activity (Wang et al., 
2008a).   
 
1.5 Nuclear Actions of PARP-1 
 
PARP-1 contributes in many unique ways to the molecular biology of nuclear 
processes, playing key roles in the maintenance of genomic integrity, the regulation of 
chromatin structure and transcription, and the establishment of DNA methylation 
patterns, as well as a host of other processes (e.g., mitotic apparatus function, cell 
death pathways) (Fig. 1.5) (Hassa and Hottiger, 2008; Kim et al., 2005).  Below, I 
highlight the newest results related to some of the key aspects of PARP-1 function.  
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1.5.1 DNA damage detection and repair 
The earliest functions ascribed to PARP-1 were related to DNA damage 
detection and repair, and much of the PARP-1 literature has been devoted to this 
aspect of PARP-1 biology (D'Amours et al., 1999).  PARP-1 has been implicated in at 
least three distinct DNA repair pathways: base excision repair (BER), single-strand 
break (SSB) repair, and double-strand break (DSB) repair (Bouchard et al., 2003; 
Woodhouse and Dianov, 2008).  PARP-2 has also been implicated in DNA repair 
pathways, including BER (Schreiber et al., 2002; Yelamos et al., 2008).  Although 
neither PARP-1 nor PARP-2 is individually required for viability in mice, Parp-1-/- or 
Parp-2-/- mice or embryonic fibroblasts exhibit a variety of DNA repair defects and 
chromosomal abnormalities (de Murcia et al., 1997; Menissier de Murcia et al., 2003; 
Wang et al., 1997).  Parp-1-/-/Parp-2-/- mice show embryonic lethality with 
considerable genomic instability (Menissier de Murcia et al., 2003), indicating both 
overlapping and non-redundant functions of PARP-1 or PARP-2 in the maintenance of 
genomic integrity. 
As with other cellular stresses, DNA damage (e.g., SSBs, DSBs, oxidation, 
alkylation) elicits an immediate and dramatic PARP-1-dependent PARylation 
response targeting a variety of nuclear proteins.  This response may be transient or 
sustained depending on the extent of damage and the pathway activated (Bouchard et 
al., 2003; D'Amours et al., 1999; Woodhouse and Dianov, 2008).  The link between 
DNA damage and enhancement of PARP-1 enzymatic activity makes PARP-1 an 
excellent DNA damage sensor.  In response to low levels of DNA damage, PARP-1 
promotes cell survival and DNA repair.  With severe DNA damage, PARP-1 promotes 
cell death through at least two distinct pathways: (1) energy failure-induced necrosis, 
which results from depletion of NAD+ (and ultimately ATP) and (2) apoptosis-
inducing factor-dependent apoptosis (Bouchard et al., 2003; Kim et al., 2005).  Thus, 
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PARP-1 has a vital role in determining cellular outcomes in response to DNA damage. 
 As might be expected, PARP-1 interacts physically and functionally with other 
key DNA damage detection and response proteins, including the ATM kinase and p53 
(Bouchard et al., 2003).  For example, PARP-1 deficient cells exhibit impaired ATM-
kinase activity and reduced formation H2AXγ foci (Aguilar-Quesada et al., 2007; 
Menisser-de Murcia et al., 2001).  PARP-1-dependent PARylation of the Spt6 
component of the histone chaperone FACT inhibits the exchange of variant H2AX 
with conventional H2A in the context of the nucleosome (Heo et al., 2008).  PARP-1 
also interacts with proteins involved in the DNA repair pathways noted above and may 
play a role in recruiting these proteins to sites of DNA damage (Woodhouse and 
Dianov, 2008).  These include XRCC-1 in the BER pathway, which requires PARP-1 
for its recruitment to sites of DNA damage (El-Khamisy et al., 2003; Heale et al., 
2006; Masson and Caldwell, 1998; Okano et al., 2003).  Some BER proteins (e.g., 
XRCC1, DNA ligase III) may also bind PAR (Pleschke et al., 2000), although the 
functional consequences of this binding are not clear.  PARP-2 has also been shown to 
interact with XRCC1, as well as DNA polymerase β and DNA ligase III (Schreiber et 
al., 2002), which suggests contributions of PARP-2 to the BER process.  Although an 
initial set of PARP-1 and PARP-2 interactions with genome maintenance factors has 
been determined, this list is unlikely to be complete.  In addition, although these 
interactions are suggestive of possible mechanisms, the detailed mechanisms that 
might underlie the contributions of PARP-1 and PARP-2 to DNA damage detection 
and repair have not yet been revealed. 
 
1.5.2 Chromatin structure and transcription 
Although historically the focus has been on PARP-1’s role in DNA damage 
detection and repair, studies over the past decade have revealed important roles for 
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PARP-1 in transcriptional regulation (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 
2003; Tulin et al., 2003).  The ability of PARP-1 to modulate chromatin structure and 
function underlies its contributions to this process.  In fact, the ability to disrupt 
chromatin structure by PARylating histones (e.g., H1 and H2B) and destabilizing 
nucleosomes was one of the earliest functional effects of PARP-1 to be characterized 
(Huletsky et al., 1989; Mathis and Althaus, 1987; Poirier et al., 1982).  More recent 
biochemical studies have shown that, in the absence of NAD+ or significant 
autoPARylation, PARP-1 binds to nucleosomes and promotes the compaction of 
chromatin by bringing together neighboring nucleosomes (Kim et al., 2004; Wacker et 
al., 2007).  In the presence saturating levels of NAD+, which lead to considerable 
autoPARylation of PARP-1 in the presence of nucleosomes, the compaction is nearly 
completely reversed (Kim et al., 2004; Wacker et al., 2007).   
PARP-1 localizes to the promoters of almost all actively transcribed genes 
(Krishnakumar et al., 2008), which suggests that it plays a role in promoting the 
formation of chromatin structures that are permissive to transcription.  In this regard, 
PARP-1 has been shown to block the binding of the linker histone H1, a repressive 
chromatin architectural protein, to promoter chromatin (Ju et al., 2006; Kim et al., 
2004; Krishnakumar et al., 2008).  PARP-1 also PARylates DEK, another repressive 
chromatin-associated protein, and promotes its release from chromatin (Gamble and 
Fisher, 2007).  Yet, PARP-1 only regulates a subset of the genes to which it binds and 
it has both positive and negative effects of transcription (Frizzell et al., 2009; 
Krishnakumar et al., 2008).  Thus, gene regulation by PARP-1 is a complex process 
that is likely to involve multiple mechanisms and be modulated by additional inputs. 
PARP-1 regulates transcription in multiple ways, including (1) regulating 
chromatin structure and composition (as discussed in the preceding paragraph), (2) 
functioning as a classical coregulator with a wide variety of signal-regulated, 
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sequence-specific DNA binding transcriptional activators, (3) functioning as a direct 
enhancer-binding factor, and (4) regulating the actions of insulators and insulator-
binding factors, such as CTCF.  These aspects of PARP-1 function have been 
reviewed extensively elsewhere (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 2003; 
Tulin et al., 2003).  In the ‘coregulator’ mode, PARP-1 may be recruited to target 
promoters as a functional endpoint of signaling pathways to regulate components of 
the transcription complex assembled at the promoter.  In some cases, the enzymatic 
activity of PARP-1 is required (e.g., with HES1 and Elk1) (Cohen-Armon et al., 2007; 
Ju et al., 2004), while in others it is not (e.g., NF-κB and RAR) (Hassa and Hottiger, 
2002; Kraus and Lis, 2003; Pavri et al., 2005).  When acting as a coregulator during 
signal-regulated transcriptional responses, PARP-1 can function as a promoter-specific 
‘exchange factor’ that promotes the release of inhibitory factors and the recruitment of 
stimulatory.  In this regard, PARP-1 has been shown to promote the exchange of (1) a 
TLE1 corepressor complex for a HAT-containing coactivator complex during signal-
dependent gene regulation in neuronal cells (Ju et al., 2004) (2) an inactive cdk8-
positive Mediator for an active cdk8-negative Mediator during retinoic acid-regulated 
activation (Pavri et al., 2005).  PARP-1 has also been reported to promote the 
recruitment of topoisomerase IIβ (TopoIIβ) to hormone-regulated promoters, leading 
to promoter DNA cleavage, factor exchange, and transcriptional activation (Ju et al., 
2006).  The DNA cleavage has been proposed to resolve a topological barrier and 
allow for favorable structural changes at the promoter (Ju et al., 2006), but this model 
has yet to be proven.  
Drosophila has been a useful model organism for studying the role of PARP-1 
in the regulation of chromatin structure and transcription because flies only have two 
genes encoding PARPs: PARP-1 like (dPARP), which is expressed as three isoforms, 
and tankyrase-like (Hanai et al., 1998; Miwa et al., 1999).  In Drosophila larvae, 
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inhibition of PARP activity or disruption of dPARP gene expression blocks PAR 
accumulation, chromatin decondensation, and transcription at loci containing highly 
inducible genes, such as those regulated by heat shock or ecdysone) (Tulin et al., 
2003).  dPARP may also play a role in maintaining the compaction of heterochromatin 
(Tulin et al., 2002).  Interestingly, in the case of the Hsp70 gene in Drosophila S2 
cells, dPARP (as well as heat shock factor and GAGA factor) is required for a heat 
shock-dependent, transcription-independent disruption of nucleosomes across the 
entire gene, which occurs within 30 seconds of activation - faster than the rate of Pol II 
transcription (Petesch and Lis, 2008).  dPARP exhibits ecdysteroid-regulated 
localization to Cajal bodies and histone locus bodies, where it PARylates resident 
proteins and maintains organelle integrity (Kotova et al., 2009).  dPARP can also 
PARylate the nucleosome remodeling ATPase, ISWI, leading to its inactivation (Sala 
et al., 2008).  Together, these studies in Drosophila have helped to uncover and clarify 
the roles of PARP-1 in regulating chromatin structure and transcription. 
 
1.5.3 DNA methylation 
Studies over the past decade have begun to link PARP-1-dependent 
PARylation with DNA methylation, a stable epigenetic mark that can be passed to 
daughter cells upon cell division and is associated with the repression of gene 
expression (Attwood et al., 2002; Caiafa and Zampieri, 2005).  One of the ways in 
which PARP-1 affects DNA methylation is by regulating the expression and activity 
of the DNA methyltransferase Dnmt1 (Caiafa et al., 2009; Caiafa and Zlatanova, 
2009).  PARP-1 binds to the promoter of the Dnmt1 gene and can protect it from DNA 
methylation-induced silencing in a PAR-dependent manner (Zampieri et al., 2009).  In 
this regard, overexpression of poly(ADP-ribose) glycohydrolase (PARG), an enzyme 
that degrades PAR (see below), leads to aberrant methylation of a CpG island in the 
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promoter of the Dnmt1 gene in mouse fibroblasts, which in turn inhibits its 
transcription (Zampieri et al., 2009).  The loss of Dnmt1 expression leads to 
widespread passive hypomethylation of genomic DNA.   
In addition to PARP-1’s role in regulating Dnmt1 gene expression, PARP-1 
also been shown to interact with Dnmt1 in a complex that contains PAR (Reale et al., 
2005).  The non-covalent binding of PAR polymers by Dnmt1 within the complex 
inhibits Dnmt1 DNA methyltransferase activity, probably through an inhibitory steric 
mechanism (Reale et al., 2005).  Interestingly, the effects of PARP-1 on DNA 
methylation are modulated by CTCF, which may promote PARP-1 automodification, 
CTCF PARylation, the accumulation of PAR polymers, and ultimately the inhibition 
of Dnmt1 DNA methyltransferase activity (Guastafierro et al., 2008).  Future studies 
will be required to determine the extent to which PARP-1 plays a role in the dynamic 
regulation of DNA methylation in different physiological and disease states. 
 
1.5.4 Functional interplay with Sirt1 
Recent studies have identified functional interplay between PARP-1 and the 
NAD+-dependent protein deacetylase Sirt1.  Sirt1 is an important regulator of 
metabolism, cell differentiation and senescence, stress responses, and cancer, which is 
does by regulating chromatin structure and gene expression (Zhang and Kraus, 2009).  
PARP-1 and Sirt1 have been shown to function antagonistically; chemical activation 
of SIRT1 leads to reduced PARP-1 activity and knockout of Sirt1 increases PARP-1 
activity (Kolthur-Seetharam et al., 2006). PARP-1 and Sirt1 are thought to compete 
for nuclear NAD+, and a byproduct of the reactions they catalyze, nicotinamide, can 
inhibit both of their activities (Kim et al., 2005; Zhang and Kraus, 2009). This sets the 
stage for a tightly regulated interplay between these two proteins. 
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Recent studies have begun to elucidate the mechanisms of this interplay that go 
beyond simple competition for NAD+.  As noted above, acetylation of PARP-1 by 
PCAF is required for stress-induced cell death pathways.  Deacetylation of PARP-1 by 
Sirt1 promotes cell survival (Rajamohan et al., 2009).  In mice, double knockout of 
PARP-1 in a Sirt1 background increases the late post-natal lethality before weaning 
that is observed in Sirt1 knockout animals, but also rescues the abnormal pericentric 
heterochromatin formation, nucleolar disorganization, and mitotic defects that are 
observed in Sirt1-deficient cells (El Ramy et al., 2009).  Unchecked PARP-1 activity 
in the absence of Sirt1 results in apoptosis inducing factor-mediated cell death.  In 
mammalian cells, Sirt1 inhibits the expression of the PARP-1 gene, adding another 
layer of complexity to the functional interplay (Rajamohan et al., 2009).  In 
Drosophila, dPARP and dPARG may promote chromatin silencing by regulating the 
localization and function of dSir2 (the Drosophila homolog of mammalian Sirt1) 
(Tulin et al., 2006).  These results establish a functional link between PARP-1 and 
Sirt1 that plays key roles in chromatin structure, the maintenance of genomic integrity, 
and cell viability. 
 
1.6 Chemical Biology and Dynamics of PAR 
 
PAR is a negatively charged molecule that resembles single stranded nucleic 
acid polymers.  As described above, it functions as a covalent post-translational 
modification, as well as a protein-binding matrix.  Much of the focus on PAR to date 
has been on its synthesis and degradation, both of which occur on the time scale of 
minutes in the cell.   
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1.6.1 Dynamic synthesis and degradation of PAR 
PAR is synthesized rapidly in response to a variety of physiologic (e.g., 
hormone signaling) and stress-related (e.g., heat shock, DNA damage) stimuli 
(D'Amours et al., 1999; Hakme et al., 2008).  As noted above, these stimuli ultimately 
result in the allosteric activation of PARP-1 catalytic activity, which in turn can lead to 
the autoPARylation of PARP-1, as well as the transmodification of other protein 
targets.  If extensive, autoPARylation can inhibit PARP-1 enzymatic activity, which 
can block further PAR synthesis (D'Amours et al., 1999; Hakme et al., 2008).  Very 
rapidly after synthesis (within seconds to minutes), PAR is degraded to ADP-ribose 
monomers, which may have signaling functions in the nucleus (see below) (Gagne et 
al., 2006; Min and Wang, 2009).  Structurally different types of PAR are degraded at 
different rates (i.e., short more rapidly than long, linear more rapidly than branched), 
which may influence their biological functions (Hassa and Hottiger, 2008).   
Most PAR in the cell is degraded by the enzyme poly(ADP-ribose) 
glycohydrolase PARG), an enzyme with both exo and endoglycosidase activities 
(actually a family of isoforms all encoded by the same gene) (Gagne et al., 2006; Min 
and Wang, 2009) (Fig. 1.4).  In mice, targeted deletion of the 110 kDal PARG 
isoforms results in increased lethality in response to genotoxin exposure and septic 
shock relative to wild-type animals (Cortes et al., 2004).  Mice with complete deletion 
of all PARG isoforms are embryonic lethal.  Trophoblast stem cells from these 
animals are viable only when cultured in the presence of a PARP inhibitor and they 
exhibit reduced growth, accumulation of PAR, and increased sensitivity genotoxic 
stress (Koh et al., 2004).  In Drosophila, increasing or decreasing dPARG levels 
phenocopies dPARP mutation, supporting a role for dPARG in removing PAR and, 
perhaps, facilitating multiple cycles of catalysis by individual PARP molecules (Tulin 
et al., 2006).  The available data highlight the importance of PAR catabolism for 
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embryonic development, the maintenance of normal physiological states, and 
protection against genotoxic stress (Cortes et al., 2004; Fisher et al., 2007; Koh et al., 
2004; St-Laurent et al., 2007). 
Recently, the enzyme ADP-ribose-protein-hydrolase-3 (ARH3) was also 
shown to possesses intrinsic PARG activity (Oka et al., 2006), suggesting that the 
mammalian genome may encode several additional proteins with PARG activities.  
Other enzymatic activities, such as poly and mono (ADP-ribosyl) protein hydrolase, as 
well as mono(ADP-ribosyl) protein lyase, may also act to remove PAR polymers and 
ADP-ribose monomers from target proteins (Hassa and Hottiger, 2008).  Although the 
dynamic nature of PAR synthesis and degradation has been elucidated, the function of 
the PAR polymer itself and the nature of its biomolecular interactions have remained 
elusive.  Recent studies, however, have begun to shed new light in this area, especially 
with the discovery of PAR-binding motifs and domains in proteins. 
1.6.2 PAR-binding motifs/domains 
Recent studies have begun to reveal the interactions and functions of PAR in 
the cell.  These studies have lead to the identification of three different motifs or 
domains that bind PAR, which are found in a variety of proteins involved in DNA 
repair or chromatin regulation (Fig. 1.7) (Kleine and Luscher, 2009; Kraus, 2009).   
• A short motif.  A series of studies have lead to the experimental and 
computational identification of an eight amino acid PAR-binding motif found in PAR-
binding proteins: [HKR]1-X2-X3-[AIQVY]4-[KR]5-[KR]6-[AILV]7-[FILPV]8, (Fig. 
1.7A) (Gagne et al., 2008; Pleschke et al., 2000).  Although the function of this motif 
has not been extensively verified in functional assays, its identification in a large set of 
proteins suggests a potentially broad role for PAR in regulating the function of nuclear 
proteins.  For example, PAR-binding motifs in the Drosophila hnRNPs Squid/hrp40 
and Hrb98DE/hrp38 may play a role in regulating alternative splicing of RNA 
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transcripts (Ji and Tulin, 2009). The prominent role that basic amino acids play as 
determinants of this consensus sequence, however, raises questions about the 
specificity of PAR binding or whether the binding reflects the general affinity of the 
basic amino acids for charged polymers (Kleine and Luscher, 2009).  
 • PAR-binding zinc finger (PBZ).  The (PBZ), a C2H2 zinc finger, represents 
another motif that can bind PAR (Fig. 1.7B) (Ahel et al., 2008; Eustermann et al., 
2010; Isogai et al., 2010; Rulten et al., 2008).  It was originally identified in CHFR 
(checkpoint protein with FHA and RING domains), APLF (aprataxin PNK-like 
factor), and other proteins involved in DNA repair and checkpoint control proteins 
(Ahel et al., 2008; Rulten et al., 2008).  Functional analyses have demonstrated that 
the actions of CHFR in the antephase checkpoint are blocked by mutations in the PBZ 
motif or by inhibition of poly(ADP-ribose) synthesis (Ahel et al., 2008).  PAR binding 
by the PBZ in APLF is required for targeting the protein to DNA strand breaks and 
may also serve to suppress further PAR synthesis (Rulten et al., 2008).  These results 
provided the first evidence of functional consequences for PAR binding through a 
specific motif. 
 • Macrodomains.  The macrodomain, an ancient and highly conserved 
structural domain (Kraus, 2009), represents a third type of motif that can bind PAR, as 
well as other metabolites of NAD+ (e.g., ADP-ribose, see above; O-acetyl-ADP-
ribose, which is generated as a by product of sirtuin-mediated deacetylation reactions 
(Zhang and Kraus, 2009)) (Fig. 1.7C) (Karras et al., 2005; Kustatscher et al., 2005; 
Neuvonen and Ahola, 2009).  Prior reports have suggested a physical and functional 
link between PARP-1 and the macrodomain-containing histone variant macroH2A 
(Nusinow et al., 2007; Ouararhni et al., 2006).  Three recent papers have gone farther 
to examine the mechanisms and functions of PAR binding by macrodomain-
containing proteins in the control  of nuclear functions (Kraus,  2009). 
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Figure 1.7.  PAR-binding motifs. 
(A) PAR binding motifs, as found in dHrp38, a protein that regulates alternative 
splicing of RNA transcripts. 
(B) PAR-binding zinc fingers (PBZs), as found in hAPLF, a protein involved in DNA 
damage checkpoints.  The structures of the two PBZs from hAPLF are shown. 
(C) Macrodomains, as found in macroH2A1.1, a histone variant involved in setting the 
chromatin environment.  The structure of the macrodomain of macroH2A1.1 bound to 
ADP-ribose is shown. 
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The macrodomain of macroH2A1.1 is required for the localization of 
macroH2A1.1 to sites of DNA damage-induced PARP-1 activation and PAR 
formation in the nucleus (Timinszky et al., 2009).  One outcome of macroH2A1.1 
localization to PARylated loci is the transient compaction of chromatin, an effect that 
might play a role in regulating DNA repair responses (Timinszky et al., 2009).  The 
macrodomain of ALC1 (a.k.a. Chd1L), an ATP-dependent nucleosome remodeling 
enzyme, is required for PAR-dependent interactions with PARP-1 and targeting to 
sites of PAR formation in the nucleus (Ahel et al., 2009; Gottschalk et al., 2009).  
Interestingly, the ATPase and nucleosome-remodeling activities of ALC1 are 
dependent on NAD+-dependent PAR synthesis by PARP-1 (Ahel et al., 2009; 
Gottschalk et al., 2009).  Thus, PAR binding through the macrodomain of ALC1 
represents another mechanism by which PARP-1 can alter chromatin structure.   
 The PAR-binding motifs/domains described herein are likely share at least two 
common functions: (1) targeting of the proteins that contain them to sites of PAR 
synthesis and (2) regulating the activity of the proteins that contain them upon PAR-
binding.  Whether there are additional PAR-binding motifs/domains present in the 
eukaryotic proteome has yet to be determined, but the future identification any such 
motifs/domains will give immediate clues as to the function of the proteins that 
contain them. 
 
1.7 PARP-1 and NAD+ Metabolism 
 
As the substrate for PARP-1-catalyzed PARylation reactions, NAD+ plays a 
central role in determining the function and activity of PARP-1.  The synthesis of 
NAD+ occurs in multiple cellular compartments, including the nucleus, which may be 
the most relevant source of NAD+ for PARP-1 (Berger et al., 2004; Rongvaux et al., 
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2003).  In mammals, NAD+ is synthesized de novo in a pathway leading from 
tryptophan, as well as through a salvage pathway leading from nicotinamide and 
catalyzed by the enzymes nicotinamide phosphoribosyltransferase (NAMPT) and 
nicotinamide mononucleotide adenylyltransferase (NMNAT; NMNAT-1 is the nuclear 
form) (Fig. 1.4) (Berger et al., 2004; Rongvaux et al., 2003).  Interestingly, 
nicotinamide is natural endogenous inhibitor of PARP-1 (and Sirt1).  Thus, the 
salvage pathway supports PARP-1 activity by depleting nicotinamide and producing 
of NAD+. 
Recent studies have illustrated how the enzymatic activities of PARP-1, 
NAMPT, and NMNAT are functionally linked.  For example, stress-induced cell death 
due to PARP-1-dependent NAD+ depletion in cardiomyocytes can be reversed by 
overexpression of NAMPT (Pillai et al., 2005), supporting the conclusion that 
NAMPT catalyzes the rate-limiting step in NAD+ synthesis (Revollo et al., 2004).   
Furthermore, in addition to producing NAD+ to support PARP-1 catalytic activity, 
NMNAT-1 also stimulates PARP-1 catalytic activity by binding to activated, 
automodified PARP-1 (Berger et al., 2007).  A recent study has shown that Sirt1 
recruits NMNAT-1 to target gene promoters, presumably to supply NAD+ for protein 
deacetylase reactions at the promoter (Zhang et al., 2009).  It is likely that a similar 
mechanism involving PARP-1 and NMNAT-1 supports PARylation of proteins at the 
promoters of PARP-1-regulated genes.  The enzymatic activities of PARP-1 and Sirt1 
may also be linked through competition for limiting supplies of nuclear NAD+ 
(review?).  Difficulty in accurately determining the concentrations of nuclear NAD+, 
however, has hampered verification of this conclusion.  Although functional interplay 
between PARP-1 and NAD+-metabolizing enzymes in the nucleus has been 
established, the molecular mechanisms remain to be clarified.  
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1.8 Cellular Signaling through PARP-1 
 
PARP-1 is a targeted endpoint of a number of distinct cellular signaling 
pathways, including those regulated by hormones, stress, and DNA damage.  As noted 
above, PARP-1 is subject to a variety of post-translational modifications in response to 
these pathways, and these modification are likely to play a key role in regulating 
PARP-1 activity and generating specificity of signaling endpoints.   
 
1.8.1 Cellular signaling pathways and functional outcomes 
The ultimate functional outcomes of PARP-1-dependent signaling pathways 
are varied.  For example, PARP-1 can act as an integrator in a number of pathways, 
including stress-dependent gene regulatory pathways, where it facilitates the 
recruitment of chromatin- and transcription-regulating proteins, and promotes the 
reorganization of chromatin at PARP-1 target genes (Frizzell et al., 2009; Hassa et al., 
2003; Petesch and Lis, 2008; Tulin and Spradling, 2003).  PARP-1 can also act as an 
“exchange factor” at target gene promoters in response to cellular signals, promoting a 
switch from the binding of repressive complexes to activating complexes at target 
gene promoters (Ju et al., 2006; Ju et al., 2004; Pavri et al., 2005).  The most well 
characterized signaling pathways in which PARP-1 plays a role are NF-κB-dependent 
pro-inflammatory responses, heat shock, cellular kinase-dependent pathways, and 
hormone signaling, although the involvement of PARP-1 in a number of other 
pathways seems likely. 
• NF-κB-dependent pro-inflammatory pathways.  PARP-1 plays a key role in 
pro-inflammatory gene expression responses.  Much of PARP-1’s function in this 
regard is as a transcriptional coregulator of NF-κB in signaling pathways leading from 
Toll-like receptors (Hassa and Hottiger, 2002).  In this regard, PARP-1 functions as a 
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coactivator of NF-κB to regulate the expression of pro-inflammatory target genes.  
This involves the acetylation of PARP-1 by p300/CBP, which is required for the 
interaction of PARP-1 with NF-κB and coactivation by the Mediator complex in 
response to inflammatory stimuli (Hassa et al., 2003; Hassa et al., 2005).  PARP-1 was 
recently shown to be required for DNA damage-induced activation of IκB kinase 
(IKK), a key protein in the pathway leading to activation of NF-κB.  In this regard, 
PARP-1 promotes the PAR-dependent assembly of a complex containing PIASy and 
ATM, both of which contain PAR-binding motifs, as well as IKKγ, which is 
subsequently SUMOylated (Stilmann et al., 2009).   
• Heat shock.  In Drosophila, PAR rapidly accumulates at heat shock loci in 
response to heat shock (Tulin and Spradling, 2003).  dPARP is required for heat 
shock-induced “puffing” (i.e., chromatin decondensation) at these loci, as described 
above (Tulin and Spradling, 2003, Petesch, 2008 #7).  Knockdown of dPARP or 
treatment with a PARP inhibitor prevents heat shock-induced nucleosome loss and 
enhanced transcription at the Hsp70 gene (Petesch and Lis, 2008).  In fact, with 
dPARP knockdown or in the presence of the PARP inhibitor, the nucleosomes remain 
in a non-heat shock state even after heat shock  (Petesch and Lis, 2008).  Currently, 
the mechanisms by which PARP-1 senses the heat shock signal is unknown, but it 
may involve interactions with heat shock factor, a DNA-binding transcription factor 
that is phosphorylated in response to heat shock. 
 • Hormone- and kinase-dependent signaling.  PARP-1 plays critical roles in 
signal-dependent gene regulation as an endpoint of neurogenic, steroid, retinoid, and 
other hormone signaling pathways (Ju et al., 2006; Ju et al., 2004; Kim et al., 2004; 
Kim et al., 2005; Kraus, 2008; Pavri et al., 2005).  PARP-1 alters the chromatin 
structure and the set of factors bound at the promoters of the target genes whose 
expression is regulated by these signaling pathways.  Some of these pathways involve 
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cellular kinases, such as ERK1/2, JNK1, PKC, and CaMKIIδ (Berger et al., 2007; 
Cohen-Armon et al., 2007; Ju et al., 2004; Kauppinen et al., 2006; Zhang et al., 2007).  
Signaling through ERK1/2 enhances PARP-1 activity, although phosphorylation of 
PARP-1 does not occur in all contexts (Cohen-Armon et al., 2007; Kauppinen et al., 
2006).  The stress-activated kinase JNK1 phosphorylates PARP-1, which promotes the 
sustained activation of PARP-1 when cells are stressed with hydrogen peroxide 
(Zhang et al., 2007).  Furthermore, PKC phosphorylates NMNAT-1, reducing its 
ability to bind PAR, providing yet another level of PARP-1 regulation by the NAD+ 
metabolic pathway (Berger et al., 2007). 
 
1.8.2 Convergence of signaling pathways: transcription and DNA repair 
A number of parallels exist between PARP-1’s roles in transcription and DNA 
repair.  For example, PARP-1 (1) interacts with and PARylates components of both 
the transcription and DNA repair machineries, (2) directs components of both 
machineries to specific sites in chromatin, and (3) is covalently modified in response 
to the signaling pathways that regulate these processes (Kim et al., 2005).  The 
transcription- and repair-related aspects of PARP-1 function may converge in some 
contexts.  For example, a recent study has suggested that upon estrogen treatment, a 
topoisomerase IIβ- and PARP-1-containing complex is recruited to target promoters, 
causing the formation of a double strand break in the promoter DNA (Ju et al., 2006).  
The function of the double strand break is not known, but it may resolve a topological 
constraint allowing a critical structural change in the promoter.  Alternatively, it may 
serve as a signal to activate PARP-1 and stimulate its factor exchange functions at the 
promoter.  Whether PARP-1 plays a role in the obligate post-transcription DNA repair 
process has not been determined, but it might explain the presence of PARP-1 at 
nearly all actively transcribed genes (Krishnakumar et al., 2008).  Another recent 
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paper has proposed a related model of estrogen-dependent gene regulation involving 
transcription-induced oxidative damage of promoter DNA, although the role of PARP-
1 in this process was not determined (Perillo et al., 2008). 
Controlled transcription-coupled DNA damage as means of regulating signal-
dependent gene expression might seem to be an inefficient and dangerous way for 
cells to respond to signals, but this is a conceptually interesting and novel view.  These 
results should be evaluated carefully and are in need of additional confirmation and 
mechanistic analyses. 
 
1.9 Physiology and Pathology of PARP-1 
 
 Studies over the past decade have begun to reveal the ways in which the 
nuclear functions of PARP-1 contribute to specific physiological and pathological 
outcomes.  However, a much greater understanding of the specific biological roles of 
PARP-1 and how they are regulated is needed.  Based on studies in animal models, 
PARP-1 has been implicated in development, the function of the immune and nervous 
systems, aging, and cancer, all of which have been reviewed in detail previously 
(Beneke and Burkle, 2004; Burkle et al., 2004; Kim et al., 2005; Peralta-Leal et al., 
2008).  Below I highlight some of the key results from animal models, as well as 
discuss the roles of PARP-1 in inflammation and development. 
 
1.9.1 Animal models of PARP-1 function 
PARP-1 knockout mice are viable and show only mild phenotypes (Wang et 
al., 1995), although some interesting phenotypes have been revealed in response to 
certain chemical agents and in some genetic backgrounds.  For example, Parp-1-/- 
mice are more sensitive to chemically-induced genotoxic stress (de Murcia et al., 
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1997; Wang et al., 1995; Wang et al., 1997).  They also show resistance in various 
models of inflammation (Ha, 2004; Mabley et al., 2001; Oliver et al., 1999), as well as 
increased tumor formation in some genetic backgrounds (e.g., p53-/- and SCID) and in 
chemically-induced models of cancer (Masutani et al., 2005; Morrison et al., 1997; 
Tong et al., 2001).  The mild phenotypes observed in the PARP-1 knockout mice may 
be due to redundancy with other PARP family members.  In this regard, genetic 
ablation of dPARP in Drosophila, which has only one PARP-1-like gene, causes 
lethality at the larval stage (Miwa et al., 1999; Tulin et al., 2003; Tulin et al., 2002).  
Furthermore, double knockout of PARP-1 and PARP-2 in mice causes embryonic 
lethality (Menissier de Murcia et al., 2003).  Likewise, individual tankyrase 1/PARP-
5a and tankyrase 2/PARP-5b knockout mice (i.e., Tnks1-/- and Tnks2-/-) are largely 
normal, but double knockout causes early embryonic lethality, indicating redundancy 
in mouse development (Chiang et al., 2008; Hsiao et al., 2006).  
 
1.9.2 Inflammatory responses  
PARP-1 has long been recognized as a key component of innate immunity and 
inflammatory responses, and these are the best characterized PARP-1-dependent 
biological responses (Cuzzocrea, 2005).  PARP-1 is heavily automodified in response 
to bacterial infection (Nossa et al., 2009) and PARP inhibitors inhibit lymphocyte 
proliferation and lymphokine induction (Weltin et al., 1995).  Parp-1-/- mice are 
resistance to inflammation in various experimental models, including LPS-induced 
septic shock and streptozotocin-induced diabetes (Ha, 2004; Mabley et al., 2001; 
Oliver et al., 1999).  Moreover, PARP-deficient Drosophila exhibit defects in innate 
immunity and are more susceptible to bacterial infection that their wild-type 
counterparts (Tulin and Spradling, 2003).  As these results indicate, PARP-1 plays a 
central role in supporting inflammatory responses.  In pathological states, this can 
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have dire consequences, leading to tissue damage.  Hence the potential utility of PARP 
inhibitors in treating inflammatory disorders (Graziani and Szabo, 2005).  
 Interestingly, PARP-1-dependent pro-inflammatory responses are not limited 
to cells of the immune system.  Recent studies have implicated PARP-1 in 
pathological pro-inflammatory stress responses in cells of the central nervous and 
cardiovascular systems (Moroni, 2008; Pacher and Szabo, 2007).  In a mouse model of 
multiple sclerosis, PARP-1 knockout reduces the severity of the disease outcome 
(Farez et al., 2009; Selvaraj et al., 2009).  Furthermore, PARP-1 knockout has been 
shown to improve various aspects of cardiac function in mice (Pacher and Szabo, 
2007).  These results suggest a number of exciting potential therapeutic applications 
for PARP inhibitors. 
 
1.9.3 Development: stem cells and differentiation  
Although PARP-1 knockout mice develop normally (Wang et al., 1995), the 
embryonic lethal phenotype of PARP-1/PARP-2 double knockout mice indicate that 
PARPs are critical for embryonic development (Menissier de Murcia et al., 2003).  
The requirement for PARP-1 and PARP-2 in development is due, at least in part, to 
the roles they play in the maintenance of genomic stability (Menissier de Murcia et al., 
2003).  The extent to which they control other specific developmental processes is not 
clear, although new studies have suggested roles for PARP-1 in stem cells and during 
differentiation.   
• Stem cell function.  In embryonic stem (ES) cells from Parp-1-/- mice, about 
10% of genes analyzed showed altered expression compared to about 3% of genes in 
livers from the same animals (Ogino et al., 2007).  The number of genes down-
regulated by PARP-1 knockout was about two-fold more than the number of up-
regulated genes in both cases, indicating a major role for PARP-1 in keeping genes 
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active in ES and liver cells (Ogino et al., 2007).  The large panel of genes whose 
expression is dependent on PARP-1 in ES cells suggests a role for PARP-1 in the 
developmental programming of these cells.  A recent study has revealed some of the 
molecular mechanisms whereby PARP-1 might help to promote the differentiation of 
stem cells (Gao et al., 2009).  Specifically, PARP-1 antagonizes the DNA-binding 
transcription factor Sox2 to stimulate expression of the gene encoding fibroblast 
growth factor 4 (FGF4), a growth factor that promotes differentiation.  PARP1 binds 
to the FGF4 enhancer and interacts with Sox2.  In response to appropriate cellular 
signals, PARP-1 PARylates Sox2, which promotes its dissociation and degradation.  
Knockdown or chemical inhibition of PARP-1 PARylation of Sox2 decreases and 
association its binding to the FGF4 enhancers increases, leading to reduced expression 
of FGF4.  These results indicate that PARP-1 can regulate the pluripotent state of ES 
cells by controlling the activity of key stem cell transcription factors.   
• Cellular differentiation programs.  PARP-1, as well as PARP-2, has been 
implicated in the differentiation of other cell types as well.  For example, in a model of 
neuronal differentiation, PARP-1 is required for the exchange of corepressors for 
coactivators at the promoters of genes regulated by the transcription factor HES1 (Ju 
et al., 2004).  PARP-1 is also required for T-cell dependent immunoglobulin class 
switching in B-cells (Ambrose et al., 2009; Morrison et al., 1997).  In a model of 
endodermal differentiation, PARP-1 and PARP-2 play distinct roles in a pathway 
involving physical and functional interactions with the heterochromatin-associated 
proteins HP1 and TIF1β: PARP-2 is required for differentiation of mouse embryonal 
carcinoma cells into primitive endoderm-like cells in response to retinoic acid, while 
PARP-1 is required for subsequent differentiation into parietal endoderm-like cells in 
response to retinoic acid and dibutyryl cAMP (Quenet et al., 2008).   
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PARP-2 is required for adipogenesis (Bai et al., 2007) and spermiogenesis 
(Dantzer et al., 2006), and T-cell survival during thymopoiesis (Yelamos et al., 2006).  
During adipogenesis, PARP-2 functions as a coactivator of the adipogenic 
transcription factor PPARγ (Bai et al., 2007).  During thymopoiesis, PARP-2 prevents 
the activation of a DNA damage-dependent apoptotic response through multiple 
rounds of T-cell receptor gene rearrangements (Yelamos et al., 2006).  Whether 
PARP-1 plays a similar, or perhaps an antagonistic role, in these same differentiation 
pathways has yet to be determined. 
 
 
1.10 PARP Inhibitors 
 
With the identification of PARP-1 and other PARP family members as key 
players in cellular pathways that contribute to disease (Kim et al., 2005), the 
development of specific, potent, effective, and safe PARP inhibitors has become an 
area of active research and much recent excitement in the PARP field (Rouleau et al., 
2010).  The focus has been on competitive inhibitors of PARP catalytic activity (Fig. 
1.8) that may be useful as research tools, as well as clinical therapies.   
 
1.10.1 Pharmacology 
 3-aminobenzamide (3-AB) (Fig. 1.8) was the first PARP inhibitor to be 
extensively characterized, but it lacks the requisite selectivity and potency to be useful 
as a research tool or in the clinic (Rouleau et al., 2010).  Over the past decade, a large 
number of compounds with the ability to inhibit one or more PARP family members 
have been synthesized and screened by various laboratories and companies (Pacher 
and Szabo, 2007; Ratnam and Low, 2007; Rouleau et al., 2010).  These include 
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compounds derived from isoquinolines, phenanthridines, phthalazines, and other 
structural derivatives (Fig. 1.8), and a number of them are currently being tested in 
clinical trials as cancer therapies (Ratnam and Low, 2007; Rouleau et al., 2010).  
Although these inhibitors are highly specific for PARPs and most have nanomolar 
affinities, developing inhibitors that are specific for a single specific PARP has proven 
to be considerably more difficult given the high level of conservation of PARP 
catalytic domains (Hakme et al., 2008; Schreiber et al., 2006) (Fig. 1.2). Although 
quinazolinone and quinoxaline derivatives may be more selective for PARP-1 and 
PARP-2, respectively (Hassa and Hottiger, 2008), increasing specificity is an 
important area focus for the future.  PARP inhibitors are likely to be useful for treating 
a wide variety of diseases related to genome integrity (e.g., cancers; (Ratnam and 
Low, 2007)), as well as stress and acute inflammatory responses (e.g., cardiovascular 
disease; (Pacher and Szabo, 2007)). 
 
1.10.2 Clinical trials: focus on cancers 
 A number of clinical trials are now underway examining the safety and 
efficacy of PARP inhibitors as treatments for a variety of cancers, including breast, 
uterine, and ovarian cancers (Rouleau et al., 2010).  In many cases, this may be due to 
synthetic lethality between PARP inhibition and a genetic lesion in the cancer cells.  
For example, p53-deficient breast cancer cells treated with a PARP inhibitor lose 
resistance to doxorubicin, a clinically active antitumor anthracycline antibiotic that 
promotes apoptosis (Munoz-Gamez et al., 2005).  Similarly, germline mutations in the 
familial breast cancer genes BRCA1 or BRCA2 sensitize breast cancer cells to PARP 
inhibitors in a PARP-1-dependent manner (Bryant et al., 2005; Farmer et al., 2005).  
The goal of this approach is to target cells defective in one DNA repair pathway by  
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Figure 8.  Structures of PARP inhibitors.  
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inhibiting another.  A clinical trial based on this approach has shown selective anti-
tumor activity for the PARP inhibitor, olaparib (Fig. 1.8), in breast and ovarian 
cancers containing BRCA1 and BRCA2 mutations at safely administrable doses with 
minimal side-effects (Fong et al., 2009).  RNAi-based synthetic lethal screens may be 
a useful way of identifying other genes that mediate sensitivity to a PARP inhibitors; a 
recent study has identified a set of kinases whose silencing sensitized cells to a PARP 
inhibitor (Turner et al., 2008).  Another study has suggested that breast cancer cells 
may be generally sensitive to the PARP inhibitor, PJ34 (Inbar-Rozensal et al., 2009) 
(Fig. 1.8), although this may be due synthetic lethality with unknown genetic 
alterations in the cells examined.   
 Tankyrase may also be a useful target for the treatment of cancers.  In this 
regard, chemical inhibition of tankyrase shows synthetic lethality with BRCA1 or 
BRCA2 mutations in breast cancer cells, much like inhibition of PARP-1 (McCabe et 
al., 2009).  Furthermore, XAV939 (Fig. 1.8), an inhibitor of tankyrases 1 and 2 
regulates Wnt signaling in colon cancer cells by prolonging the half-life of axin and 
promote β-catenin degradation, a target that may be useful for treating Wnt pathway-
dependent cancers (Huang et al., 2009).  These and other related clinical discoveries 
have moved PARP-1 and other PARP family members from interesting subjects of 
molecular analyses to the forefront as clinical targets for cancer treatment (Rouleau et 
al., 2010). 
 
1.11 Future Directions 
 
Based on the literature reviewed herein, it is evident that the functions of PARP-1 are 
as diverse as they are numerous.  In many cases, however, I lack a clear mechanistic 
understanding of how PARP-1 contributes to the nuclear processes in which it 
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participates.  There are many questions and issues that remain to be addressed in 
future studies.  For example, our knowledge of PARP-1 structure is incomplete.  A 
structure of full length PARP-1, alone or in combination with its binding partners 
(e.g., DNA, nucleosomes, transcription factors), will be required to achieve a full 
understanding of PARP-1 function.  In addition, our understanding of the 
physiological functions of PARP-1 is limited.  More sophisticated and specific animal 
models, such as tissue-specific knockout mice, will be required to address this issue.  
Furthermore, our understanding of how the diverse functions of PARP-1 are integrated 
and controlled is limited.  In this regard, the field must reconcile the roles played by 
PARP-1 plays in distinct, but inter-related biological processes, such as transcription 
and DNA repair.  Finally, more specific PARP inhibitors will be required both as tools 
and therapeutics.  The next decade promises to be an exciting one for the field. 
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CHAPTER 2 
 
 
 
Reciprocal Binding of PARP-1 and Histone H1 at Promoters Specifies 
Transcriptional Outcomes* 
 
 
 
 
*This work was published as Krishnakumar R, Gamble MJ, Frizzell KM, Berrocal JG, 
Kininis M, Kraus WL. Reciprocal binding of PARP-1 and histone H1 at promoters 
specifies transcriptional outcomes.  Science. 2008 Feb 8;319(5864):819-21.  The text 
is reprinted here with permission from the publisher.  Minor modifications have been 
made.  Contributions by other authors to this work were as follows:  M.J.G., ChIP-chip 
array design and data analysis (Figs 2.1, 2.2, 2.4, 2.6); K.M.F., gene expression analysis 
(Figs. 2.7, 2.8, 2.10); J.G.B, gene expression analysis (Figs. 2.7, 2.8, 2.10); M.K., 
nucleosome positioning analysis (Fig. 2.5).   
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2.1 Summary 
Nucleosome-binding proteins act to modulate the promoter chromatin 
architecture and transcription of target genes.  We use genomic and gene-specific 
approaches to show that two such factors, histone H1 and poly(ADP-ribose) 
polymerase-1 (PARP-1), exhibit a reciprocal pattern of chromatin binding at many 
RNA polymerase II-transcribed promoters.  PARP-1 is enriched and H1 is depleted at 
these promoters.  This pattern of binding is associated with actively transcribed genes.  
Furthermore, we show that PARP-1 acts to exclude H1 from a subset of PARP-1-
stimulated promoters, suggesting a functional interplay between PARP-1 and H1 at the 
level of nucleosome binding.  Thus, although H1 and PARP-1 have similar nucleosome-
binding properties and effects on chromatin structure in vitro, they have distinct roles in 
determining gene expression outcomes in vivo. 
 
2.2 Introduction 
Gene expression outcomes are determined, in part, by the composition of 
promoter chromatin, including the post-translational modification state of nucleosomal 
histones (Berger, 2002), the incorporation of histone variants (Kamakaka and Biggins, 
2005), and the presence of nucleosome-binding proteins (McBryant, et al., 2006).  
Linker histone H1 and poly(ADP-ribose) polymerase-1 (PARP-1) are examples of 
nucleosome-binding proteins that modulate the chromatin architecture and transcription 
of target genes (Kim, et al., 2005, Woodcock, et al., 2006).  H1 and PARP-1 bind to 
overlapping sites on nucleosomes at or near the dyad axis where the DNA exits the 
nucleosome (Kim, et al., 2004, Vignali and Workman, 1998).  Unlike H1, PARP-1 has 
an intrinsic NAD+-dependent enzymatic activity that regulates its association with 
chromatin (Kim, et al., 2004).  Previous work from our lab has shown that H1 and 
PARP-1 bind in a competitive and mutually exclusive manner to nucleosomes in vitro 
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and localize to distinct nucleosomal fractions in vivo (Kim, et al., 2004), suggesting 
distinct roles for these factors in the regulation of gene expression.  However, little is 
known about how H1 and PARP-1 are distributed across the mammalian genome and 
how they interact to regulate global patterns of gene expression in vivo.  
 
2.3 Results 
To determine the patterns of H1 and PARP-1 localization across selected 
regions of the human genome, we performed chromatin immunoprecipitation (ChIP) in 
MCF-7 breast cancer cells using antibodies specific to PARP-1 and H1 (Kim et al.,; 
Kininis et al., 2007), coupled with hybridization of the enriched genomic DNA to 
custom microarrays (i.e., ChIP-chip) (Buck and Lieb, 2004).  Each array represented 57 
Mb of genomic DNA, including all 44 of the ENCODE regions (2004), as well as an 
additional 1117 promoter regions selected from genes regulated by enzymes in the 
nuclear NAD+ signaling pathway (Kim, et al., 2005) (approximately -25 kb to +5 kb 
relative to the transcription start site (TSS)).  The raw ChIP-chip signal to input ratios 
were processed and aligned to the TSSs for all 1517 RNA polymerase II (Pol II)-
transcribed promoters on the array (i.e., ENCODE + selected).  A single array error 
model was generated using a 1 kb moving window with 250 bp steps in which both the 
mean probe log2 ratio and p-values from a nonparametric Wilcoxon signed-rank test 
were calculated for each window.  We observed an enrichment of PARP-1 and a 
depletion of H1 in the region surrounding the TSSs (Fig. 2.1A).  Significant peaks were 
defined as the center of three consecutive windows with positive means, the center 
window with a mean greater than either adjacent window, and all windows having p-
values less than 0.01 (Wilcoxon signed-rank test).  Significant troughs were defined as 
the center of three consecutive windows with negative means, the center window with a 
mean less than either adjacent window, and all windows having p-values 
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Figure 2.1.  Distinct patterns of genomic localization for H1 and PARP-1.  (A) Heat 
maps of H1 and PARP-1 ChIP-chip data for 1517 promoters tiled from -25 kb to +5 kb 
relative to the TSS.  The promoters are ordered top to bottom based on increasing 
intensity of the PARP-1 signal in a 10 kb window surrounding the TSS.   (B) 
Histograms showing the number of statistically significant peaks and troughs of PARP-
1 and H1 across the entire 30 kb tiled region for the 1517 promoters on the ChIP-chip 
array.   
 
 
 
 
 
 
 
 
 
  
68 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
B
Nu
m
be
r o
f P
ea
ks
 o
r T
ro
ug
hs
PARP-1
H1
200
150
100
50
0
50
50
0
50
100
150
200
Peaks Troughs
Position (Kb from TSS)
-2
35
00
-2
20
00
-2
05
00
-1
90
00
-1
75
00
-1
60
00
-1
45
00
-1
30
00
-1
15
00
-1
00
00
-8
50
0
-7
00
0
-5
50
0
-4
00
0
-2
50
0
-1
00
0 0
10
00
25
00
40
00
-2
3.
5
-2
0.
5
-1
7.
5
-1
4.
5 4.
0
1.
0
-1
.0
-8
.5
-1
1.
5
-5
.5
-2
.5
-2
2.
0
-1
9.
0
-1
6.
0
-1
3.
0
-7
.0
-1
0.
0
-4
.0 2.
5
Position Relative to the TSS (kb)
-25 -20 -15 -10 -5 0 5 -25 -20 -15 -10 -5 0 5
15
17
 p
ro
m
ot
er
s
PARP-1 H1
A
  
69 
less than 0.01 (Wilcoxon signed-rank test).  The use of our peak/trough selection 
criteria were justified by a low false positive rate (FPR) as determined by ChIP-qPCR 
(PARP-1 peak FPR = 0.11; H1 trough FPR = 0.08).  Significant peaks of PARP-1 and 
troughs of H1 were clustered around the TSSs, but were also found in upstream and 
intergenic regions (Figs. 2.1B, 2.2A, 2.2B, and 2.3).  This pattern of PARP-1 and H1 
localization was also revealed by averaging the ChIP-chip data over the 30 kb tiled 
region for all promoters on the array or in a 20 kb region centered around significant 
PARP-1 peaks or H1 troughs (p-value < 0.01 from a Wilcoxon signed-rank test) (Fig. 
2.4).  Collectively, our ChIP-chip data identify a reciprocal relationship for chromatin 
binding by PARP-1 and H1 across the genome. 
Although eukaryotic promoters generally show reduced nucleosome occupancy 
(Heintzman, et al., 2007, Mito, et al., 2007), this was not an important determinant for 
the reciprocal pattern of PARP-1 and H1 binding.  Note, for example, that whereas 
PARP-1 peaks and H1 troughs are strongly correlated at promoters (Spearman 
correlation: -0.495, p = 3.7 x 10-94), they show little correlation with the presence of H3 
(Fig. 2.6A).  The Spearman correlation between PARP-1 and H1 was also determined 
for PARP-1-regulated genes only (108 genes total).  These genes had a p value < 0.05, a 
fold change greater or less then 0.5 or -0.5, respectively, and were flagged present or 
marginal in two out of the three replicates for both PARP-1 knockdown and control cell 
lines.  The correlation was as follows: -0.309, p = 1.17 x 10-3. 
  In addition, the pattern of PARP-1 and H1 binding at promoters (e.g., low 
versus high PARP-1/H1 ratios) is independent of the pattern of H3 occupancy at 
promoters (Fig. 2.6B).  Finally, the reciprocal pattern of PARP-1 and H1 binding is 
observed in intergenic regions where H3 is not depleted (Fig. 2.4B).  In spite of the  
reduced H3 occupancy at promoters, well-positioned nucleosomes are present at PARP-
1-bound promoters that likely serve as targets for the binding of PARP-1 (Fig. 2.5).  To 
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Figure 2.2. Diagram of statistically significant peaks and troughs of PARP-1 and 
H1 across ENCODE regions from Chr. 1 and Chr. 11.  Annotated RefSeq genes are 
represented by arrows indicating the length of the gene, direction of transcription, and 
expression in MCF-7 cells (green = expressed, as determined by expression 
microarrays; red = unexpressed or highly unlikely to be expressed in MCF-7 cells; grey 
= ambiguous or no information available).  Asterisks indicate genomic locations with a 
PARP-1 peak and a H1 trough.   
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Figure 2.3. Gene-specific confirmation of PARP-1 and H1 ChIP-chip results.  
Gene-specific ChIP-qPCR analyses of H1 and PARP-1 binding at promoter (prom.) and 
upstream (upstr.; approx. -10 kb) regions for selected genes.  Each bar = mean + SEM, 
n = 3. 
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explore the relationships between PARP-1, H1, and gene expression in more detail and 
under physiological NAD+ concentrations, we coupled our ChIP-chip analyses with 
gene expression microarray analyses for MCF-7 cells grown under the same conditions.  
PARP-1 peaks showed a significant positive correlation with gene expression 
(Spearman rank correlation associated p-value of 7.1 x 10-49), whereas H1 showed a 
significant negative correlation with gene expression (Spearman rank correlation 
associated p-value of 7.85 x 10-39) (Fig. 2.6A).  In addition, PARP-1 was enriched and 
H1 was depleted near the TSSs of expressed genes relative to unexpressed genes (Fig. 
2.6B).  For a gene to be classified as unambiguously expressed or unexpressed, all 
probe sets from all three replicates corresponding to the gene must have been flagged 
unanimously present or absent, respectively.  Any genes not meeting these criteria were 
marked as ambiguous and were removed from the expression-based categorization 
analysis.  We then grouped all genes containing both a significant PARP-1 peak and a 
significant H1 trough (p-value < 0.01 from a Wilcoxon signed-rank test), and compared 
them to a group that lacked both a PARP-1 peak and an H1 trough.  For this analysis, 
peaks and troughs identified at p-values between 0.01 and 0.1 were labeled as 
ambiguous due to high false positive and false negative rates.  More than 90 percent of 
the genes containing both a PARP-1 peak and an H1 trough at the promoter were 
expressed, whereas less than 45 percent of the genes lacking both a PARP-1 peak and 
an H1 trough at the promoter were expressed (Fig. 2.6C).  This correlation was also 
observed when looking broadly across ENCODE regions enriched in expressed or 
unexpressed genes (Fig. 2.2; see asterisks). Together, these results indicate that the 
pattern of PARP-1 and H1 promoter localization is indicative of gene expression 
outcomes.   
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Figure 2.4. Reciprocal binding patterns for H1 and PARP-1 at promoter, 
upstream, and far distal sites.  (A) Averaging analysis of the log2 enrichment ratios 
from H1, PARP-1, and H3 ChIP-chip for all 1517 genes on the array.  (B) Averaging 
analysis of the log2 enrichment ratios from H1, PARP-1, and H3 ChIP-chip centered 
around significant PARP-1 peaks (left) or significant H1 troughs (right).  The data are 
grouped based on the location of the defining peak relative to the TSS of the nearest 
gene ( 2 kb or > 2 kb away).  These data show that the reciprocal relationship for the 
binding of PARP-1 and H1 is observed: (1) whether the PARP-1 peak or H1 trough is 
located promoter-proximally (i.e.,  2 kb from the TSS) or promoter-distally (i.e., > 2 
kb from the TSS) and (2) in intergenic regions where H3 is not depleted. 
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Figure 2.5. Micrococcal nuclease mapping of positioned nucleosomes at PARP-1-
occupied promoters.  (A) Averaging analysis and alignment of PARP-1 and H3 ChIP-
chip data with available MNase protection information (Ozsolak, et al., 2007) for 121 
unambiguously bound genes.  The yellow boxes highlight regions of significant 
protection and indicate the average location of positioned nucleosomes.  These high-
resolution mapping data demonstrate regions of significant MNase protection under the 
PARP-1 peak, indicating the presence of positioned nucleosomes.  (B) A similar 
analyses to (A), but showing individual genes.  The yellow ovals indicate the location of 
positioned nucleosomes.  Together, these data indicate that in spite of the reduced 
occupancy of H3, PARP-1 bound promoters contain well-positioned nucleosomes that 
likely function as targets for PARP-1 binding. 
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Finally, to explore further the functional relationships between PARP-1, H1, and gene 
expression, we identified subsets of PARP-1-bound genes either down-regulated or up-
regulated in MCF-7 cells by stable short hairpin RNA (shRNA)-mediated knockdown 
of PARP-1  (Fig. 2.7A).  The target genes used for this analysis were identified in a 
microarray expression screen and were then confirmed by RT-qPCR as having either a 
two-fold reduction or two-fold increase in expression upon shRNA-mediated 
knockdown of PARP-1.  For each gene, we assayed: (1) promoter binding by PARP-1 
and H1 using ChIP-qPCR and (2) expression by RT-qPCR, with or without PARP-1 
knockdown.  The subset of genes positively regulated by PARP-1 (i.e., genes whose 
expression decreased upon PARP-1 knockdown) showed a 3- to 5-fold increase in H1 
binding at the promoter in response to PARP-1 knockdown without changes in H3 
occupancy (Figs. 2.7B, 2.8, and 2.9).  These results provide a functional link between 
the chromatin binding and gene regulatory actions of PARP-1 and H1 at this subset of 
target promoters.  Specifically, they suggest that PARP-1 acts to exclude H1 from these 
promoters and that upon PARP-1 knockdown, H1 is able to re-bind and inhibit 
transcription.  In contrast, the subset of genes negatively regulated or not regulated by 
PARP-1 (i.e., genes whose expression decreased or was unchanged upon PARP-1 
knockdown) showed little or no change in H1 binding at the promoter in response to 
PARP-1 knockdown (Figs. 2.7C and 2.10).  These genes, some of which show a 
reciprocal pattern of PARP-1 and H1 localization at their promoters (Figs. 2.7C and 
2.10), may be subject to other PARP-1-related transcriptional regulatory mechanisms 
(Kim, et al., 2005, Kraus and Lis, 2003) or indirect regulatory effects.  
 
2.4 Discussion 
Collectively, our data reveal the genomic localization patterns of H1 and PARP-
1, highlighting the reciprocal relationship for their binding at promoters and other 
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Figure 2.6. A high PARP-1:H1 ratio specifies actively transcribed promoters.  (A) 
Correlation analyses of PARP-1, H1, and H3 occupancy as determined by ChIP-chip (at 
the -250 bp-centered window) with gene expression as determined by microarrays 
(Expr.).  (B) Averaging analysis of the log2 enrichment ratios from H1 and PARP-1 
ChIP-chip for unambiguously expressed (top) or unambiguously unexpressed genes 
(bottom).  (C) Top, Averaging analysis of the log2 enrichment ratios from H1 and 
PARP-1 ChIP-chip for genes: (1) having both a PARP-1 peak and an H1 trough within 
1.5 kb of the TSS (left), or (2) unambiguously lacking both a PARP-1 peak and an H1 
trough within 1.5 kb of the TSS (right).  Bottom, Percentage of expressed and 
unexpressed genes in each category.  P-values are from a Chi-squared test and indicate 
significant differences relative to the total genes gene set (n = 878; percent expressed = 
71.1). 
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genomic locations.  In addition, our results provide a functional link between chromatin 
binding by PARP-1 and H1 at a subset of target promoters and the corresponding gene 
expression outcomes.  Finally, our results suggest that PARP-1 acts to exclude H1 from 
a subset of PARP-1-regulated promoters in vivo.   
In a previous study (Kim, et al., 2004), we concluded that PARP-1 may act to repress 
Pol II transcription based on the observation that (1) PARP-1 represses in vitro 
transcription by Pol II with chromatin templates in the absence of NAD+ and (2) PARP-
1 does not colocalize with active Pol II (Ser5-P) on Drosophila polytene chromosomes.  
Although these results may seem at odds with our current data, a careful comparison of 
the two s tudies  reveals  that  th is  i s  not  the case,  as  described below. 
 
(1) NAD+ concentrations (in vivo versus in vitro) 
The biochemical assays presented in our previous study (Kim, et al., 2004) 
examined the effects of PARP-1 on transcription at sub-physiological and supra-
physiological extremes of NAD+ (i.e., the absence of NAD+ and saturating levels of 
NAD+).  Based on these results, we concluded that PARP-1 could (i) compact 
chromatin and repress transcription in the absence of NAD+ and (ii) become auto(ADP-
ribosyl)ated and release from chromatin in the presence of saturating concentrations of 
NAD+ (i.e., >200 µM).  In our current studies, we have examined PARP-1 localization 
and effects on transcription at physiological (in vivo) concentrations of nuclear NAD+ 
(estimated in the literature to be ~70 µM; (Zhang, et al., 2002)).  Under these 
conditions, PARP-1 clearly occupies the promoters of active genes, perhaps to exclude 
H1 and allow the binding of RNA Pol II. 
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Figure 2.7. PARP-1 excludes H1 from PARP-1-regulated promoters.  (A) Western 
blot showing the shRNA-mediated depletion of PARP-1 in MCF-7 cells versus control 
luciferase knockdown cells (Luc).  (B and C) Gene-specific analysis of PARP-1, H1, 
and H3 promoter binding by ChIP-qPCR and mRNA expression by RT-qPCR in MCF-
7 cells with or without PARP-1 knockdown.  Expression data are standardized to β-
actin transcripts.  Each bar = mean + SEM, n  3.  
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Figure 2.8. Additional gene-specific analyses showing that PARP-1 excludes H1 
from genes down-regulated by PARP-1 knockdown.  Gene-specific analysis of 
PARP-1 and H1 promoter binding by ChIP-qPCR and mRNA expression by RT-qPCR 
in MCF-7 cells with or without PARP-1 knockdown.  Each bar = mean + SEM, n  3.  
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(2) Outcomes of nucleosome binding by PARP-1 (in vivo versus in vitro) 
 When comparing our current and previous results, one should consider how 
nucleosome binding by PARP-1 is "interpreted" in vivo.  With chromatin templates in 
vitro, most factors that bind to nucleosomes and compact chromatin will repress 
transcription relative to a naked DNA template.  From this view, chromatin compaction 
is a negative regulator of transcription.  In vivo, the binding of PARP-1 to chromatin 
may promote the localized compaction of chromatin, but these structures may be less 
repressive than chromatin bound and compacted by H1.  Thus, by excluding H1, PARP-
1 may have a positive effect on Pol II binding and transcription.  
 
(3) PARP-1 genomic localization on Drosophila polytene chromosomes 
In our previous study, we showed that the immunofluorescent staining patterns 
of PARP-1 and Pol II Ser5-P on Drosophila polytene chromosomes were largely, but 
not completely, distinct (Kim, et al., 2004).  From this initial analysis, we concluded 
that "PARP-1 occupies chromosomal domains that are distinct from transcriptionally 
active loci".  These results, however may have had a higher resolution and revealed 
more information than we initially appreciated.  A more careful analysis of these 
results, especially in the context of our current ChIP-chip results, suggests that we were 
detecting distinct localization patterns for PARP-1 and active RNA Pol II along the 
length of the gene (i.e., PARP-1 just upstream of the TSS and Pol II Ser5-P at the TSS 
and in the body of the gene).  Previous studies have shown that this type of analysis can 
resolve transcription factors bound to DNA elements immediately upstream of the TSS 
and elongating Pol II in the body of the gene (Boehm, et al., 2003, Simon, et al., 1985).  
Thus, PARP-1 and Pol II Ser5-P may not colocalize on Drosophila polytene 
chromosomes, but they can both localize to different regions of the same 
transcriptionally active gene. 
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Figure 2.9. Gene-specific analyses showing that H3 levels at promoters to not 
change upon PARP-1 knockdown.  Gene-specific analysis of PARP-1 and H3 
promoter binding by ChIP-qPCR in MCF-7 cells with or without PARP-1 knockdown.  
Each bar = mean + SEM, n  3.  
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Figure 2.10. Additional gene-specific analyses showing that PARP-1 does not 
exclude H1 from genes up-regulated by PARP-1 knockdown.  Gene-specific 
analysis of PARP-1 and H1 promoter binding by ChIP-qPCR and mRNA expression by 
RT-qPCR in MCF-7 cells with or without PARP-1 knockdown.  Each bar = mean + 
SEM, n  3.  
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Our data fit well with and extend the results of previous biochemical and cell-
based assays showing a role for PARP-1 in the transcription-related regulation of 
chromatin structure (Kim, et al., 2004, Tulin and Spradling, 2003, Wacker, et al., 2007) 
and functional interplay between H1 and PARP-1 (Huletsky, et al., 1989, Ju, et al., 
2006, Kim, et al., 2004).  Further, our results show that although H1 and PARP-1 have 
similar nucleosome-binding properties and effects on chromatin structure in vitro (Kim, 
et al., 2004, Wacker, et al., 2007), they have distinct roles in regulating gene expression 
outcomes in vivo.  Future studies will examine the determinants that direct the specific 
pattern of H1 and PARP-1 binding at promoters, including the role of PARP-1's NAD+-
dependent enzymatic activity.  
 
2.5 Materials and Methods 
Cells lines.  MCF-7 human breast cancer cells were kindly provided by Dr. Benita 
Katzenellenbogen (University of Illinois, Urbana-Champaign).  The cells were 
maintained in MEM supplemented with 5% calf serum and plated for experiments in  
MEM supplemented with 5% charcoal-dextran treated calf serum.  PARP-1-depleted 
MCF-7 cells were generated by retroviral-mediated gene transfer of two short hairpin 
RNA sequences specifically targeting the PARP-1 mRNA using the pSUPER.retro 
system (Oligoengine).  Control cells harboring short hairpin RNA sequences directed 
against luciferase were generated in parallel. 
 
Antibodies.  A custom rabbit polyclonal anti-PARP-1 antibody was generated by using 
an antigen comprising the amino-terminal half of PARP-1 (Kim, et al., 2004).  A mouse 
monoclonal anti-H1 antibody was obtained from Upstate Biotech (05-475).  A rabbit 
polyclonal anti-H3 antibody was obtained from Abcam (ab1791-100).  The antibodies 
were screened for: (1) specificity by Western blotting MCF-7 cell extracts and (2) the 
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ability to immunoprecipitate their cognate antigens from formaldehyde crosslinked 
chromatin samples by a ChIP-Western protocol (Kim, et al., 2004).  The mouse 
monoclonal anti-β-actin antibody used for Western blotting was obtained from Sigma-
Aldrich (A5316). 
 
Primers.   
mRNA expression primers 
β-ACTIN forward 5’-AGCTACGAGCTGCCTGAC-3’ 
β-ACTIN reverse 5’-AAGGTAGTTTCGTGGATGC-3’ 
GDF15 forward 5’-CTACAATCCCATGGTGCTCA-3’ 
GDF15 reverse 5’-TATGCAGTGGCAGTCTTTGG-3’ 
ITPR1 forward 5’- TGCCTCCACAATTCTACG-3’ 
ITPR1 reverse 5’- TGAATGTCCCACAGTTGC-3’ 
NAT1 forward 5’-CTTCACCCTCACCCATAGGA-3’ 
NAT1 reverse 5’-TTTGGGCACAAGCTTTCTCT-3’ 
NELL2 forward 5’-TGAAGGGAACCACCTACC-3’ 
NELL2 reverse 5’-ATTTGCCATCCACATACG-3’ 
NFAT5 forward 5’-ACCTCTTCCAGCCCTACCAT-3’ 
NFAT5 reverse 5’-CCTCTTCGGTGTTGATGGAT-3’ 
SOCS2 forward 5’-ACACGTCAGCACCATCTCTG-3’ 
SOCS2 reverse 5’-TGGCACCGGTACATTTGTTA-3’ 
TMOD3 forward 5’-GGAAGTAGTAATGGTGTTGACC-3’ 
TMOD3 reverse 5’-GCTCATCAAATACCGGAAG-3’ 
PVALB forward 5’-CTGAACGCTGAGGACATC-3’ 
PVALB reverse 5’-TTCACATCATCCGCACTC-3’ 
ABHD2 forward: 5’ - CACCTCTCTGAGCCTGTTCC- 3’ 
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ABHD2 reverse: 5’ - CGCAGATGTTCAGCAATGTT- 3’ 
PARP-1 forward: 5’ - GTGTGGGAAGACCAAAGGAA - 3’ 
PARP-1 reverse: 5’ - TTCAAGAGCTCCCATGTTCA - 3’ 
TMSL8 forward: 5’ - AACCTGCTATGATGGGTGCT - 3’ 
TMSL8 reverse: 5’ - CTGCAAAAGCATGCAACTTC - 3’ 
PFDN1 forward 5’-TGCCTTCTCCCATACATTCC-3’ 
PFDN1 reverse 5’-CAGGATTATGGCGTCCATCT-3’ 
ATXN10 forward - 5’-AAGCACCTTTGTGGATCAG-3’ 
ATXN10 reverse - 5’-ACAGTCATTTCGCACAGG-3’ 
 
 
ChIP primers 
ABHD2 promoter forward: 5’ - GCCTCCACTCTGAGGAACAG - 3’ 
ABHD2 promoter reverse: 5’ - TTGTTCATTGGGCAGTTCAG - 3’ 
GDF15 promoter forward: 5’ - CTCAGATGCTCCTGGTGTTG - 3’ 
GDF15 promoter reverse: 5’ - CTCGGAATCTGGAGTCTTCG - 3’ 
ITPR1 promoter forward: 5’ - GAGCCCTAAGCAGCGTGTAG - 3’ 
ITPR1 promoter reverse: 5’ - CTCTCCAAGAGCTCCGAATG - 3’ 
NELL2 promoter forward: 5’ - TCCCCGGAGGAGCAGTCT - 3’ 
NELL2 promoter reverse: 5’ - CGCCCGAACCTGTTGTAAAG - 3’ 
SCN1A promoter forward: 5’ - ACCCTCCTCTCTCTCCTTGC - 3’ 
SCN1A promoter reverse: 5’ - GGGAGGAGGAGAAATTCGTT - 3’ 
TMSL8 promoter forward: 5’ - CGCGGGAACGCTAACCT - 3’ 
TMSL8 promoter reverse: 5’ - GTCCTCACCTGAAAGCTTGAAGA - 3’ 
NVL promoter forward: 5’ - TGCAACCAAACGGATCAATA - 3’ 
NVL promoter reverse: 5’ - TGAATTAAGTATTAGATTTCCCACTCA - 3’ 
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PTBP2 promoter forward: 5’ - CAATGGCAGAAACAAGAGCA - 3’ 
PTBP2 promoter reverse: 5’ - CACTCAGCATTCCGTCTTGA - 3’ 
STC1 promoter forward: 5’ - AAGCCTGCATTGACACCTCT - 3’ 
STC1 promoter reverse: 5’ - TGCTGACAGTTGGAGGACAG - 3’ 
PEG10 promoter forward: 5’ - AAGGATTAAACGTGCGGTTG - 3’ 
PEG10 promoter reverse: 5’ - GGTGGCGATTACGAGGTTTA - 3’ 
ATXN10 promoter forward: 5’ - GACGCGCCCCTCTTTCTC - 3’ 
ATXN10 promoter reverse: 5’ - TGTGTTGATGTGGCCGTAACA - 3’ 
PFDN1 promoter forward: 5’ - CTGGAAGATACGGAGGAGCA - 3’ 
PFDN1 promoter reverse: 5’ - CTGCGCATGAGTTGGACTAA - 3’ 
PVALB promoter forward: 5’ - GCTCCCCTATCTGCACACTC - 3’ 
PVALB promoter reverse: 5’ - CAAAGGCTGTTTGGAAGCTC - 3’ 
NFAT5 promoter forward: 5’ - ACTTTTGGCTCCACGAACAG - 3’ 
NFAT5 promoter reverse: 5’ - GCAAAGATGGAGGAAGAACG - 3’ 
SOCS2 promoter forward: 5’ - TTCAAGCTTTCGAGCAGTGA - 3’ 
SOCS2 promoter reverse: 5’ - CCCTTAACAATCACGGGAAA - 3’ 
NAT1 promoter forward: 5’ - CCGGCTGAAATAACCTGGTA - 3’ 
NAT1 promoter reverse: 5’ - TATGTGCCAGCCACACTTTC - 3’ 
BRAF promoter forward: 5’ - AGCGCCTTCCTACGTAAACA - 3’ 
BRAF promoter reverse: 5’ - TCAGCCAATCGTGACCTTC - 3’ 
TGFB2 promoter forward: 5’ - ACTTTTGGAACTACTGGCCTTTTC - 3’ 
TGFB2 promoter reverse: 5’ - CAATCTAGTCAATGCCCAACAGAA - 3’ 
TMOD3 promoter forward: 5’ - GGCACACCCTTTTTGTGATT - 3’ 
TMOD3 promoter reverse: 5’ - CAGACAGATCAAACCGGTGA - 3’ 
ITPR1 upstream forward: 5’ - GTGCCACTCTTTTGCTTCAA - 3’ 
ITPR1 upstream reverse: 5’ - GAGGCACCAACGTTAAAAAGA - 3’ 
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NVL upstream forward: 5’ - AATCAGAGGTCCAGGTCAGG - 3’ 
NVL upstream reverse: 5’ - AGACAGCAATCCCATGTGTG - 3’ 
PTBP2 upstream forward: 5’ - TGGCTAGACCACTACAATCTCAA - 3’ 
PTBP2 upstream reverse: 5’ - TGCTCAATTTTCCATAACATCAAA - 3’ 
STC1 upstream forward: 5’ - TTGTCAGCAGCAGAGAGAGC - 3’ 
STC1 upstream reverse: 5’ - CCTGATGAAGCAGCTTAGGG - 3’ 
PEG10 upstream forward: 5’ - TCTTGAACATGTTTACATGATAGCAC - 3’ 
PEG10 upstream reverse: 5’ - CACATAGCAGAAAATGATGTAGCC - 3’ 
ABHD2 upstream forward: 5’ - TGACTCCAAATCCCCTTGTC - 3’ 
ABHD2 upstream reverse: 5’ - CATTGGTAAGCAGGGGAGAG - 3’ 
 
Chromatin immunoprecipitation (ChIP).  ChIP was performed essentially as 
described previously (Kininis, et al., 2007).  Briefly, MCF-7 breast cancer cells were 
grown to ~80 to 90% confluence, cross-linked with 1% paraformaldehyde in PBS for 10 
min. at 37°C, and quenched in 125 mM glycine in PBS for 5 min at 4°C.  The cells 
were collected by centrifugation and sonicated in lysis buffer (1% SDS, 10 mM EDTA, 
50 mM Tris•HCl, pH 7.9, 1x protease inhibitor cocktail) to generate chromatin 
fragments of ~500 bp in length.  The material was clarified by centrifugation, diluted 
10-fold in dilution buffer (0.5% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM 
Tris•HCl, pH 7.9, 1x protease inhibitor cocktail), and pre-cleared with protein A-
agarose beads.  The pre-cleared, chromatin-containing supernatant was used in 
immunoprecipitation reactions with antibodies against PARP-1 or H1, or without 
antibodies as a control.  The immunoprecipitated genomic DNA was cleared of protein 
and residual RNA by digestion with proteinase K and  RNase H, respectively.  The 
DNA was then extracted with phenol:chloroform:isoamyl alcohol and precipitated with 
ethanol.  For gene-specific ChIP analyses, quantitative real-time PCR (qPCR) was used 
  
92 
to determine the enrichment of immunoprecipitated material relative to the input 
material using gene-specific primer sets to the specified regions.   Each ChIP 
experiment was conduced a minimum of three times with independent chromatin 
isolates to ensure reproducibility.  For the ChIP-chip analyses, the immunoprecipitated 
genomic DNA was blunted, amplified by ligation-mediated PCR (LM-PCR), and used 
to probe a custom DNA microarray (Kininis, et al., 2007). 
 
ChIP-chip.  LM-PCR amplified genomic DNA samples were used to probe a custom 
human (HG18) oligonucleotide genomic array from Nimblegen.  The custom array 
contained ~400,000 features (tiling interval of 76 bp for the ~50-mer probes) 
representing 57 Mb of genomic DNA, including all 44 of the ENCODE regions(2004), 
as well as an additional 1117 promoter regions.  In total, the array contained 1517 
annotated RNA polymerase II-transcribed promoters (approximately -25 kb to +5 kb 
relative to the transcription start site for most promoters).  About one quarter of the 
promoters (i.e., 400) were from the ENCODE regions, while the remaining promoters 
(i.e., 1117) were selected based on their regulation in "knockdown-expression 
microarray experiments" by enzymes in the nuclear NAD+ signaling pathway (e.g., 
NMNAT-1, NAMPT, SIRT1, PARG, and PARP-1) (Kim, et al., 2005).  Detailed 
information about the genomic regions tiled on the custom array is included with the 
data submission to NCBI/Gene Expression Omnibus (GEO; see below) or can be 
obtained by contacting the corresponding author.  The PARP-1 and H1 ChIP-chip 
analyses were run a minimum of two times to ensure reproducibility. 
 
Genomic data analyses.  Genomic data analysis was performed using the statistical 
programming language R (R Development Core Team) (Team, 2006).  All data 
processing scripts are available upon request from the corresponding author and the raw 
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data sets can be accessed through NCBI/GEO (series record GSE9417).  The log2 ratio 
data from each of the arrays was subjected to lowess normalization (Smyth and Speed, 
2003).  A single array error model was generated using a 1 kb moving window with 250 
bp steps in which both the mean probe log2 ratio and p-values were calculated for each 
window. The p-values are from a nonparametric Wilcoxon signed-rank test.   
 
• Peak and trough finding.  Significant peaks were defined as the center of 
three consecutive windows with positive means, the center window with a mean greater 
than either adjacent window, and all windows having p-values less than 0.01.  
Significant troughs were defined as the center of three consecutive windows with 
negative means, the center window with a mean less than either adjacent window, and 
all windows having p-values less than 0.01.  The use of these peak/trough selection 
criteria were justified by our high confirmation rate (CR) and low false positive rate 
(FPR) as determined by ChIP-qPCR (PARP-1 peak FPR = 0.11; H1 trough FPR = 
0.08).  The TSS anchored heatmaps used to visualize the ChIP-chip data (Fig. 2.1A) 
were generated with Java Treeview (Saldanha, 2004).  For genes with multiple TSS the 
most 5’ TSS was used. 
 
• Correlation analyses.  Spearman correlations between PARP-1, H1, H3, and 
gene expression (Fig. 2.2A) were determined using the ChIP-chip data for each factor 
from the sliding window centered at -250 bp relative to the TSS, as well as the data 
from three replicates of MCF-7 expression microarray experiments (Affymetrix, 
U133A) for the corresponding genes.  For ChIP-chip to ChIP-chip correlations, 1512 
total genes were used.  For ChIP-chip to expression correlations, 1284 total genes were 
used.  To determine the correlation between PARP-1 and H1 at PARP-1-regulated 
genes only, 108 total genes were used.  These genes had a p value < 0.05, a fold change 
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greater or less then 0.5 or -0.5, respectively, and were flagged present or marginal in 
two out of the three replicates for both PARP-1 knockdown and control cell lines. 
 
• Averaging analyses.  The ChIP/input ratios for each window of ChIP-chip 
data over the 30 kb tiled region (or other specified region) was averaged for all 1517 
promoters on the array (or specified subset of promoters).  The maximum signal from 
the PARP-1 peak average analysis is centered at -250 bp relative to the TSS, whereas 
the minimum signal from the H1 trough average analysis is centered at -750 bp relative 
to the TSS.  The minimum signal from the H3 trough average analysis is centered at 
+500 bp relative to the TSS. 
 
• Peak/trough to TSS distances.  The distance of each peak and trough to the 
closest TSS (e.g., Fig. 2.1B) was determined using RefSeq gene annotations from the 
UCSC genome browser.  A chi squared test was used to determine the significance of 
the patterns observed in the peak and trough histograms, comparing the peak and trough 
data to the background pattern obtained by determining the distance of all windows to 
the closest transcription start site. 
 
• Expression-based categorization of genes.  For the expression-based 
categorization (Fig. 2.2B), three replicates of MCF-7 expression microarray data 
(Affymetrix, U133A) were used to categorize the genes represented on the ChIP-chip 
array as unambiguously expressed or unexpressed.  For a gene on the ChIP-chip array 
to be marked as unambiguously expressed or unexpressed, all probe sets from all three 
replicates corresponding to the gene must have been flagged unanimously present or 
absent, respectively.  Any genes on the array not meeting these criteria were marked as 
ambiguous and were removed from the expression based categorization analysis. 
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• ChIP-chip-based categorization of genes.  For the ChIP-chip-based 
categorization (Fig. 2.6C), genes on the array were placed into one of 4 categories based 
on two criteria: (1) the presence (p < 0.01) or absence (p > 0.1) of a significant PARP 
peak centered within 1500 bp of the TSS and (2) the presence (p  0.01) or absence (p > 
0.1) of a significant H1 trough within 1500 bp of the TSS.  Peaks and troughs identified 
at p-values between 0.01 and 0.1 were labeled as ambiguous due to increased false 
positive and false negative rates.  Genes containing only ambiguous peaks or troughs 
were not included in the categorization.  The significance of the distribution of 
expressed and unexpressed genes within each category compared to all genes with 
expression information on the ChIP-chip array was assessed using a chi squared test. 
 
• Nucleosome mapping by MNase protection.  MNase protection information 
from a previously published genomic analysis of nucleosome positioning at 3,692 
promoters (-1500 to +500) in MCF-7 cells (Ozsolak, et al., 2007) was meta-analyzed 
and matched to the significant PARP-1 peaks from our ChIP-chip analysis (Fig. 2.5).  
The log2 MNase (digested/input) and PARP-1 (IP/input) signals for the overlapping 
gene set (121 genes) were averaged across the promoter regions.  Regions of significant 
MNase protection were determined by applying a one-tailed t-test to comparisons 
between adjacent peaks and troughs through the region. 
 
Gene-specific expression analyses.  Luciferase knockdown and PARP-1 knockdown 
MCF-7 cells were seeded at ~1.5 x 105 cells per well in 6-well plates and grown for at 
least 3 days in the conditions noted above.  The cells were collected at about 80 percent 
confluence, and total RNA was isolated using Trizol Reagent (Invitrogen) according to 
the manufacturer's protocols.  The total RNA was reverse transcribed and subjected to 
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real-time quantitative PCR using gene-specific primers.  All target gene transcripts were 
normalized to the β-actin transcript.  Each experiment was conduced a minimum of 
three times with independent isolates of total RNA to ensure reproducibility.  
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CHAPTER 3 
 
 
 
PARP-1 Regulates Chromatin Structure and Transcription  
Through a KDM5B-Dependent Pathway 
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3.1 Summary 
 
Poly(ADP-ribose) polymerase-1 (PARP-1) is a ubiquitous and abundant 
nuclear enzyme that regulates chromatin structure to control gene expression, although 
the detailed molecular mechanisms of this regulation are unclear.  In this study, I 
examined the functional interplay between PARP-1, histone 3 lysine 4 trimethylation 
(H3K4me3), and the linker histone H1 in the chromatin-dependent control of gene 
expression.  I find that PARP-1 is required for a series of molecular outcomes at the 
promoters of target genes whose expression is dependent on PARP-1.  Specifically, I 
show that PARP-1 establishes a permissive chromatin environment at the promoters of 
these genes by promoting (1) the trimethylation of H3K4 through the poly(ADP-
ribosyl)ation and exclusion of KDM5B, an H3K4me3 demethylase, (2) the exclusion 
of H1, and (3) increased accessibility of the promoter DNA at the TSS.  Upon 
depletion of PARP-1, these outcomes do not occur efficiently.  The permissive 
chromatin environment is required for the loading of the Pol II transcription 
machinery (e.g., Pol II, TBP, TFIIB) and subsequent transcription.  I also find that 
some cellular signaling pathways use the regulated depletion of PARP-1 from 
promoters to modulate these molecular outcomes, including gene expression.  
Collectively, my results assign new functions for PARP-1 in the regulation of 
chromatin structure and transcription.  More broadly, my results help to clarify the 
molecular mechanisms by which specific chromatin-binding and histone-modifying 
proteins interact to alter chromatin structure and function to regulate gene transcription. 
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3.2 Introduction 
 
Chromatin, a repeating array of nucleosomes and nucleosome-binding proteins, 
is the physiological template for nuclear processes involving genomic DNA.  It plays 
key roles in the regulation of gene transcription by limiting the loading of the RNA 
polymerase II (Pol II) machinery at gene promoters, the initiation of transcription from 
transcription start sites (TSSs), and the elongation of transcripts through the bodies of 
genes (Li et al., 2007; Morse, 2003).  Several properties of chromatin contribute to its 
gene-regulating effects, including its composition (e.g., types and extent of histones 
modifications, repertoire of nucleosome-bound proteins) and structure (e.g., rotational 
and translational positioning of nucleosomes, spacing of nucleosomes) (Li et al., 2007; 
Morse, 2003).  Under many conditions, the former can modulate the latter.  Although 
great strides have been made in understanding the molecular mechanisms that underlie 
chromatin-dependent transcriptional regulation, many fundamental questions remain.  
For example, the molecular mechanisms by which specific chromatin-binding and 
histone-modifying proteins interact to alter chromatin structure and function to 
regulate gene transcription require further analysis. 
Nucleosome-binding architectural proteins, such as poly(ADP-ribose) 
polymerase-1 (PARP-1) and the linker histone H1, promote structural alterations in 
chromatin and, as a consequence, modulate transcriptional responses (Kraus, 2008; 
Kraus and Lis, 2003; McBryant et al., 2006; Woodcock et al., 2006).  Both PARP-1 
and H1 bind at or near the dyad axis of the nucleosome and contact the linker DNA as 
it exits the nucleosome (Happel and Doenecke, 2009; Kim et al., 2004; Vignali and 
Workman, 1998).  They are also both able to alter nucleosome spacing and promote 
the compaction of nucleosomal arrays (Kim et al., 2004; Robinson and Rhodes, 2006; 
Wacker et al., 2007; Woodcock et al., 2006).  In the case of PARP-1, this may occur 
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through a localized mechanism that brings together adjacent nucleosomes (Wacker et 
al., 2007).  Although PARP-1 and H1 elicit grossly similar alterations in chromatin 
structure in vitro (Kim et al., 2004; Wacker et al., 2007), their effects on chromatin 
structure may be interpreted differently in vivo (Kraus, 2008).  I have shown that 
PARP-1 and H1 compete for binding to nucleosomes (Kim et al., 2004) and exhibit a 
reciprocal pattern of binding at actively transcribed promoters: H1 is depleted and 
PARP-1 is enriched (Krishnakumar et al., 2008).  Both PARP-1 and H1 are widely 
distributed across the genome (Braunschweig et al., 2009; Kim et al., 2004; 
Krishnakumar et al., 2008; Tulin and Spradling, 2003) and their depletion can promote 
large scale alterations in chromatin structure (Fan et al., 2005; Lu et al., 2009; Petesch 
and Lis, 2008; Tulin and Spradling, 2003; Tulin et al., 2002), but their effects on 
transcription are limited to a subset of specific target genes (Fan et al., 2005; Frizzell 
et al., 2009; Lu et al., 2009).  
Unlike H1, PARP-1 possesses an intrinsic enzymatic activity that catalyzes the 
polymerization of ADP-ribose units from donor NAD+ molecules on target proteins 
(Kim et al., 2005).  Although PARP-1 is the major target for PARP-1-mediated 
poly(ADP-ribosyl)ation (PARylation) in vivo through an automodification reaction, a 
number of other targets have been also described, including core histones, H1, and a 
variety of nuclear proteins involved in gene regulation (Kim et al., 2005; Kraus, 2008; 
Kraus and Lis, 2003).  PARylation of protein targets by PARP-1 alters their function, 
typically in an inhibitory manner (Ju et al., 2006; Ju et al., 2004; Kim et al., 2005; 
Kraus, 2008; Kraus and Lis, 2003).  For example, extensive PARylation of PARP-1 
can inhibit its ability to bind nucleosomes (Kim et al., 2004; Wacker et al., 2007), 
while more modest PARylation of components of the TLE1 corepressor complex can 
promote its dissociation from target gene promoters (Ju et al., 2004).  Although 
PARP-1 enzymatic activity has been shown to play a key role in the regulation of 
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transcription in some contexts (Cohen-Armon et al., 2007; Ju et al., 2006; Ju et al., 
2004; Kraus, 2008; Kraus and Lis, 2003), in others it is dispensable (Hassa and 
Hottiger, 2002; Pavri et al., 2005).  A clear consensus about the targets and role(s) of 
PARP-1 enzymatic activity during transcription has yet to emerge.  
In addition to nucleosome-binding proteins, covalent posttranslational 
modifications of the amino-terminal tails of histone proteins, such as acetylation, 
phosphorylation, and methylation, can affect chromatin structure and function.  These 
modifications can alter the charge of the histone tails and promote structural changes 
in nucleosomes, as well as create or destroy binding sites for chromatin-regulating 
proteins (Berger, 2007; Campos and Reinberg, 2009).  Different histone modifications 
‘mark’ different functional regions of chromatin.  For example, histone H3 lysine 4 
trimethylation (H3K4me3) is enriched at TSSs and positively correlates with gene 
expression (Barski et al., 2007; Bernstein et al., 2005; Guenther et al., 2007; Santos-
Rosa et al., 2002; Schneider et al., 2004).  This modification creates a binding site for 
structural modules within a variety of proteins that regulate chromatin structure and 
transcription (Ruthenburg et al., 2007), including the PHD fingers of BPTF, TAF3, 
and ING family members (Li et al., 2006; Pena et al., 2006; Shi et al., 2006; Taverna 
et al., 2006; van Ingen et al., 2008; Vermeulen et al., 2007; Wysocka et al., 2006), the 
tandem chromodomains of CHD1 (Flanagan et al., 2005; Sims et al., 2005), and the 
double tudor domain of JMJD2A/KDM4A (Huang et al., 2006).  The recruitment of 
these factors in response to H3K4 trimethylation alters chromatin structure and 
transcription.  Enzymes that remove the H3K4me3 mark, such as the KDM5 family of 
lysine-specific demethylases (e.g., KDM5B, a.k.a. JARID1B and PLU1), can reverse 
the actions of the proteins that bind the mark (Allis et al., 2007; Ruthenburg et al., 
2007; Yamane et al., 2007). 
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Although recent studies have linked PARP-1 to the regulation of DNA 
methylation and histone acetylation (Caiafa et al., 2009; Cohen-Armon et al., 2007), a 
clear understanding of how the chromatin-modulating effects of PARP-1 are 
coordinated with various covalent modifications to control transcriptional outcomes is 
lacking.  In the present study, I have examined the mechanisms by which PARP-1 
maintains an active chromatin environment at the promoters of target genes by 
exploring the sequence of events following depletion of PARP-1 that lead to 
transcriptional repression.  At the promoters of positively regulated target genes, 
PARP-1 depletion leads to an increase in the binding of H1, a decrease in the levels of 
H3K4me3, a reduction in chromatin accessibility at the TSS, and a decrease in the 
binding of the Pol II machinery.  The decreased levels of H3K4me3 are driven by the 
recruitment of the lysine-specific demethylase KDM5B.  My data indicate that PARP-
1 PARylates KDM5B, which in turn inhibits KDM5B binding at promoters and 
prevents demethylation of H3K4me3.  Interestingly, signaling pathways use a strategy 
analogous to PARP-1 knockdown to repress gene expression, which involves 
dismissal of PARP-1 from the promoter, an increase in the binding of H1 and KDM5B, 
a decrease in the levels of H3K4me3, and a decrease in the binding of the Pol II 
machinery.  Collectively, my results elucidate a new pathway for chromatin-dependent 
gene regulation by PARP-1 involving histone methylation.  These results demonstrate 
a mechanism by which the chromatin-modulating effects of PARP-1 are coordinated 
with a histone modification to regulate transcription. 
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Table 3.1.  Genes whose regulation was examined in this study. 
 
 
a From GeneCards®, a searchable, integrated database of human genes that provides 
concise genomic, proteomic, transcriptomic, genetic and functional information on 
all known and predicted human genes.  http://www.genecards.org/index.shtml 
b Based on the GeneCards® description.  
 
 
 
 
 
Gene 
Symbol 
 
Gene Name 
GeneCards® 
Accession No.a 
 
Protein Functionb 
Regulation by 
PARP-1 
ABHD2 Alpha/beta hydrolase 
domain containing 
protein 2  
GC15P087432 Contains an alpha/beta hydrolase fold, 
which is found in a very wide range of 
enzymes.  Function unknown. 
Not regulated 
GDF15 Growth and 
differentiation  
factor 15 
GC19P018358 Member of the transforming growth 
factor β superfamily.  Regulates tissue 
differentiation and maintenance.  
Negatively 
regulated 
TMSL8 Thymosin-like protein 8 GC0XM101657 By homology, is thought to play a role 
in the organization of the cytoskeleton 
by binding to and sequestering actin 
monomers, thereby inhibiting actin 
polymerization 
Positively 
regulated 
SCN1A Sodium channel protein 
type I  
subunit alpha 
GC02M166553 Ion channel that mediates the voltage-
dependent sodium ion permeability of 
excitable membranes 
Positively 
regulated 
NELL2 Neural epidermal 
growth factor-like 2 
GC12M043188 A glycoprotein containing several  
epidermal growth factor (EGF)-like 
domains.  Acts to control cell growth 
and differentiation, as well 
oncogenesis. 
Positively 
regulated 
ITPR1 Inositol 1,4,5-
triphosphate  
receptor, type 1  
GC03P004486 Intracellular channel that mediates 
calcium release from the endoplasmic 
reticulum following stimulation by 
inositol 1,4,5-trisphosphate 
Positively 
regulated 
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Figure 3.1.  PARP-1 promotes the binding of RNA Pol II and components of the 
basal transcription machinery to the promoters of positively regulated target 
genes.   
(A) Western blot showing shRNA-mediated knockdown of PARP-1 with β-actin as an 
internal standard. 
(B) Analysis of mRNA expression for six genes by RT-qPCR in MCF-7 cells with 
PARP-1 knockdown.  The data are normalized to the β-actin transcript and expressed 
relative to control (Luc) knockdown cells.  Each bar represents the mean plus the SEM, 
n  3.  The differences observed for all genes except ABHD2 are significant (Student’s 
t-test, p  0.05). 
 (C - H) ChIP-qPCR analyses of factor or histone levels at the promoters of the PARP-
1 target genes from panel A in control (Luc) and PARP-1 knockdown (KD) cells.  
Each bar represents the mean plus the SEM, n  3.  The differences observed for the 
positively regulated genes (i.e., TMSL8, SCN1A, NELL2, ITPR1) are significant for 
panels C - G.  The differences observed for the negatively regulated gene (i.e., 
GDF15) are significant for panels C, F, and G (Student’s t-test, p  0.05). 
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3.3 Results 
 
PARP-1 promotes the binding of RNA Pol II and components of the basal 
transcription machinery to the promoters of positively regulated target genes 
 To better understand how PARP-1 modulates chromatin structure as a means 
of regulating gene expression, I conducted a series of molecular assays using MCF-7 
human breast cancer cells.  Given the growing interest in the role of PARP-1 in breast 
cancer biology (Drew and Plummer, 2009; Frizzell and Kraus, 2009), as well as the 
considerable gene-specific and genomic data available regarding PARP-1 localization 
and function in MCF-7 cells (Kim et al., 2005; Kraus, 2008), this is an excellent model 
system to use.  I used shRNA-mediated knockdown to explore PARP-1 function in 
these cells.  As described previously (Frizzell et al., 2009; Krishnakumar et al., 2008), 
I see a robust knockdown of PARP-1 in this system compared to a control knockdown 
(luciferase; Luc) (Fig. 3.1A).  I focused my studies on a set of previously characterized 
genes (i.e., TMSL8, SCN1A, NELL2, ITPR1; (Frizzell et al., 2009; Krishnakumar et al., 
2008) whose efficient expression requires PARP-1 (Fig. 3.1B; “positively regulated” 
genes - i.e., expression decreases by > 50 percent upon PARP-1 knockdown).  Genes 
in this set function in signaling, oncogenesis, and cell mobility (Supplemental Table 
S1).  For comparison, I also examined genes whose expression is inhibited by PARP-1 
(e.g., GDF15; “negatively regulated” - i.e., expression increases > 2-fold upon PARP-
1 knockdown) or is unaffected by PARP-1 (i.e., ABHD2; “unregulated”) (Fig. 3.1B; 
Table 3.1).  Note that terms “positively regulated”, “negatively regulated”, and 
“unregulated” are used here as a shorthand for the functional outcomes and do not 
imply specific mechanisms, although such mechanisms are revealed in the 
experiments described below.  
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 In my initial studies, I examined the effects of PARP-1 depletion on the 
binding of the linker histone H1 and components of the Pol II transcription machinery 
at the promoters of these genes by using chromatin immunoprecipitation (ChIP) assays.  
As expected, knockdown of PARP-1 caused a dramatic reduction in PARP-1 ChIP 
signal for all genes tested (Fig. 3.1C).  I have shown previously that H1 competes with 
PARP-1 for binding to promoter-proximal nucleosomes and represses gene 
transcription by Pol II (Kim et al., 2004; Krishnakumar et al., 2008).  For the genes 
positively regulated by PARP-1, knockdown of PARP-1 caused an increase in H1 
binding at the promoter (Fig. 3.1D) without a change in nucleosome density (as 
determined by histone H3 levels; Fig. 3.1H).  This was accompanied by a significant 
reduction (>60%) in the promoter occupancy of TBP, TFIIB, and Pol II for all four 
genes in this group (Fig. 3.1, E – G).  Opposite effects were observed for the 
negatively regulated gene GDF15 (i.e., the increase in gene expression upon PARP-1 
knockdown was accompanied by a significant increase in the binding of TBP, TFIIB, 
and Pol II; Fig 3.1, E - G).  As expected, ABHD2, a gene whose expression is not 
affected by PARP-1, showed no changes in these parameters upon PARP-1 
knockdown (Fig 3.1, E - G).  Taken together, these results indicate that PARP-1 
modulates the occupancy of H1, TBP, TFIIB, and Pol II at target promoters to control 
gene expression.  
 
PARP-1 maintains an open chromatin architecture at the TSSs of positively 
regulated target genes 
Previous studies have shown that PARP-1 can regulate chromatin structure, 
nucleosome compaction, and the accessibility of DNA in chromatin (Kim et al., 2004; 
Kraus, 2008; Kraus and Lis, 2003).  Based on these results, as well as the data 
presented in Fig. 3.1, I hypothesized that PARP-1 might act to maintain an open 
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chromatin architecture at the promoters of positively regulated target genes.  To test 
this hypothesis, I examined the accessibility of promoter DNA surrounding the 
transcription start sites (TSSs; ca. -300 to +300 bp) to digestion by micrococcal 
nuclease (MNase).  Mononucleosome-sized genomic DNA fragments (~160 bp; Fig. 
3.2A) were released by MNase digestion from chromatin isolated from control and 
PARP-1 knockdown MCF-7 cells.  I then used quantitative real-time PCR (qPCR) to 
tile through the promoter region with overlapping amplicons (21 amplicons for ~600 
bp, ~30 bp overlap; Fig. 3.2B) to determine the extent of MNase digestion.  As 
expected, for all genes I observed regions of increased MNase protection on either 
side of the TSS, likely due to -1 and +1 nucleosomes (Ozsolak et al., 2007; Schones et 
al., 2008) (Fig. 3.2C).  In addition, I observed a dip in protection at or near the TSS, as 
described previously (Krishnakumar et al., 2008; Ozsolak et al., 2007; Schones et al., 
2008).  Knockdown of PARP-1 caused a significant increase in the MNase protection 
(i.e., decreased accessibility or a closed chromatin architecture) at or near the TSS for 
the positively regulated genes relative to the control knockdown (Fig. 3.2C; TMSL8, 
SCN1A, NELL2, ITPR1).  This effect was not observed for GDF15 or ABHD2 (Fig. 
3.2C).  Together, the results from Figs. 3.1 and 3.2 are consistent with a model in 
which PARP-1 acts to maintain an open chromatin structure at the promoters of 
positively regulated target genes to allow loading of the transcriptional machinery and 
subsequent transcription by Pol II.  
 
PARP-1 binding correlates with histone H3 lysine 4 trimethylation at many 
promoters across the genome 
How might PARP-1 regulate promoter chromatin architecture?  I considered the 
possibility of a mechanism involving histone modifications, which have been shown  
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Figure 3.2. PARP-1 maintains an open chromatin architecture at the TSSs of 
positively regulated target genes.   
MNase protection experiments in control (Luc) and PARP-1 knockdown (KD) MCF-7 
cells.  qPCR with overlapping amplicons (see Fig. 3.2B) was used to determine the 
enrichment of MNase digested DNA relative to sonicated genomic DNA ("relative 
protection") at specific genomic locations spanning from -300 to +300 bp relative to 
the TSS for each gene indicated.  Each point represents the mean ± the SEM, n  3.  
The shaded region indicates statistically significant differences between the Luc and 
PARP-1 knockdown conditions (Student’s T-test, p  0.05).  
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Figure 3.3.  PARP-1 binding correlates with histone H3 lysine 4 trimetylation at 
promoters across the genome. 
ChIP-chip analysis of PARP-1, H3K4me3, and H3 at ~23,500 promoters (-3 kb to +3 
kb). 
(A) Heatmaps showing a visual representation of the ChIP-chip data. 
(B) Average PARP-1, H3K4me3, and H3 ChIP-chip signals across promoters either 
containing or lacking a peak of PARP-1.  
(C) Multiple correlation analysis for PARP-1, H3K4me3, and H3 ChIP-chip signals at 
the TSS.  The Spearman correlation coefficients and the p-value are shown. 
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in many contexts to be correlated with specific chromatin states (Berger, 2007; 
Campos and Reinberg, 2009).  I focused on histone H3 lysine 4 trimethylation 
(H3K4me3), which localizes to promoters and positively correlates with gene 
expression (Barski et al., 2007; Bernstein et al., 2005; Guenther et al., 2007; Santos-
Rosa et al., 2002; Schneider et al., 2004), much like PARP-1 (Krishnakumar et al., 
2008).  I used ChIP coupled with hybridization to RefSeq promoter arrays (i.e., ChIP-
chip) to determine if the binding of PARP-1 to promoters might correlate with 
H3K4me3 at promoters across the genome.  Indeed, the striking pattern of PARP-1 
promoter localization that I have observed previously (Krishnakumar et al., 2008) was 
similar to the pattern of H3K4me3 (Fig. 3.3, A and B).  I found statistically significant 
peaks of both PARP-1 and H3K4me3 at or near the TSSs of about one third of the 
~23,500 promoters on the array using stringent peak finding criteria (Fig. 3.3; see 
Experimental Procedures).  PARP-1 and H3K4me3 showed a positive correlation 
(Spearman’s correlation coefficient 0.60, p < 2.2 x 10-16), and both were positively 
correlated with gene expression (Spearman’s correlation coefficients of 0.42 and 0.50, 
respectively, p < 2.2 x 10-16 for both) (Fig. 3.3C).  The strong correlation of PARP-1 
and H3K4me3 suggests a functional link between the two.  I explored this possibility 
in the experiments noted below. 
 
PARP-1 prevents KDM5B-dependent demethylation of H3K4me3 at the 
promoters of positively regulated target genes 
To determine if PARP-1 might play an active role in establishing or 
maintaining H3K4me3 at target gene promoters, I examined the effect of PARP-1 
knockdown on H3K4me3 levels.  For the positively regulated genes, H3K4me3 levels 
decreased by more than 65 percent upon PARP-1 knockdown (Fig. 3.5A).  For the 
negatively regulated gene, GDF15, the opposite effect was observed, and for the  
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Figure 3.4.  KDM5B is the most highly expressed KDM5 isoform in MCF-7 cells. 
Average signal intensity for KDM5 isoforms from Affymetrix expression arrays 
hybridized with probes derived from MCF-7 cell total RNA.  The Affymetrix data are 
from the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/), 
accession numbers GSM234903, GSM234904, and GSM234905.  For each KDM5 
isoform, the signal intensities from all probes for one replicate were averaged and then 
all three replicates were averaged.  Standard error of the mean was calculated from the 
three replicate values.   
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unegulated gene, ABHD2, no effect was observed (Fig. 3.5).  These results correlate 
well with the effects of PARP-1 knockdown on Pol II, TBP, and TFIIB binding noted 
above (Fig. 3.1).  Interestingly, TAF3 (a subunit of the TBP-containing complex 
TFIID) has been shown to bind to H3K4me3 (Vermeulen et al., 2007).  Thus, the 
PARP-1-dependent reduction in H3K4me3 may reduce TBP binding, leading to a 
reduction in Pol II occupancy at the promoter, as previously shown (Vermeulen et al., 
2007).   
I considered the possibility that PARP-1 might regulate promoter H3K4me3 
levels by recruiting a histone methyltransferase or by blocking the recruitment of a 
histone demethylase.  A number of methyltransferases in the TRX/MLL family can 
trimethylate H3K4 in mammalian cells (Berger, 2007), while the KDM5 demethylases 
(A – D) are the only enzymes known to remove the modification (Nottke et al., 2009; 
Ruthenburg et al., 2007).  Of the four KDM5 isoforms, KDM5B (lysine demethylase 
5B; a.k.a. PLU-1 or JARID1B) is the most highly expressed in MCF-7 cells (Fig. 3.4). 
Thus, in my studies of PARP-1 function in MCF-7 cells, I focused on KDM5B.  
Knockdown of PARP-1 affected KDM5B binding at the promoters of the six genes 
tested in a predictable manner that precisely matched the effects on H3K4me3 levels 
(Fig. 3.5B).  For example, PARP-1 knockdown increased KDM5B levels and 
decreased H3K4me3 levels at the promoters of the positively regulated genes, but not 
the negatively regulated or unregulated genes.  These results suggest that PARP-1 
prevents demethylation of H3K4me3 by KDM5B at the promoters of positively 
regulated target genes.  
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Figure 3.5.  PARP-1 prevents demethylation of H3K4me3 at the promoters of 
positively regulated target genes by PARylating KDM5B and blocking its 
recruitment. 
(A - D) ChIP-qPCR analysis of H3K4me3 and KDM5B levels at target gene 
promoters in control (Luc) and PARP-1 knockdown (KD) MCF-7 cells in the absence 
(panels A and B) or presence (panels C and D) of 5 µM PJ34 for 1.5 hours before 
collection.  Each bar represents the mean plus the SEM, n  3.  The differences 
observed for TMSL8, SCN1A, NELL2, ITPR1 are significant for panels C - G.  The 
differences observed for GDF15 are significant for panels A and B (Student’s t-test, p 
 0.05). 
(E and F) PARP-1 binds to and PARylates KDM5B in MCF-7 cells in the absence, 
but not the presence, of 5 µM PJ34 for 1.5 hours before collection (panel E), and in 
control knockdown (Luc), but not PARP-1 knockdown, cells (panel F).  KDM5B was 
immunoprecipitated (IP) from nuclear extracts and the immunoprecipitated material 
was subjected to Western blotting (WB) using antibodies to KDM5B, PARP-1, and 
PAR.  C, non-specific control antibody; K, KDM5B antibody; In, input. 
 
 
 
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WB / IP
A B
0
0.2
0.4
0.1
0.3
0 0
4
8
2
6
5
25
10
15
20
0
0.12
0.18
Pe
rc
en
t I
np
ut
  (
AB
HD
2)
KDM5B ChIP
0
20
40
10
30
0
2
10
4
6
8
Pe
rc
en
t I
np
ut
(A
BH
D2
, T
M
SL
8,
 IT
PR
1)
H3K4me3 ChIP
AB
HD
2
GD
F1
5
TM
SL
8
SC
N1
A
NE
LL
2
ITP
R1
AB
HD
2
GD
F1
5
TM
SL
8
SC
N1
A
NE
LL
2
ITP
R1
Percent Input (all others)
H3K4me3 ChIP Percent Input (all others) Pe
rc
en
t I
np
ut
  (
AB
HD
2)
KDM5B ChIP
AB
HD
2
0.06
Pe
rc
en
t I
np
ut
(A
BH
D2
, T
M
SL
8,
 IT
PR
1)
GD
F1
5
TM
SL
8
SC
N1
A
NE
LL
2
ITP
R1
AB
HD
2
GD
F1
5
TM
SL
8
SC
N1
A
NE
LL
2
ITP
R1
C D
Luc KD
PARP-1 KD
Control
PJ34
K
Control
C In
PJ34
E
PAR
KDM5B
In
Control
In
PARP-1 KD
F
PARP-1
KC KC KCIn
KDM5B
WB / IP
PAR
PARP-1
120 
 
 
 
 
 
 
 
 
Figure 3.6. The PARP-1 inhibitor PJ34 has little or no effect on some PARP-1-
dependent molecular outcomes. 
(A) Analysis of mRNA expression for six genes by RT-qPCR in MCF-7 cells treated 
with or without 5 µM PJ34 for 1.5 hours before collection.  The data are normalized to 
the β-actin transcript and expressed relative to untreated cells.  Each bar represents the 
mean plus the SEM, n  3.  None of the differences are significant (Student’s t-test, p 
 0.05). 
(B - F) ChIP-qPCR analyses of factor or histone levels at the promoters of the PARP-1 
target genes from panel A in MCF-7 cells treated with or without 5 µM PJ34 for 1.5 
hours before collection.  Each bar represents the mean plus the SEM, n  3. None of 
the differences are significant (Student’s t-test, p  0.05). 
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PARP-1 catalytic activity is required to prevent the binding of KDM5B at the 
promoters of positively regulated target genes 
PARP-1 is an enzyme that catalyzes the addition of poly(ADP ribose) (PAR) 
chains on acceptor proteins using NAD+ as a donor of ADP-ribose (Kim et al., 2005).  
Previous studies from our lab and others have shown that PARP-1 catalytic activity is 
required for the PARP-1-dependent expression of some, but not all, target genes 
(Frizzell et al., 2009; Hassa and Hottiger, 2002; Ju et al., 2006; Kim et al., 2005; Kraus, 
2008; Kraus and Lis, 2003; Pavri et al., 2005).  In some cases, PARP-1 catalytic 
activity may be required for one or more steps in the gene regulatory pathway, while 
the PARP-1 protein itself may be required for other steps.  To test this possibility, I 
determined the effects of the PARP inhibitor, PJ34, on the same target genes and 
functional endpoints that I examined above.  Our lab has shown previously that PJ34 
effectively inhibits PARP-1 enzymatic activity in MCF-7 cells (Frizzell et al., 2009).  
Interestingly, PJ34 had no effect on gene expression or the binding of PARP-1, H1, or 
Pol II at the promoters of the genes examined (Fig. 3.6).  These results indicate that, 
unlike depletion of PARP-1 protein, inhibition of PARP-1 catalytic activity is not 
sufficient to inhibit the expression of the positively regulated genes, suggesting that 
the physical presence of the PARP-1 protein at the promoter is key for maintaining 
gene expression.  However, PJ34 did reduce the levels of H3K4me3 and increase the 
levels of KDM5B at the same promoters (Fig. 3.5, C and D).  Thus, of the various 
endpoints examined, PARP-1 catalytic activity specifically targets H3K4 
trimethylation by KDM5B. 
Based on these results, I hypothesized that PARP-1 might interact with and 
poly(ADP-ribosyl)ate (PARylate) KDM5B in cells, thus preventing KDM5B from 
binding to promoters.  To test this, I immunoprecipitated KDM5B from MCF-7 
nuclear extracts and subjected the immunoprecipitated material to Western blotting  
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Figure 3.7.  Generation and confirmation of PARP-1/KDM5B double knockdown 
cells.   
Retrovirus-mediated gene transfer was used to generate MCF-7 cells with stable 
knockdown (KD) of PARP-1 + Luc (PL), KDM5B + Luc (KL), or PARP-1 + KDM5B 
(PK), matched with an appropriate control cell line expressing two shRNAs targeting 
luciferase (LL). 
(A) Western blot of nuclear extracts showing the depletion of PARP-1 and KDM5B in 
the knockdown cell lines noted above.  Also shown are Western blots for H3K4me3 
and H3.   
(B and C) RT-qPCR analysis of PARP-1 (panel B) and KDM5B (panel C) mRNA 
expression in the knockdown cell lines noted above.  Each bar represents the mean 
plus the SEM, n  3.  All knockdown effects are significant (ANOVA, p  0.05). 
(D) ChIP-qPCR analysis in MCF-7 Luc and KDM5B knockdown cells showing that 
KDM5B knockdown reduces the corresponding ChIP signal at the promoters of two 
target genes, ABHD2 and GDF15.  Each bar represents the mean plus the SEM, n  3.  
The observed effects of knockdown are significant (Student’s t-test, p  0.05).  
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using antibodies to KDM5B, PARP-1, and PAR.  I found that KDM5B 
immunoprecipitates PARP-1 and is modified by PARylation (Fig 3.5E).  Treatment of  
the cells with PJ34 (Fig. 3.5E) and knockdown of PARP-1 (Fig. 3.5F) inhibited 
KDM5B PARylation, indicating that PARP-1 is the enzyme mediating the 
modification.  Taken together, these results indicate that PARP-1 acts to promote 
H3K4 trimethylation at the promoters of positively regulated target genes by 
PARylating KDM5B, which blocks its recruitment. 
 
Antagonism of KDM5B-dependent H3K4me3 demethylation by PARP-1 
facilitates the expression of positively regulated target genes 
To further explore the role of PARP-1-dependent antagonism of KDM5B in 
target gene expression, I examined the effects of KDM5B knockdown using a 
previously reported shRNA sequence (Scibetta et al., 2007).  According to my model, 
a key role of PARP-1 is to prevent KDM5B-dependent demethylation of H3K4me3; 
shRNA-mediated knockdown of PARP-1 allows demethylation of H3K4me3 and 
subsequent inhibition of transcription of the positively regulated genes.  If this model 
is correct, then depletion of KDM5B should reverse the effects of PARP-1 knockdown.  
To test this model, I generated a set of cell lines with knockdown of PARP-1 + Luc 
(PL), KDM5B + Luc (KL), or PARP-1 + KDM5B (PK), matched with an appropriate 
control cell line expressing two shRNAs targeting luciferase (LL).  I confirmed the 
knockdown of PARP-1 and KDM5B by Western blotting and RT-qPCR (Fig. 3.7, A - 
C).  In addition, I showed that knockdown of KDM5B reduced its signal in ChIP 
assays (Fig. 3.7D).  Although KDM5B knockdown alone had little effect on the 
expression of positively regulated target genes, it reversed the effect of PARP-1 
knockdown (Fig. 3.8A).  In contrast, for the negatively regulated gene, GDF15, 
knockdown of KDM5B did not reverse the effect of PARP-1 knockdown, suggesting a  
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Figure 3.8.  Antagonism of KDM5B-dependent H3K4me3 demethylation by 
PARP-1 promotes a transcriptionally permissive environment at the promoters 
of positively regulated target genes. 
The experiments in this figure used MCF-7 cells with knockdown of PARP-1 + Luc 
(PL), KDM5B + Luc (KL), or PARP-1 + KDM5B (PK), matched with an appropriate 
control cell line expressing two shRNAs targeting luciferase (LL). 
(A) Analysis of mRNA expression for six genes by RT-qPCR in PARP-1 and 
KDM5B knockdown MCF-7 cells.  The data are normalized to the β-actin transcript 
and expressed relative to LL cells.  Each bar represents the mean plus the SEM, n  3.  
The differences observed for PL relative to LL are significant for all genes except 
ABHD2 (ANOVA, p  0.05). 
(B) ChIP-qPCR analysis of factor, histone, or histone modification levels at the 
promoter of the PARP-1 target gene, ITPR1, in MCF-7 cells with PARP-1 and 
KDM5B knockdown, as indicated.  Each bar represents the mean plus the SEM, n  3.  
The differences observed for PL relative to LL are significant for all ChIPs except H3 
(ANOVA, p  0.05).  Results for additional genes are shown in Supplemental Fig. S4. 
(C) MNase protection experiments in MCF-7 cells with PARP-1 and KDM5B 
knockdown, as indicated, for ITPR1.  Each point represents the mean ± the SEM, n  
3.  The shaded region indicates statistically significant differences between the LL and 
PL cells (Student’s t-test, p  0.05).  Results for additional genes are shown in 
Supplemental Fig. S6. 
(D) MNase protection data at the TSS from panel C, above.  Each bar represents the 
mean plus the SEM, n  3.  The differences observed for PL relative to LL are 
significant (ANOVA, p  0.05). 
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Figure 3.9. Antagonism of KDM5B-dependent H3K4me3 demethylation by 
PARP-1 promotes the recruitment of the Pol II transcription machinery, the 
exclusion of H1, and the maintenance of H3K4 trimethylation at the promoters of 
positively regulated target genes. 
The experiments in this figure used MCF-7 cells with knockdown of PARP-1 + Luc 
(PL), KDM5B + Luc (KL), or PARP-1 + KDM5B (PK), matched with an appropriate 
control cell line expressing two shRNAs targeting luciferase (LL).   
(A - C) ChIP-qPCR analysis of PARP-1, Pol II, and TBP at the promoters of six genes, 
as indicated.  Each bar represents the mean plus the SEM, n  3.  The differences 
observed for PL and PK relative to LL are significant for all genes in panel A 
(ANOVA, p  0.05).  The differences observed for PL relative to LL are significant 
for all genes except ABHD2 and GDF15 in panel B, and all genes except ABHD2 in 
panel C (ANOVA, p  0.05). 
(D – F) ChIP-qPCR analyses of H1, H3K4me3, and H3 at the promoters of six genes, 
as indicated.  Each bar represents the mean plus the SEM, n  3.  The differences 
observed for PL relative to LL are significant for all genes except ABHD2 and GDF15 
in panels A and B (ANOVA, p  0.05).  The differences in panel F are not significant. 
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different mode of regulation (Fig. 3.8A).  These results indicate that a loss of PARP-1 
at the promoters of positively regulated target genes can be overcome by removing 
KDM5B, consistent with the hypothesis that these two proteins act antagonistically in 
the same pathway.  
Next, to determine the consequences of PARP-1 antagonism of KDM5B, I 
assayed factor binding (Pol II, TBP, H1) and H3K4 trimethylation at the promoters of 
the PARP-1 target genes in the double knockdown cells.  The results for the positively 
regulated gene, ITPR1, are shown in Figs. 3.8B and 3.8C for illustrative purposes, 
while the results for additional genes are shown in Fig. 3.9.  As I showed above, 
knockdown of PARP-1 decreased the binding of Pol II and TBP, as well as the levels 
of H3K4me3, at the promoters of the positively regulated genes, while increasing the 
binding of H1 (Fig. 3.8B; Fig. 3.9).  As I observed with gene expression, knockdown 
of KDM5B had little effect on its own, but was able to reverse all of the effects of 
PARP-1 knockdown on the positively regulated genes (Pol II, TBP, H1, H3K4me3; 
Fig. 3.8B; Fig. 3.9).  These results indicate that removal of H3K4me3 is required, but 
not sufficient (based on the results from Fig. 3.5), for the binding of H1 and the 
eviction of Pol II from the promoters of positively regulated target genes.  
Interestingly, knockdown of KDM5B was also able to reverse the effects of PJ34 
treatment on H3K4me3 (Fig. 3.10).  Together these data support a model in which 
antagonism of KDM5B binding and H3K4me3 demethylation by PARP-1 facilitates 
the expression of positively regulated target genes.   
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Figure 3.10.  PARP-1 catalytic activity is required to antagonize the actions of 
KDM5B. 
(A - C) ChIP-qPCR analyses of KDM5B, H3K4me3, and H3 at the promoters of six 
genes in Luc or KDM5B knockdown (KD) MCF-7 cells with or without of 5 µM PJ34 
treatment for 1.5 hours before collection, as indicated.  Each bar represents the mean 
plus the SEM, n  3.  The differences observed for Luc/PJ34 relative to Luc/Control 
are significant for all genes except ABHD2 and GDF15 in panels A and B (ANOVA, p 
 0.05).  The differences in panel C are not significant. 
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Antagonism of KDM5B-dependent H3K4me3 demethylation by PARP-1 
maintains an open chromatin architecture at the TSSs of positively regulated 
target genes 
In Fig. 3.2, I showed that PARP-1 is required to maintain an open chromatin 
architecture at the TSSs of positively regulated genes.  To determine if PARP-1's 
antagonism of KDM5B and enhancement of H3K4 trimethylation levels plays a role  
in this process, I used the MNase protection assay described in Fig. 3.2 with PARP-1 
and KDM5B double knockdown cells.  As with the gene expression outcomes 
described above, if my model is correct, then depletion of KDM5B should reverse the 
effects of PARP-1 knockdown.  As seen in Fig. 3.2, PARP-1 knockdown caused a 
significant increase in the MNase protection (i.e., decreased accessibility or a closed 
chromatin architecture) relative to the control knockdown at near the TSSs of the 
positively regulated genes ITPR1 (Fig. 3.8, C and D) and SCN1A (Fig. 3.11A), but not 
for the unregulated gene ABHD2 (Fig. 3.11B).  Although KDM5B knockdown alone 
had little effect on the promoter chromatin architecture of ITPR1 and SCN1A, it 
reversed the effect of PARP-1 knockdown on these genes (Fig. 3.10 C and D; Fig. 
3.11A).  These results indicate that PARP-1 maintains an open chromatin architecture 
at the TSSs of positively regulated genes by inhibiting KDM5B-mediated 
demethylation of H3K4me3.  
 
Removal of PARP-1 from promoters is a mechanism utilized by signaling 
pathways to negatively regulate gene expression 
Having determined a specific role for PARP-1 in maintaining constitutive gene 
expression in MCF-7 cells under basal growth conditions, I next asked whether the 
PARP-1-dependent regulatory mechanisms which I uncovered might be applicable to 
signal-regulated transcription.  MCF-7 cells initiate well characterized transcriptional  
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Figure 3.11.  Antagonism of KDM5B-dependent H3K4me3 demethylation by 
PARP-1 promotes an open chromatin architecture at the promoters of positively 
regulated target genes. 
The experiments in this figure used MCF-7 cells with knockdown of PARP-1 + Luc 
(PL), KDM5B + Luc (KL), or PARP-1 + KDM5B (PK), matched with an appropriate 
control cell line expressing two shRNAs targeting luciferase (LL).   
(A and B) MNase protection experiments in MCF-7 cells with PARP-1 and KDM5B 
knockdown, as indicated, for SCN1A and ABHD2.  Each point represents the mean ± 
the SEM, n  3.  The shaded region in panel A indicates statistically significant 
differences between the LL and PL cells (Student’s t-test, p  0.05).  
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responses to a wide variety of stimuli, including the phorbol ester 12-O-
tetradecanoylphorbol-13-acetate (TPA; a.k.a. phorbol 12-myristate 13-acetate; (Liu 
and Heckman, 1998)) .  TPA, which resembles the natural agonist of protein kinase C, 
diacylglycerol, is a potent activator of the protein kinase C pathway (Liu and 
Heckman, 1998).  Many genes in MCF-7 cells are responsive to TPA treatment 
(Cunliffe et al., 2003; Lacroix et al., 2004), including SCN1A and ITPR1 (Fig. 3.12A).   
The expression of these two genes was inhibited by treatment with TPA (100 ng/ml 
TPA for 3 hours), an effect that was similar to PARP-1 knockdown (Fig. 3.12A).  The 
expression of ABHD2, which I examined for comparison, was unaffected by TPA or 
PARP-1 knockdown (Fig, 3.12A).   
I considered the possibility that TPA-dependent signaling might inhibit the 
expression of SCN1A and ITPR1 by blocking the localization and/or function of 
PARP-1 at their promoters.  Treatment with TPA promoted the release of PARP-1 
from these promoters (Fig. 3.12B), perhaps as a direct target endpoint of the signaling 
pathway.  Given that TPA promoted the release of PARP-1 from the SCN1A and 
ITPR1 promoters, I expected that TPA might promote the same molecular outcomes as 
PARP-1 knockdown at these promoters.  In this regard, I observed an increase in H1 
binding (Fig. 3.12C), a decrease in Pol II and TBP binding (Fig. 3.12, D and E), and a 
decrease in the levels of H3K4me3 (Fig. 3.12, F and G) upon TPA treatment.  Thus, 
for these endpoints, TPA treatment and PARP-1 knockdown are functionally similar.  
To determine if KDM5B might be involved in this pathway as well, I monitored 
H3K4me3 and KDM5B binding at the promoters in response to TPA treatment.  As 
with PARP-1 knockdown, TPA treatment caused a decrease in H3K4me3 levels and 
an increase in KDM5B binding to the promoters (Fig. 3.12, G and H).  Also, I found 
that TPA-mediated repression of these genes was inhibited by knockdown of KDM5B 
(Fig. 3.12I).  Together, these results indicate that cellular signaling pathways, like  
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Figure 3.12.  Signaling in the PKC pathway promotes the removal of PARP-1 
from promoters to negatively regulate gene expression. 
(A) Analysis of mRNA expression for three genes by RT-qPCR in MCF-7 cells 
treated with 100 ng/ml TPA for 3 hours versus MCF-7 cells with PARP-1 knockdown.  
The data are normalized to the β-actin transcript and expressed relative to untreated 
LL cells.  Each bar represents the mean plus the SEM, n  3.  The differences 
observed for all genes except ABHD2 are significant (ANOVA, p  0.05). 
(B - H) ChIP-qPCR analysis of factor, histone, or histone modification levels at the 
promoters of three genes, as indicated, in MCF-7 cells with or without 100 ng/ml TPA 
treatment for 3 hours.  Each bar represents the mean plus the SEM, n  3.  The 
differences observed with TPA are significant for SCN1A and ITPR1 for panels C, D, 
E, G, and H (ANOVA, p  0.05).   
(I) Analysis of mRNA expression for three genes by RT-qPCR in MCF-7 cells with 
KDM5B knockdown.  The data are normalized to the β-actin transcript and expressed 
relative to untreated LL cells.  Each bar represents the mean plus the SEM, n  3.  The 
differences observed for SCN1A and ITPR1 are significant (ANOVA, p  0.05). 
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those mediated by TPA, can regulate gene expression by abrogating PARP-1 binding 
at the promoter, which in turn allows H1 binding, KDM5B binding, and the removal 
of H3K4me3. 
 
Other histone modifications, such as H3K27me3, play a role in mediating PARP-
1-dependent transcriptional regulation 
 During my investigation of various histone modifications, I found that in 
addition to H3K4me3, PARP-1 depletion also affected the levels of H3K27me3 
(histone H3, lysine 27 trimethylation) at target promoters (Fig 3.13A).  Based on this 
data, I investigated the role of the corresponding histone methyltransferase responsible 
for depositing this particular modification, EZH2 (Enhancer of Zeste Homolog 2, a 
member of PRC2 [Polycomb Repressive Complex 2]).  Upon PARP-1 knockdown 
EZH2 was recruited to target promoters of positively regulated genes, correlating with 
a decrease in the modification (Fig. 3.13B).  I then examined whether altering levels of 
H3K4me3 (via knockdown of KDM5B) could affect this modification, and I found 
that knockdown of KDM5B did not alter H3K27me3, and double knockdown of 
PARP-1 and KDM5B did not change the effect of PARP-1 knockdown (Fig. 3.13C).  
Taken together, this suggests that the while PARP-1 acts to maintain low levels of 
H3K27me3, this occurs either upstream or independently of PARP-1 preventing the 
binding of KDM5B and the removal. of H3K4me3.  Finally, I also found that the 
increase of H3K27me3 upon removal of PARP-1 from promoters also occurs in the 
TPA-dependent signaling pathway described previously (Fig. 3.12, 3.13D).  It will be 
interesting to further investigate the role of H3K27me3, EZH2, and other members of 
the PRC2 complex in PARP-1 dependent transcriptional regulation, as well as the 
interplay between H3K4me3, H3K27me3 and other chromatin modifications in these 
regulatory pathways.   
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Figure 3.13.  PARP-1 regulates H3K27me3 levels via modulation of EZH2 
recruitment. 
(A, B) ChIP-qPCR analyses of H3K27me3 (A) and EZH2 (B) levels at the promoters 
of the PARP-1 target genes from panel A in control (Luc) and PARP-1 knockdown 
(KD) cells.  Each bar represents the mean plus the SEM, n  3.  (C) The experiments 
in this panel used MCF-7 cells with knockdown of PARP-1 + Luc (PL), KDM5B + 
Luc (KL), or PARP-1 + KDM5B (PK), matched with an appropriate control cell line 
expressing two shRNAs targeting luciferase (LL).  ChIP-qPCR analysis of H3K27me3 
levels at the promoters of three genes, as indicated, in LL, PL, KL and PK MCF-7.  
Each bar represents the mean plus the SEM, n  3.   
(D) ChIP-qPCR analysis of H3K4me3 levels at the promoters of three genes, as 
indicated, in MCF-7 cells with or without 100 ng/ml TPA treatment for 1 hour.  Each 
bar represents the mean plus the SEM, n  3.   
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3.4 Discussion 
 
In this study, I explored the role of PARP-1 in the chromatin-dependent control 
of gene expression.  In particular, I examined functional interplay between PARP-1, 
H3K4 trimethylation, and the linker histone H1.  I found that PARP-1 is required for a 
series of molecular outcomes at the promoters of genes that are positively regulated by 
PARP-1 (i.e., genes whose expression is dependent on PARP-1) (Fig. 3.14).  
Specifically, my experiments using shRNA-mediated knockdown showed that PARP-
1 establishes a permissive chromatin environment at the promoters of these genes by 
promoting the (1) trimethylation of H3K4 through the exclusion of KDM5B, (2) 
exclusion of H1, and (3) accessibility of the promoter DNA at the TSS.  Upon 
depletion of PARP-1, these outcomes do not occur efficiently.  The permissive 
chromatin environment is required for the efficient loading of the Pol II transcription 
machinery (e.g., Pol II, TBP, TFIIB) and subsequent transcription (Fig. 3.14).  Finally, 
my results indicate that cellular signaling pathways use the regulated depletion of 
PARP-1 from promoters to inhibit gene expression.  Collectively, my results assign 
new functions for PARP-1 in the regulation of chromatin structure and transcription. 
 
PARP-1 promotes H3K4 trimethylation at the promoters of positively regulated 
genes by antagonizing KDM5B 
PARP-1 has long been known to regulate chromatin structure, perhaps through 
direct PARylation of core histones or H1, yet the underlying mechanisms and targets 
have not been clearly determined (Kim et al., 2005; Kraus, 2008; Kraus and Lis, 2003).  
My results indicate that PARP-1 regulates chromatin in at least two ways.  First, it 
regulates the covalent posttranslational modification of chromatin by promoting H3K4 
trimethylation, a histone modification that is positively correlated with gene  
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Figure 3.14.  Model of PARP-1-dependent gene regulation. 
This model is derived from the data shown herein and the literature.  PARP-1 acts 
upstream of a host of molecular events at the promoters of positively regulated target 
genes to control chromatin architecture and the loading of the Pol II transcriptional 
machinery.  Additional details are provided in the Discussion. 
 
 
PARP - 1 
KDM5B 
Chromatin 
Accessibility 
Pol II and Basal 
Transcription 
Machinery 
Gene 
Expression 
H3K4me3 H1 
Catalytic 
Activity 
Nucleosome 
Binding 
TFIID 
Binding 
Inhibitory 
Signaling 
Pathways 
144 
expression (Ruthenburg et al., 2007).  Second, it regulates the composition of 
chromatin by promoting the exclusion of H1, a nucleosome-binding protein associated 
with gene repression (Happel and Doenecke, 2009).  With respect to the former, I have 
shown herein that PARP-1 promotes the exclusion of the H3K4me3 demethylase 
KDM5B from promoter chromatin (Fig. 3.5B) through a mechanism that requires 
PARP-1 catalytic activity (Fig. 3.5D).  As such, PARP-1 is able keep the levels of 
H3K4me3 elevated at the promoters of positively regulated genes, which helps to 
maintain an active chromatin environment.  The intimate interplay between PARP-1 
and KDM5B is illustrated by my studies showing that (1) PARP-1 and H3K4me3 
colocalize on many promoters across the genome (Fig. 3.3) and (2) the requirement for 
PARP-1 to maintain a variety of molecular outcomes at the promoters of positively 
regulated target genes (e.g., Pol II and TBP binding, H1 exclusion, transcription) is 
abrogated upon KDM5B knockdown (Figs. 3.8, 3.9 and 3.10).  In addition, my data 
suggest that while H3K4me3 demethylation by KDM5B is necessary for reducing 
gene expression, it is not sufficient, and that PARP-1 protein must also be physically 
removed from the promoter to allow for H1 binding and subsequent changes in 
chromatin structure. 
How does PARP-1 exclude KDM5B and prevent KDM5B-dependent 
H3K4me3 demethylation?  My results indicate that PARP-1 binds to and PARylates 
KDM5B (Figs. 3.5E and 3.5F), which inhibits the binding of KDM5B to promoter 
chromatin (Fig. 3.5D).  PARP-1-mediated PARylation has been shown to be an 
effective mechanism for inhibiting the activity of transcription-related proteins due to 
its ability to block protein-protein or protein-DNA interactions (Kraus, 2008; Kraus 
and Lis, 2003).  Although not directly tested in my experiments, inhibition of KDM5B 
enzymatic activity by PARylation is also possible.  Previous studies have implicated 
PARP-1 enzymatic activity in the regulation of factor binding or exchange at target 
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promoters.  For example, PARP-1 enzymatic activity is required to promote the 
exchange of a TLE1 corepressor complex for a HAT-containing coactivator complex 
during signal-dependent gene regulation in neuronal cells (Ju et al., 2004).  In this 
regard, PARP-1’s effects on KDM5B might be part of a broader process designed to 
establish a set of histone modification permissive to transcription (i.e., regulating the 
binding of enzymes that elevate H3K4me3 and H3/H4 acetylation, or reduced 
H3K27me3).  These possibilities will be explored in future studies.  
What role might H3K4me3 play in the PARP-1-dependent transcription 
process?  Previous studies have shown that this modification creates a binding site for 
structural modules within a variety of proteins that regulate chromatin structure and 
transcription (Ruthenburg et al., 2007), including the PHD fingers of BPTF, TAF3, 
and ING family members (Li et al., 2006; Pena et al., 2006; Shi et al., 2006; Taverna 
et al., 2006; van Ingen et al., 2008; Vermeulen et al., 2007; Wysocka et al., 2006), the 
tandem chromodomains of CHD1 (Flanagan et al., 2005; Sims et al., 2005), and the 
double tudor domain of JMJD2A/KDM4A (Huang et al., 2006).  The binding of 
H3K4me3 by TAF3, a component of TFIID, has been shown to direct the binding of 
TFIID to promoters.  In this regard, I found that depletion of PARP-1, which reduces 
the levels of H3K4me3 at positively regulated promoters, also reduces the binding of 
TBP, another component of TFIID (Fig. 3.1F).  These effects of PARP-1 on TBP 
binding are antagonized by KDM5B, and the requirement for PARP-1 to maintain 
TBP levels is abrogated upon knockdown of KDM5B (Figs. 3.8B, 3.9).  Thus, one 
aspect of PARP-1-dependent maintenance of H3K3 trimethylation may be the 
promotion of TFIID binding (Fig. 3.14).   
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PARP-1 promotes the exclusion of H1 and the formation of open chromatin 
structures at the promoters of positively regulated genes 
In addition to promoting the exclusion of KDM5B, PARP-1 antagonizes the 
binding of H1 at the promoters of positively regulated target genes (Figs. 3.1D and 
3.14), likely through competition for overlapping binding sites on nucleosomes (Kim 
et al., 2004).  PARP-1 catalytic activity is not required for this effect (Fig. 3.6), 
consistent with the results of previous biochemical assays showing that PARP-1 
catalytic activity is not required for the displacement of H1 from nucleosomes (Kim et 
al., 2004) and PARylation of H1 does not block its binding to chromatin (Poirier et al., 
1982).  These results are also consistent with my genomic assays showing that PARP-
1 and H1 exhibit a reciprocal pattern of binding at promoters across the genome (i.e., 
H1 is depleted where PARP-1 is enriched) (Krishnakumar et al., 2008).  My current 
results, however, suggest that additional mechanisms may also contribute to the 
PARP-1-dependent exclusion of H1 from promoter chromatin.  For example, the 
effects of PARP-1 knockdown on H1 binding are abrogated upon KDM5B 
knockdown (Figs. 3.8B, 3.9), suggesting a role for KDM5B.  The actions of KDM5B 
in this PARP-1-dependent process may be through demethylation of H3K4me3 (Fig. 
3.14), or perhaps demethylation of H1 (Kuzmichev et al., 2004; Trojer et al., 2009) or 
a chromatin- and transcription-related factor (Paik et al., 2007).   
A key consequence of PARP-1-dependent antagonism of H1 binding is the 
maintenance of an open chromatin architecture at the TSSs of positively regulated 
genes.  Previous studies have shown that H1 binding to nucleosomes can promote the 
formation of a closed chromatin architecture that is repressive to transcription (Happel 
and Doenecke, 2009; McBryant et al., 2006; Woodcock et al., 2006).  In such cases, 
removal of H1 is required for efficient transcription.  In this regard, I found that 
PARP-1-dependent antagonism of H1 binding correlates with an open chromatin 
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architecture (Fig. 3.2) and the binding of the Pol II transcription machinery (Pol II, 
TBP, and TFIIB; Fig. 3.1, E, F and G).  My studies suggest a scenario with PARP-1 
acting upstream of an ordered series of events including removal of H1, opening of the 
promoter chromatin architecture, and binding of the Pol II transcription machinery 
(Fig. 3.14).  This is consistent with models proposed in the literature (Li et al., 2007; 
Morse, 2003).   
 
Requirement for PARP-1 catalytic activity at the promoters of positively 
regulated target genes 
The role of PARP-1 enzymatic activity in transcriptional regulation has been 
studied in various gene contexts with different transcriptional activators (Frizzell et al., 
2009; Kraus, 2008; Kraus and Lis, 2003).  In some cases, PARP-1 enzymatic activity 
was found to be required (e.g., with HES1 and Elk1) (Cohen-Armon et al., 2007; Ju et 
al., 2004), while in others it was not (e.g., NF-κB and retinoic acid receptor) (Hassa 
and Hottiger, 2002; Pavri et al., 2005).  I found that PARP-1 enzymatic activity is not 
required for PARP-1-dependent effects on the transcription of positively regulated 
target genes per se (Fig. 3.6A), but it is required for some of the specific molecular 
outcomes that I tested.  For example, PARP-1 enzymatic activity was required for the 
promotion of H3K4 trimethylation through inhibition of KDM5B binding (Fig. 3.5, C 
and D; Fig. 3.10), while it was dispensable for the inhibition of H1, Pol II, and TBP 
binding (Figs. 3.14; Fig. 3.6 D and F; Table 3.2).   
Why might increased KDM5B binding upon PARP-1 knockdown (Fig. 3.5B), 
which inhibits the transcription of positively regulated target genes (Fig. 3.1B), have a 
different effect than increased KDM5B binding upon PARP-1 inhibition with PJ34 
(Fig. 3.5D), which does not inhibit transcription of those genes (Fig. 3.6)?  The answer 
is likely that with PARP-1 knockdown, the PARP-1 protein is removed, while with  
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Table 3.2.  Requirement for PARP-1 protein and PARP-1 catalytic activity for 
specific molecular outcomes at the promoters of positively regulated genes. 
 
 
              PARP-1 protein                             PARP-1 catalytic 
  Outcomea                                required?b                                      activity required?c 
Gene expression Yes  (Fig. 3.1B) No  (Fig. 3.6A) 
H1 binding Yes  (Fig. 3.1D) No  (Fig. 3.6C) 
Pol II binding Yes  (Fig. 3.1E) No  (Fig. 3.6D) 
TBP binding Yes  (Fig. 3.1F) No  (Fig. 3.6F) 
TFIIB binding Yes  (Fig. 3.1G) n.d. 
Open chromatin architecture  
at TSS Yes  (Fig. 3.2C) n.d. 
Promoting H3K4  
trimethylation Yes  (Fig. 3.5A) Yes (Fig. 3.5C) 
Inhibiting KDM5B binding Yes  (Fig. 3.5B) Yes (Fig. 3.5D) 
 
 
a Expression was determined by RT-qPCR.  H3K4 trimethylation and factor binding 
were determined by ChIP.  Chromatin architecture at the TSS was determined by 
MNase protection assays. 
b As determined by PARP-1 knockdown.  The figure demonstrating the effect is listed 
in parentheses. 
c As determined by PARP-1 inhibition with PJ34.  The figure demonstrating the effect 
is listed in parentheses. 
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PJ34, it is not (Fig. 3.6).  These results suggest that although PARP-1 enzymatic 
activity might prevent certain steps in the pathway involving KDM5B, the presence of 
the PARP-1 protein itself is required to inhibit the binding of H1 and allow subsequent 
steps, such as promoting an open chromatin architecture, facilitating Pol II binding, 
and allowing transcription (Fig. 3.14).  Although the specific molecular role(s) played 
by PARP-1 enzymatic activity in the transcription process have been difficult to sort 
out (Cohen-Armon et al., 2007; Frizzell et al., 2009; Hassa and Hottiger, 2002; Ju et 
al., 2006; Ju et al., 2004; Pavri et al., 2005), my results have helped to discern the 
distinct molecular roles played by PARP-1 protein and PARP-1 enzymatic activity. 
 
Cellular signaling pathways regulate PARP-1-dependent molecular outcomes at 
target gene promoters 
PARP-1 has been implicated in a number of different signal-dependent gene 
regulatory pathways, including those mediated by activation of PKC, CaM kinase IIδ, 
estrogen signaling, retinoic acid signaling, or NF-κB-dependent proinflammatory 
signaling (Hassa and Hottiger, 2002; Ju et al., 2006; Ju et al., 2004; Kim et al., 2004; 
Kraus, 2008; Pavri et al., 2005).  A previous study has shown that activation of PKC 
pathways in MCF-7 cells by TPA can stimulate PARP-1-dependent gene expression 
(Ju et al., 2006).  I found that these same pathways can inhibit the expression of a 
subset of genes positively regulated by PARP-1, including SCN1A and ITPR1 (Fig. 
3.12, A and B), which encode signal-regulated ion channels that control sodium and 
calcium fluxes, respectively (Table 3.1).  My molecular analyses indicate that TPA 
promotes the loss of PARP-1 from the promoters of these genes (Fig. 3.12B).  Like 
shRNA-mediated knockdown of PARP-1, the TPA-dependent reduction of PARP-1 
binding at these promoters leads to an increase in the binding of H1 and KDM5B (Fig. 
3.12, C and H), as well as a reduction in the binding of Pol II and TBP (Fig. 3.12, D 
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and E), and the levels of H3K4me3 (Fig. 3.12G).  Thus, modulation of PARP-1 
binding to chromatin as an endpoint of cellular signaling pathways can provide a 
means for regulating gene expression outcomes.  
 
PARP-1 and KDM5B have opposing effects in a common molecular pathway: 
Implications for breast cancers 
My results indicate that KDM5B, an enzyme that demethylates H3K4me3, acts 
antagonistically to PARP-1 at the promoters of genes positively regulated by PARP-1 
(Fig. 3.9), and vice versa (Fig. 3.8).  Does this molecular antagonism manifest itself in 
some broader biological outcomes?  There is a growing interest in the roles of both 
KDM5B and PARP-1 in breast cancers.  KDM5B was initially isolated as a transcript 
overexpressed in human breast cancer cell lines (Lu et al., 1999), and as many as 90% 
of invasive ductal carcinomas express KDM5B (Barrett et al., 2007).  Knockdown of 
KDM5B in MCF-7 cells increases the expression of the negative growth regulator 
BRCA1 and inhibits cell proliferation by interfering with G1 progression (Scibetta et 
al., 2007; Yamane et al., 2007).  A number of studies have also implicated PARP-1 in 
the biology of breast cancers, and PARP inhibitors have been shown to be effective in 
killing breast cancer cells with hereditary mutations in BRCA1 and BRCA2 (Frizzell 
and Kraus, 2009; Lord and Ashworth, 2008). Interestingly, both KDM5B and PARP-1 
mRNA levels may increase with increasing tumor grade in breast cancers (Fig. 3.15) 
(Zhao et al., 2004), suggesting a possible compensation by PARP-1 in an attempt to 
inhibit the growth promoting effects of KDM5B.  The interplay between PARP-1 and 
KDM5B at the molecular level and in more complex biological processes will be an 
interesting area of investigation in future studies.  
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Figure 3.15.  PARP-1 and KDM5B mRNA levels increase with increasing tumor 
grade in breast cancers. 
The relative expression levels of PARP-1 and KDM5B in breast cancer samples were 
obtained from previously published data (Zhao et al., 2004) through Oncomine.  The 
patients had varying grades of tumors, ranging from 1 to 3, with 3 being the most 
advanced grade.  All samples were compared to normal breast tissue (denoted as 
“grade 0”).  Box limits represent the 25th and 75th percentiles, error bar limits represent 
the outer-most data points minus the outliers on either side, and the dots represent the 
upper and lower outlier data points.  The differences are statistically significant by 
Student’s t-test (p < 0.01).   
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Collectively, my results have defined a functional interplay between PARP-1, 
H3K4 trimethylation, and the linker histone H1 at the promoters of genes positively 
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regulated by PARP-1.  More broadly, my results have helped to clarify the molecular 
mechanisms by which specific chromatin-binding and histone-modifying proteins 
interact to alter chromatin structure and function to regulate gene transcription. 
 
 3.5 Materials and Methods 
 
Cells lines, shRNA-mediated knockdown, and treatment with TPA 
MCF-7 human breast cancer cells were kindly provided by Dr. Benita 
Katzenellenbogen (University of Illinois, Urbana-Champaign).  The cells were 
maintained and plated for experiments in MEM supplemented with 5% calf serum.  
MCF-7 cells with stable shRNA-mediated depletion of PARP-1 and KDM5B were 
generated by retroviral-mediated gene transfer using the pSUPER.retro system with 
puromycin- and Geneticin (G418)-selectable markers (Oligoengine).  For 
experiments with PARP-1 knockdown only, I used cells harboring two short hairpin 
RNA sequences specifically targeting PARP-1, as described previously (Frizzell et al., 
2009).  For experiments with multiple factor knockdowns (e.g., PARP-1/KDM5B 
double knockdown), I used a control-matched set of cells stably expressing (1) an 
shRNA sequence targeting either PARP-1 (5’-GGGCAAGCACAGTGTCAAA-3’) 
(Frizzell et al., 2009) or KDM5B (5’-GGCATTGAAGCTTGCACCT-3’) (Scibetta et 
al., 2007) plus a control shRNA targeting luciferase (Luc; 5’-
GATATGGGCTGAATACAAA-3’) (Frizzell et al., 2009) (named PL and KL, 
respectively; see Fig. 5), (2) separate shRNAs targeting PARP-1 and KDM5B (PK), or 
(3) two shRNAs targeting luciferase (LL).  The cells were selected and maintained 
under appropriate drug selection (i.e., 0.5 µg/ml puromycin and/or 800 µg/ml G418).  
For experiments involving TPA (12-O-tetradecanoylphorbol-13-acetate; Biomol, cat. 
no. PE-160) treatment, the cells were grown as described for the various experiments 
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noted below and treated with 100 ng/ml TPA dissolved in ethanol or a vehicle control.  
For experiments with PJ34 (Alexis Biochemicals, cat. no. ALX-270-289), the cells 
were grown as described and treated for 1 hour with 1 µM.   
 
Antibodies 
I used a previously characterized custom rabbit polyclonal anti-PARP-1 antibody for 
ChIP and Western blotting (Kim et al., 2004).  The other ChIP grade antibodies, which 
were also used for Western blotting as appropriate, were as follows: H1 
(Upstate/Millipore, cat. no. 05-475), H3 (Abcam, cat. no.  ab1791), H3K4me3 (Abcam, 
cat. no.  ab8580 or ab1012, or Active Motif cat. no. 3915), KDM5B (Abcam, cat. no.  
ab50958, ), Pol II (Santa Cruz, cat. no.  SC-899 and SC-900, mixed in a 1:4 ratio), 
TFIIB (Santa Cruz, cat. no.  SC274X), and TBP (Santa Cruz, cat. no.  SC273X).  For 
immunoprecipitation experiments, the antibodies were as follows: KDM5B (see 
above), PAR (Trevigen, cat. no.  4335-AMC-050), and Rabbit IgG (Upstate/Millipore, 
cat. no.  12-370).  Secondary antibodies for Western blotting were as follows: goat 
anti-rabbit HRP-conjugated IgG (Pierce, cat. no. 31460) and goat anti-mouse HRP-
conjugated IgG (Pierce, cat.no. 31430).   
 
mRNA expression analyses 
Cells were seeded at ~1.5 x 105 cells per well in 6-well plates and grown for at least 3 
days in the conditions noted above.  The cells were collected at about 80% confluence, 
and total RNA was isolated using Trizol Reagent (Invitrogen) according to the 
manufacturer's protocols.  The total RNA was reverse transcribed using oligo(dT) and 
subjected to real-time quantitative PCR using gene-specific primers (see primer 
sequences listed below; Section 2).  All target gene transcripts were normalized to the 
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β-actin transcript.  Each experiment was conducted a minimum of three times with 
independent isolates of total RNA to ensure reproducibility. 
 
 
 
Chromatin immunoprecipitation (ChIP) assays 
ChIP was performed essentially as described previously (Kininis et al., 2007).  Briefly, 
cells were grown to ~80 to 90% confluence, cross-linked with 1% formaldehyde in 
PBS for 10 min. at 37°C, and quenched in 125 mM glycine in PBS for 5 min. at 4°C.  
For ChIP assays with the KDM5B antibody, I included an additional crosslinking step 
with 10 mM dimethyl suberimidate (DMS; Pierce, cat. no. 20700) for 10 min. prior to 
treatment with paraformaldehyde.  The cells were collected by centrifugation and 
sonicated in Lysis Buffer [Tris•HCl pH 7.9, 10 mM EDTA, 50 mM NaCl, 1% SDS, 
and 1x protease inhibitor cocktail (Roche, cat no. 04 693 124 001)] to generate 
chromatin fragments of ~500 bp in length.  The material was clarified by 
centrifugation, diluted 10-fold in Dilution Buffer (20 mM Tris•HCl pH 7.9, 2 mM 
EDTA, 150 mM NaCl, 0.5% Triton X-100, 1x protease inhibitor cocktail), and pre-
cleared by incubation with protein A-agarose beads.  The pre-cleared, chromatin-
containing supernatant was used in immunoprecipitation reactions with antibodies 
against the factor of interest, or without antibodies as a control.  Note that non-specific 
IgGs gave similar results as the no antibody controls (data not shown).  The 
immunoprecipitated genomic DNA was cleared of protein and residual RNA by 
digestion with proteinase K and RNase H, respectively.  The DNA was then extracted 
with phenol:chloroform:isoamyl alcohol and precipitated with ethanol.  Quantitative 
real-time PCR (qPCR) was used to determine the enrichment of immunoprecipitated 
material relative to the input material using gene-specific primer sets to the specified 
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regions (see primer sequences listed below; Section 2).   Each ChIP experiment was 
conducted a minimum of three times with independent chromatin isolates to ensure 
reproducibility. 
 
Micrococcal nuclease (MNase) protection assays 
Two 15 cm diameter plates of cells seeded at ~5 x 105 (for each condition) were 
grown to ~80 to 90% confluence, cross-linked with 1%  formaldehyde in PBS for 10 
min. at 37°C, and quenched in 125 mM glycine in PBS for 5 min. at 4°C.  The cells 
were then collected, pelleted by centrifugation, and resuspended in 2 ml of Buffer A 
(10 mM HEPES pH 7.6, 10 mM KCl, 1.5 mM MgCl2, 0.34 M sucrose, 10% glycerol, 
1 mM DTT, 1x protease inhibitor cocktail).  Triton-X-100 was added to a final 
concentration of 0.1 % and the mixture was incubated at 4°C for 8 min.  The nuclei 
were collected by centrifugation (4000 rpm in a refrigerated microcentrifuge for 5 
min.) and washed twice with Buffer A.  The nuclear pellet was then resuspended in 1 
ml of Buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 1x protease inhibitor 
cocktail) and incubated at 4°C for 30 min. to lyse the nuclei.  The chromatin was 
collected by centrifugation (4500 rpm in a refrigerated microcentrifuge for 5 min.) and 
washed twice with Buffer B.  The pellet was then resuspended in 1 ml of MNase 
Buffer (50 mM Tris•HCl pH 7.4, 25 mM KCl, 12.5% glycerol, 10 mM CaCl2, 4 mM 
MgCl2 and 1 mM PMSF).  The 1 ml of chromatin was divided into two 500 µl aliquots, 
and 400 units of MNase were added to one aliquot.  Both aliquots were then incubated 
at 37°C for 8 min., after which EDTA (12.5 mM final concentration) and SDS (0.5% 
final concentration) were added to stop the reaction.  For the control samples (without 
MNase), the genomic DNA was lightly sheared by sonication (27% amplitude for 3 
rounds of 12 seconds using a Branson Sonifier) so that it could be subjected to PCR 
analysis.  All samples were then incubated at 65°C overnight to reverse the 
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formaldehyde crosslinks.  The DNA was cleared of protein and residual RNA by 
digestion with proteinase K and RNase H, respectively.  The DNA was then extracted 
with phenol:chloroform:isoamyl alcohol and precipitated with ethanol.  qPCR with 
overlapping amplicons (see below) was used to determine the enrichment of MNase 
digested DNA relative to sonicated genomic DNA ("relative protection") at specific 
genomic locations (see primer sequences listed below; Section 2).  Each experiment 
was conducted a minimum of three times with independent biological replicates to 
ensure reproducibility. 
 
Quantitative real-time PCR (qPCR) 
Reverse transcribed mRNA, ChIPed DNA, and MNase digested DNA were analyzed 
by quantitative PCR.  Briefly, DNA, 1x SYBR Green PCR master mix, and forward 
and reverse primers (250 nM) were used in 40 to 45 cycles of amplification (95!C for 
15 sec, 60!C for 1 min) following an initial 10 min incubation at 95!C using an 
Applied Biosystems 7900 HT 384-well Sequence Detection System.  Melting curve 
analysis was performed to ensure that only the targeted amplicon was amplified.  The 
sequences of all primers used for RT-qPCR, ChIP-qPCR, and MNase-qPCR are listed 
in Section 2 below. 
 
Statistical tests for the gene-specific assays 
Each gene-specific experiment (i.e., RT-qPCR, ChIP-qPCR, MNase-qPCR) was 
conducted a minimum of three times with independent biological replicates to ensure 
reproducibility.  The significance of differences between experimental and control 
samples was determined using a Student's t-test.  Significance and p-values are listed 
in the figures legends, 
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Immunoprecipitation of KDM5B and detection of PARylation  
Nuclear extract and immunoprecipitation protocols were adapted from Dignam et al. 
(1983) and Sif et al. (1998), respectively (Dignam et al., 1983; Sif et al., 1998).  Two 
15 cm diameter plates of cells seeded at ~5 x 105 (for each condition) were grown to 
~80 to 90% confluence, treated if required, collected, and pelleted by centrifugation.  
The cells were incubated in Hypotonic Buffer for swelling (10 mM Tris pH 7.9, 20% 
glycerol, 1.5 mM MgCl2, 0.1 mM EDTA, 10 mM KCl, 1x protease inhibitor cocktail, 
with 100 µM tannic acid to prevent degradation of existing PAR chains by poly(ADP-
ribose) glycohydrolase) and lysed by Dounce homogenization using a 0.4 mm 
clearance pestle.  The nuclei were collected by centrifugation (3000 rpm in a 
refrigerated microcentrifuge for 5 min.) and extracted in Extraction Buffer (20 mM 
HEPES pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, and 1x 
protease inhibitor cocktail) for 10 min. on ice with intermittent agitation.  The nuclear 
extract was clarified by centrifugation (maximum speed in a refrigerated 
microcentrifuge for 15 min) and diluted with Extraction Buffer lacking NaCl to bring 
the final NaCl concentration to 0.21 M.  The extracts were incubated with 5 µl of 
KDM5B antibody (or rabbit IgG as a control) and protein A-agarose beads for 16 
hours on ice with mixing.  The beads were subjected to sequential washes in Wash 
Buffer (20 mM HEPES pH 7.9, 20% glycerol, 2 mM EDTA) containing 100 mM, 150 
mM, or 300 mM KCl for each sequential wash.  The beads were heated to 100 °C for 
5 min in SDS-PAGE loading buffer to release the bound proteins.  The 
immunoprecipitated material was subjected to Western blotting with the KDM5B 
(1:1000), PARP-1 (1:2000) and PAR (1:500) antibodies described above.  The 
immunoprecipitation assays were preformed at least twice to ensure reproducibility.   
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Western blotting of nuclear extracts 
Nuclear extracts were prepared as above.  The resulting lysate was subjected to SDS-
PAGE and Western blotting with antibodies to the following factors: PARP-1 (5 µg of 
total protein loaded, primary antibody used at 1:2000), H3 (5 µg of total protein 
loaded, primary antibody used at 1:2000), H3K4me3 (5 µg of total protein loaded, 
primary antibody used at 1:1000), and KDM5B (20 µg of total protein loaded, primary 
antibody used at 1:1000).  
 
ChIP-chip 
For the ChIP-chip analyses, the immunoprecipitated genomic DNA was blunted, 
amplified by ligation-mediated PCR (LM-PCR), and used to probe a custom, non-
isothermal human (HG18) oligonucleotide genomic array from Nimblegen.  The 
custom array contained ~2,100,000 features (tiling interval of 76 bp for the ~50-mer 
probes) containing 23,551 annotated RNA polymerase II-transcribed promoters 
(approximately -3 kb to +3 kb relative to the transcription start site for most 
promoters).  Detailed information about the genomic regions tiled on the custom array 
is included with the data submission to NCBI/Gene Expression Omnibus (GEO 
accession number GSE19619).  The ChIP-chip analyses were run a minimum of two 
times to ensure reproducibility. 
 
Genomic data analyses 
Genomic data analyses were performed using the statistical programming language R 
(R Development Core Team, 2006), as previously described (Krishnakumar et al., 
2008).  All data processing scripts are available upon request from the corresponding 
author and the raw data sets can be accessed through NCBI/GEO (accession number 
GSE19619).  The log2 ratio data from each of the arrays was subjected to lowess 
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normalization (Smyth and Speed, 2003).  A single array error model was generated 
using a 1 kb moving window with 250 bp steps in which both the mean probe log2 
ratio and p-values were calculated for each window.  The p-values are from a 
nonparametric Wilcoxon signed-rank test.  Significant peaks were defined as the 
center of three consecutive windows with positive means, the center window with a 
mean greater than either adjacent window, and all windows having p-values less than 
0.016.  Correlation analyses, averaging (metagene) analyses, and gene categorization 
were done as previously described (Krishnakumar et al., 2008). 
 
Primers for ChIP-qPCR, RT-qPCR, and MNase protection 
 
• RT-qPCR:  
b-ACTIN mRNA Fwd:  5’ - AGCTACGAGCTGCCTGAC -3 ’ 
b-ACTIN mRNA Rev:  5’ - AAGGTAGTTTCGTGGATGC - 3’ 
ABHD2 mRNA Fwd:  5’ - CACCTCTCTGAGCCTGTTCC- 3’ 
ABHD2 mRNA Rev:  5’ - CGCAGATGTTCAGCAATGTT- 3’ 
GDF15 mRNA Fwd:  5’ - CTACAATCCCATGGTGCTCA - 3’ 
GDF15 mRNA Rev:  5’ - TATGCAGTGGCAGTCTTTGG - 3’ 
ITPR1 mRNA Fwd:  5’ - TGCCTCCACAATTCTACG - 3’ 
ITPR1 mRNA Rev:  5’ - TGAATGTCCCACAGTTGC - 3’ 
KDM5B mRNA Fwd:  5’ - CGACAAAGCCAAGAGTCTCC - 3’ 
KDM5B mRNA Rev:  5’ - CTGCCGTAGCAAGGCTATTC - 3’ 
NELL2 mRNA Fwd:  5’ - TGAAGGGAACCACCTACC - 3’ 
NELL2 mRNA Rev:  5’ - ATTTGCCATCCACATACG - 3’ 
PARP-1 mRNA Fwd:  5’ - GTGTGGGAAGACCAAAGGAA - 3’ 
PARP-1 mRNA Rev:  5’ - TTCAAGAGCTCCCATGTTCA - 3’ 
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SCN1A mRNA Fwd:  5’ - ATTGAAGGGAACCGATTG- 3’ 
SCN1A mRNA Rev:  5’ - ATCCCACATCCTTTGCTC- 3’ 
TMSL8 mRNA Fwd:  5’ - AACCTGCTATGATGGGTGCT - 3’ 
TMSL8 mRNA Rev:  5’ - CTGCAAAAGCATGCAACTTC - 3’ 
 
• ChIP-qPCR:  
ABHD2 promoter Fwd:  5’ - GCCTCCACTCTGAGGAACAG - 3’ 
ABHD2 promoter Rev:  5’ - TTGTTCATTGGGCAGTTCAG - 3’ 
GDF15 promoter Fwd:  5’ - CTCAGATGCTCCTGGTGTTG - 3’ 
GDF15 promoter Rev:  5’ - CTCGGAATCTGGAGTCTTCG - 3’ 
ITPR1 promoter Fwd:  5’ - GAGCCCTAAGCAGCGTGTAG - 3’ 
ITPR1 promoter Rev:  5’ - CTCTCCAAGAGCTCCGAATG - 3’ 
NELL2 promoter Fwd:  5’ - TCCCCGGAGGAGCAGTCT - 3’ 
NELL2 promoter Rev:  5’ - CGCCCGAACCTGTTGTAAAG - 3’ 
SCN1A promoter Fwd:  5’ - ACCCTCCTCTCTCTCCTTGC - 3’ 
SCN1A promoter Rev:  5’ - GGGAGGAGGAGAAATTCGTT - 3’ 
TMSL8 promoter Fwd:  5’ - CGCGGGAACGCTAACCT - 3’ 
TMSL8 promoter Rev:  5’ - GTCCTCACCTGAAAGCTTGAAGA - 3’ 
 
• MNase-qPCR: 
(Note:  The primers labeled “a” to “u” tile from -300 to +300 bp relative to the TSS 
with approximately 30 bp spacing)  
 
i) ABHD2 
ABHD2a_Fwd:  5’ - GAGCTGGAAGAGGCCATAGA - 3’ 
ABHD2a_Rev:  5’ - ACCCGAAGGAGAGGAAAAGA - 3’ 
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ABHD2b_Fwd:  5’ - CCTCCACATCTTTTCCTCTCC - 3’ 
ABHD2b_Rev:  5’ - GAGGAAGAAGGGTCGTGAGTC - 3’ 
ABHD2c_Fwd:  5’ - TGACTCACGACCCTTCTTCC - 3’ 
ABHD2c_Rev:  5’ - CAGGGGTGAAATTTGAGGTC - 3’ 
ABHD2d_Fwd:  5’ - TCACGACCCTTCTTCCTCTC - 3’ 
ABHD2d_Rev:  5’ - AGGCCGACTGACTGACTCAC - 3’ 
ABHD2e_Fwd:  5’ - ACCCCTGCGAAATTTGAGTA - 3’ 
ABHD2e_Rev:  5’ - TAGCTCAGCTGGGGCTCTTA - 3’ 
ABHD2f_Fwd:  5’ - GGCCTGGACCCATAAGAGC - 3’ 
ABHD2f_Rev:  5’ - CTGGTAGCTCAGCTGCTGGT - 3’ 
ABHD2g_Fwd:  5’ - AGCTACCAGCCGACCTCAT - 3’ 
ABHD2g_Rev:  5’ - AGAGGGCTGGGTAAGGTCA - 3’ 
ABHD2h_Fwd:  5’ - GTCGACAGCTGACCTTACCC - 3’ 
ABHD2h_Rev:  5’ - GGGTAATTGTGACCGCAAAC - 3’ 
ABHD2i_Fwd:  5’ - ACCCAGCCCTCTAAAGCAGT - 3’ 
ABHD2i_Rev:  5’ - GGGGTGAAGAGACGGGTAAT - 3’ 
ABHD2j_Fwd:  5’ - GTTTGCGGTCACAATTACCC - 3’ 
ABHD2j_Rev:  5’ - GGTCGTGTTTGATGTCGATG - 3’ 
ABHD2k_Fwd:  5’ - CCATCGACATCAAACACGAC - 3’ 
ABHD2k_Rev:  5’ - ATAAGGCCAGCCCGGAGT - 3’ 
ABHD2l_Fwd:  5’ - TCAAACACGACCCACCTTCT - 3’ 
ABHD2l_Rev:  5’ - CTTTAGTCCAGGGACCCAGA - 3’ 
ABHD2m_Fwd:  5’ - GGGCTGGCCTTATCCAGTAG - 3’ 
ABHD2m_Rev:  5’ - CATTTGACGGCTTTAGTCCA - 3’ 
ABHD2n_Fwd:  5’ - CCTGGACTAAAGCCGTCAAA - 3’ 
ABHD2n_Rev:  5’ - AGTGGAGGCGGGATTCTTAG - 3’ 
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ABHD2o_Fwd:  5’ - TGAGGAGCTCTCCCCTAAGA - 3’ 
ABHD2o_Rev:  5’ - GATCAGCGAAGCTGTTCCTC - 3’ 
ABHD2p_Fwd:  5’ - CTAAGAATCCCGCCTCCACT - 3’ 
ABHD2p_Rev:  5’ - GGATCCATTGATCAGCGAAG - 3’ 
ABHD2q_Fwd:  5’ - AATGGATCCCCTCCTAGACG - 3’ 
ABHD2q_Rev:  5’ - CTTGTTCATTGGGCAGTTCA - 3’ 
ABHD2r_Fwd:  5’ - GATCCCCTCCTAGACGCAAT - 3’ 
ABHD2r_Rev:  5’ - TTGTTCATTGGGCAGTTCAG - 3’ 
ABHD2s_Fwd:  5’ - GTGGAGAAGCGGCTGAACT - 3’ 
ABHD2s_Rev:  5’ - CCCCTAACCACGGAAACC - 3’ 
ABHD2t_Fwd:  5’ - AAGCGGTTTCCGTGGTTAG - 3’ 
ABHD2t_Rev:  5’ - TCATGGATATACAGCCGGAAC - 3’ 
ABHD2u_Fwd:  5’ - GTGGCGGCAGTTACTTGG - 3’ 
ABHD2u_Rev:  5’ - GGCGCTCATGGATATACAGC - 3’ 
 
ii) GDF15 
GDF15a_Fwd:  5’ - GGCAGAGAGGCATGACACAT - 3’ 
GDF15a_Rev:  5’ - TTGGGGTCAAAGGCTAAAGA - 3’ 
GDF15b_Fwd:  5’ - CCCTTCCTGGCTCCATCTA - 3’ 
GDF15b_Rev:  5’ - CCCATGGGATTTCCTCTCTT - 3’ 
GDF15c_Fwd:  5’ - TGCTTCCTTTGTTTTTCACCA - 3’ 
GDF15c_Rev:  5’ - GACAAGAGTTTAAGAGGTGGCTGT - 3’ 
GDF15d_Fwd:  5’ - CTTTGACCCCAACCAAAAAG - 3’ 
GDF15d_Rev:  5’ - GGGAGTCTTTTTGGAGGAAAA - 3’ 
GDF15e_Fwd:  5’ - CCTTTGACCCCAACCAAAA - 3’ 
GDF15e_Rev:  5’ - CTGGGAGTCTTTTTGGAGGAA - 3’ 
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GDF15f_Fwd:  5’ - AGGAAATCCCATGGGCATAGA - 3’ 
GDF15f_Rev:  5’ - AGCCTGGGAGTCTTTTTGGA - 3’ 
GDF15g_Fwd:  5’ - AACTCTTGTCTGGAATTTTTCACAT - 3’ 
GDF15g_Rev:  5’ - GGCCTCAGTATCCTCTTCCTC - 3’ 
GDF15h_Fwd:  5’ - TTTTTCCTCCAAAAAGACTCC - 3’ 
GDF15h_Rev:  5’ - GGGCGCTCCTAGTAAAGCTA - 3’ 
GDF15i_Fwd:  5’ - AGGCTGGAATGGTGTCCTC - 3’ 
GDF15i_Rev:  5’ - TAGGGGGAGGATCTTTAGGTG - 3’ 
GDF15j_Fwd:  5’ - TACTGAGGCCCAGAAATGTG - 3’ 
GDF15j_Rev:  5’ - AAACACTCCAATGACCACAGC - 3’ 
GDF15k_Fwd:  5’ - CCAGAAATGTGCCCTAGCTT - 3’ 
GDF15k_Rev:  5’ - TAAACACTCCAATGACCACAGC - 3’ 
GDF15l_Fwd:  5’ - CACCTAAAGATCCTCCCCCTA - 3’ 
GDF15l_Rev:  5’ - CGTCTCCGCCTGCTCAGT - 3’ 
GDF15m_Fwd:  5’ - GATCCTCCCCCTAAATACACC - 3’ 
GDF15m_Rev:  5’ - TCTCCGCCTGCTCAGTCC - 3’ 
GDF15n_Fwd:  5’ - CAGCTGTGGTCATTGGAGTG - 3’ 
GDF15n_Rev:  5’ - TTTATAGTCCCCGGACTTTGTC - 3’ 
GDF15o_Fwd:  5’ - GACTGAGCAGGCGGAGAC - 3’ 
GDF15o_Rev:  5’ - CCGGACCGGCCTTTATAGT - 3’ 
GDF15p_Fwd:  5’ - AAAGTCCGGGGACTATAAAGG - 3’ 
GDF15p_Rev:  5’ - GAGCTGGGACTGACCAGATG - 3’ 
GDF15q_Fwd:  5’ - ATCTGGTCAGTCCCAGCTCA - 3’ 
GDF15q_Rev:  5’ - CCATTCACCGTCCTGAGTTC - 3’ 
GDF15r_Fwd:  5’ - GAACTCAGGACGGTGAATGG - 3’ 
GDF15r_Rev:  5’ - ACGAGAGCACCAGCAACAC - 3’ 
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GDF15s_Fwd:  5’ - CTCAGATGCTCCTGGTGTTG - 3’ 
GDF15s_Rev:  5’ - AGGGTCCCGGGAAACTTG - 3’ 
GDF15t_Fwd:  5’ - AGTTTCCCGGGACCCTCA - 3’ 
GDF15t_Rev:  5’ - TCTCGGAATCTGGAGTCTTCG - 3’ 
GDF15u_Fwd:  5’ - CTCCAGATTCCGAGAGTTGC - 3’ 
GDF15u_Rev:  5’ - AGCCTGGTTAGCAGGTCCTC - 3’ 
 
iii) ITPR1 
ITPR1a_Fwd:  5’ - AGAAATCCGAGCTCCTAGCC - 3’ 
ITPR1a_Rev:  5’ - CAAAGTCACCCCTGGGAAG - 3’ 
ITPR1b_Fwd:  5’ - CCCCAGTGACACCTGGATT - 3’ 
ITPR1b_Rev:  5’ - GAGCCAGCCGTTCAAAGTC - 3’ 
ITPR1c_Fwd:  5’ - CTTCCCAGGGGTGACTTTG - 3’ 
ITPR1c_Rev:  5’ - AGGCTTTCAGGCTGCTGAG - 3’ 
ITPR1d_Fwd:  5’ - CTTCCCAGGGGTGACTTTG - 3’ 
ITPR1d_Rev:  5’ - GAGGCTTTCAGGCTGCTG - 3’ 
ITPR1e_Fwd:  5’ - CAAGGAACAGGCTCAGCAG - 3’ 
ITPR1e_Rev:  5’ - GGGCTGGGCCCTAAATAGAC - 3’ 
ITPR1f_Fwd:  5’ - CCCGCACGCGTCTATTTA - 3’ 
ITPR1f_Rev:  5’ - TAGTCCAAGTAGCGGGTCGT - 3’ 
ITPR1g_Fwd:  5’ - CAGGGGATTCTGGGACTTGT - 3’ 
ITPR1g_Rev:  5’ - TAGTCCAAGTAGCGGGTCGT - 3’ 
ITPR1h_Fwd:  5’ - AGGGGATTCTGGGACTTGTAG - 3’ 
ITPR1h_Rev:  5’ - GCTTATATAGGCCGGGAAGC - 3’ 
ITPR1i_Fwd:  5’ - CAGGGGATTCTGGGACTTGT - 3’ 
ITPR1i_Rev:  5’ - GCTTATATAGGCCGGGAAGC - 3’ 
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ITPR1j_Fwd:  5’ - CGACCCGCTACTTGGACTAC - 3’ 
ITPR1j_Rev:  5’ - GCAGCACATCCACATGGTTA - 3’ 
ITPR1k_Fwd:  5’ - CGACCCGCTACTTGGACTAC - 3’ 
ITPR1k_Rev:  5’ - AGCAGCACATCCACATGGT - 3’ 
ITPR1l_Fwd:  5’ - ATGTGGATGTGCTGCTGAAG - 3’ 
ITPR1l_Rev:  5’ - TGCGCTTTCTCTCTCTCCAC - 3’ 
ITPR1m_Fwd:  5’ - ATGTGGATGTGCTGCTGAAG - 3’ 
ITPR1m_Rev:  5’ - TTAGGATGGAAGCGGAACAC - 3’ 
ITPR1n_Fwd:  5’ - GGGGGTGGAGAGAGAGAAAG - 3’ 
ITPR1n_Rev:  5’ - TCGTTCCGTTAGGATGGAAG - 3’ 
ITPR1o_Fwd:  5’ - AGGGGGTGGAGAGAGAGAAA - 3’ 
ITPR1o_Rev:  5’ - GTTAGGATGGAAGCGGAACA - 3’ 
ITPR1p_Fwd:  5’ - GTGTTCCGCTTCCATCCTAA - 3’ 
ITPR1p_Rev:  5’ - CGAGGAGAGGGGTTAGCAG - 3’ 
ITPR1q_Fwd: 5’ - TTCCATCCTAACGGAACGAG - 3’ 
ITPR1q_Rev:  5’ - CGAGGAGAGGGGTTAGCAG - 3’ 
ITPR1r_Fwd:  5’ - CCGGGCGCAGAAGTTTTT - 3’ 
ITPR1r_Rev:  5’ - TGCATGCACATCCATCAAG - 3’ 
ITPR1s_Fwd:  5’ - CTCTCGGGGAGATCTTGATG - 3’ 
ITPR1s_Rev:  5’ - GTAAAGGAACCCCCAAATGC - 3’ 
ITPR1t_Fwd:  5’ - CGGGGAGATCTTGATGGAT - 3’ 
ITPR1t_Rev:  5’ - AACAACTGCCCGCAGTAAAG - 3’ 
ITPR1u_Fwd:  5’ - CATGCACTTGGCATGCATTT - 3’ 
ITPR1u_Rev:  5’ - AAAACAACTGCCCGCAGTAAA - 3’ 
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iv) NELL2 
NELL2a_Fwd:  5’ - AAAGACCGCCCATCAACTTA - 3’ 
NELL2a_Rev: 5’ – TTCTCCCTCCCTCTCTCGAT - 3’ 
NELL2b_Fwd:  5’ - TTCAATCCCGAAAGGAGGTT - 3’ 
NELL2b_Rev: 5’ – GTTGCAGCCTCAGCTCTTCT - 3’ 
NELL2c_Fwd:  5’ - AGAGGGAGGGAGAAGAGCTG - 3’ 
NELL2c_Rev: 5’ - GTCTCCTGGATGCCAAACC - 3’ 
NELL2d_Fwd:  5’ - GAGAAGAGCTGAGGCTGCAA - 3’ 
NELL2d_Rev: 5’ - GGTCTCCTGGATGCCAAAC - 3’ 
NELL2e_Fwd:  5’ - CTAGACCGGGTTTGGCATC - 3’ 
NELL2e_Rev: 5’ - GAGGCGGGGTAAGGAGGA - 3’ 
NELL2f_Fwd:  5’ -CCCTCCCTCCTCCTTACCC - 3’ 
NELL2f_Rev: 5’ - GAGACGCGCGGAGAGACT - 3’ 
NELL2g_Fwd:  5’ - GCCCCTCCCTCCTCCTTA - 3’ 
NELL2g_Rev: 5’ - AGAAAGCTCCGGGAGACG - 3’ 
NELL2h_Fwd:  5’ - CCCGGAGGAGCAGTCTCT - 3’ 
NELL2h_Rev: 5’ - CGAACCTGTTGTAAAGGCAGA - 3’ 
NELL2i_Fwd:  5’ - CGTCTCCCGGAGCTTTCT - 3’ 
NELL2i_Rev: 5’ - CGCCCGAACCTGTTGTAA - 3’ 
NELL2j_Fwd:  5’ - TCTGCCTTTACAACAGGTTCG - 3’ 
NELL2j_Rev: 5’ - ACTCGCACACCCGGTAGA - 3’ 
NELL2k_Fwd:  5’ - CTGCCTTTACAACAGGTTCG - 3’ 
NELL2k_Rev: 5’ - TAAAAGCAGCCAAAGACTCG - 3’ 
NELL2l_Fwd:  5’ - TCTACCGGGTGTGCGAGT - 3’ 
NELL2l_Rev:  5’ - ATTAGCTCCCGAGCCGAATA - 3’ 
NELL2m_Fwd:  5’ - GCGAGTCTTTGGCTGCTTT - 3’ 
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NELL2m_Rev:  5’ - GCTCCGTCGGGGAATTAG - 3’ 
NELL2n_Fwd:  5’ - TTATTCGGCTCGGGAGCTA - 3’ 
NELL2n_Rev: 5’ - CAATGCGCACATCATTCC - 3’ 
NELL2o_Fwd:  5’ - TATTCGGCTCGGGAGCTA - 3’ 
NELL2o_Rev: 5’ - CTCCAATGCGCACATCATT - 3’ 
NELL2p_Fwd:  5’ - CTGCGTGTGGGAATGATGT - 3’ 
NELL2p_Rev:  5’ - GCGCGTGAAGAACTTAGACC - 3’ 
NELL2q_Fwd:  5’ - CTGCGTGTGGGAATGATGT - 3’ 
NELL2q_Rev:  5’ - GCGCGTGAAGAACTTAGACC - 3’ 
NELL2r_Fwd:  5’ - CGCATTGGAGGGTCTAAGTT - 3’ 
NELL2r_Rev: 5’ - ACGCTTTGGTTGCCTAAGAA - 3’ 
NELL2s_Fwd:  5’ - GAGGCCTCCCTTTTCTTTCT - 3’ 
NELL2s_Rev: 5’ - GCTGCCTCGGATTTACTGAT - 3’ 
NELL2t_Fwd:  5’ - TTCTTAGGCAACCAAAGCGTA - 3’ 
NELL2t_Rev: 5’ - GCGGGAAAATAACGTTTGTC - 3’ 
NELL2u_Fwd:  5’ - CAGTAAATCCGAGGCAGCAG - 3’ 
NELL2u_Rev: 5’ - TGGAATCAAGCGGGAAAATA - 3’ 
 
v) SCN1A 
SCN1Aa_Fwd:  5’ - CCTTTTCCCCTCATCCTTGT - 3’ 
SCN1Aa_Rev:  5’ - TGTGCGTATAAAGGCAAAGG - 3’ 
SCN1Ab_Fwd:  5’ - TCCTTTTCCCCTCATCCTTG - 3’ 
SCN1Ab_Rev:  5’ - TGACACACCCAGAAGATGGA - 3’ 
SCN1Ac_Fwd:  5’ - CCTTTGCCTTTATACGCACAGTCT - 3’ 
SCN1Ac_Rev:  5’ - CAGTCTGTGACACACCCAGA - 3’ 
SCN1Ad_Fwd:  5’ - CTGGGTGTGTCACAGACTGAA - 3’ 
169 
SCN1Ad_Rev:  5’ - TGGTTCAAATATGGCCTTAATCA - 3’ 
SCN1Ae_Fwd:  5’ - TTTGATTAAGGCCATATTTGAACC - 3’ 
SCN1Ae_Rev:  5’ - CAGGAACTGTGCCATGAGTTT - 3’ 
SCN1Af_Fwd:  5’ - TGATTAAGGCCATATTTGAACCA - 3’ 
SCN1Af_Rev:  5’ - ACAGGAACTGTGCCATGAGT - 3’ 
SCN1Ag_Fwd:  5’ - AACTCATGGCACAGTTCCTGTA - 3’ 
SCN1Ag_Rev:  5’ - CAAATGGTTTCTGTGTTGAGTTT - 3’ 
SCN1Ah_Fwd:  5’ - AAACTCAACACAGAAACCATTTG - 3’ 
SCN1Ah_Rev:  5’ - TCCTTAAATTGAAAGGTGATTTCTAA - 3’ 
SCN1Ai_Fwd:  5’ - AAACTCAACACAGAAACCATTTGT - 3’ 
SCN1Ai_Rev:  5’ - TTTCTCCTTAAATTGAAAGGTGATTT - 3’ 
SCN1Aj_Fwd:  5’ - CACCTTTCAATTTAAGGAGAAAACA - 3’ 
SCN1Aj_Rev:  5’ - TGTCATGAAACATGAGCTAGAGG - 3’ 
SCN1Ak_Fwd:  5’ - CACCTTTCAATTTAAGGAGAAAACA - 3’ 
SCN1Ak_Rev:  5’ - TCATGAAACATGAGCTAGAGGA - 3’ 
SCN1Al_Fwd:  5’ - GCTCATGTTTCATGACAAGAATTT - 3’ 
SCN1Al_Rev:  5’ - AGGAATACAGATATTTTAAAGAGTGGA - 3’ 
SCN1Am_Fwd:  5’ - GTCCACTCTTTAAAATATCTGTATTCC - 3’ 
SCN1Am_Rev:  5’ - TGCATATGAAATTCCTAAAATAAAAGG - 3’ 
SCN1An_Fwd: 5’ - GGAATTTCATATGCAGAATAAATGGT - 3’ 
SCN1An_Rev:  5’ - TGCTCCATCTTGTCATCCTG - 3’ 
SCN1Ao_Fwd:  5’ - TGCAGGATGACAAGATGGAG - 3’ 
SCN1Ao_Rev:  5’ - TGTCAGGTCCTGGTGGTACA - 3’ 
SCN1Ap_Fwd:  5’ - TGTACCACCAGGACCTGACA - 3’ 
SCN1Ap_Rev:  5’ - TTCTGCAATGCGTCTTTCAA - 3’ 
SCN1Aq_Fwd:  5’ - TCTCTTGCGGCTATTGAAAGA - 3’ 
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SCN1Aq_Rev:  5’ - TTGGGATTCTTTGCCTTTTC - 3’ 
SCN1Ar_Fwd:  5’ - TGAAAGACGCATTGCAGAAG - 3’ 
SCN1Ar_Rev:  5’ - GCCATTTTCGTCGTCATCTT - 3’ 
SCN1As_Fwd:  5’ - AAAAGGCAAAGAATCCCAAA - 3’ 
SCN1As_Rev:  5’ - GCCATTTTCGTCGTCATCTT - 3’ 
SCN1At_Fwd:  5’ - AAAAGATGACGACGAAAATGG - 3’ 
SCN1At_Rev:  5’ - AAGGTTCTTTCCAGCTTCCA - 3’ 
SCN1Au_Fwd:  5’ - GCCCAAAGCCAAATAGTGAC - 3’ 
SCN1Au_Rev:  5’ - TGACACCATCTCTGGAGGAA - 3’ 
 
vi) TMSL8 
TMSL8a_Fwd:  5’ - CTGGCCAAGGATTAGAGCAG - 3’ 
TMSL8a_Rev:  5’ - GCCCAAGGATGCTGTGATAA - 3’ 
TMSL8b_Fwd:  5’ - GAGCCCCACTTCCAACCTAC - 3’ 
TMSL8b_Rev:  5’ - CCGGTATTTAGGCTCTTTCG - 3’ 
TMSL8c_Fwd:  5’ - GGCCCCAATGGCTATAAAAA - 3’ 
TMSL8c_Rev:  5’ - GAGGTCCAAGCTGAATGACC - 3’ 
TMSL8d_Fwd:  5’ - ATACCGGTCATTCAGCTTGG - 3’ 
TMSL8d_Rev:  5’ - ATCTCGCCCAGTGAGCTTAG - 3’ 
TMSL8e_Fwd:  5’ - GGTCATTCAGCTTGGACCTC - 3’ 
TMSL8e_Rev:  5’ - ATCTCGCCCAGTGAGCTTAG - 3’ 
TMSL8f_Fwd:  5’ - CTAAGCTCACTGGGCGAGAT - 3’ 
TMSL8f_Rev:  5’ - TCCACATACCCTTCATCCTGA - 3’ 
TMSL8g_Fwd:  5’ - TCAGGATGAAGGGTATGTGGA - 3’ 
TMSL8g_Rev:  5’ - GGCCTCTTCCACTGCTTTAG - 3’ 
TMSL8h_Fwd:  5’ - TGGACCCTCAGGACTAAAGC - 3’ 
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TMSL8h_Rev:  5’ - GGGCTTGGTGAAGTCAGAGC - 3’ 
TMSL8i_Fwd:  5’ - GGACCCTCAGGACTAAAGCA - 3’ 
TMSL8i_Rev:  5’ - GGGGCTTGGTGAAGTCAGA - 3’ 
TMSL8j_Fwd:  5’ - GGTCGGCTCTGACTTCACC - 3’ 
TMSL8j_Rev:  5’ - GCGTCCACCCTCTCCTCTA - 3’ 
TMSL8k_Fwd:  5’ - GTCGGCTCTGACTTCACCA - 3’ 
TMSL8k_Rev:  5’ - CCTCCGCTTGAGTGTACAGA - 3’ 
TMSL8l_Fwd:  5’ - GATCCTAGAGGAGAGGGTGGA - 3’ 
TMSL8l_Rev:  5’ - CCTCCTCCGCTTGAGTGT - 3’ 
TMSL8m_Fwd:  5’ - CTGTACACTCAAGCGGAGGA - 3’ 
TMSL8m_Rev:  5’ - TCTGATTGGCCAAAGGTTTC - 3’ 
TMSL8n_Fwd:  5’ - GAAACCTTTGGCCAATCAGA - 3’ 
TMSL8n_Rev:  5’ - AGTGCTAAGCCACCCAGCAG - 3’ 
TMSL8o_Fwd:  5’ - GAAACCTTTGGCCAATCAGA - 3’ 
TMSL8o_Rev:  5’ - CGGACCAGGTTAGCGTTC - 3’ 
TMSL8p_Fwd:  5’ - CTGCTGGGTGGCTTAGCACT - 3’ 
TMSL8p_Rev:  5’ - GGGGCTGAGACCCAGACT - 3’ 
TMSL8q_Fwd:  5’ - AGCGAGTCTGGGTCTCAGC - 3’ 
TMSL8q_Rev:  5’ - AAGCTTGAAGACTCGTGAAAGG - 3’ 
TMSL8r_Fwd:  5’ - AGCGAGTCTGGGTCTCAGC - 3’ 
TMSL8r_Rev:  5’ - AAGCTTGAAGACTCGTGAAAGG - 3’ 
TMSL8s_Fwd:  5’ - ACAGCCTTTCACGAGTCTTCA - 3’ 
TMSL8s_Rev:  5’ - CATGGTCCTCTGGCTCCTG - 3’ 
TMSL8t_Fwd:  5’ - CAGCCTTTCACGAGTCTTCA - 3’ 
TMSL8t_Rev:  5’ - CATCCCCATGGTCCTCTG - 3’ 
TMSL8u_Fwd: 5’ - GACCATGGGGATGGGAAG - 3’ 
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TMSL8u_Rev:  5’ - CCAACCTCGGCTCCTCTG - 3’ 
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Analysis of NFB-Dependent Transcription in Human 
Cardiomyocytes: Roles for PARP-1 and Other Transcription Factors 
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4.1 Summary 
Cardiovascular disease (CVD) is the number one cause of death in the United State, 
claiming over 800,000 lives per year.  Although studies have elucidated a number of 
molecular mechanisms leading to CVD, many of them still remain unclear.  
Cardiomyocytes that are subjected to stress signals, such as cytokines (eg. TNFα), 
activate many different transcriptional pathways to respond to such insults, and one 
transcription factor that is central to these responses is NFB.  I are using a recently 
generated immortalized human cardiomyocyte cell line, AC16, to study the 
mechanisms of NFB-dependent transcription, as well as the role of other factors in 
regulating this response.  I show that in human cardiomyocytes, the NFB subunit p65 
is significantly recruited to the genome upon TNFα treatment, and NFB recruitment 
both up- and down-regulates the expression of a number of genes.  These genes 
specifically reprioritize the transcriptional program of the cells to focus on stress 
response.  Additionally, I find that a majority of the NFB-dependent genes are likely 
to involve other transcription factors (including CREB, which has previously been 
shown to cooperate with NFB), suggested to us by the lack of a canonical NFB 
binding site at a majority of target promoters.  Finally I show that Poly (ADP ribose) 
Polymerase-1 (PARP-1), which has been shown to play a prominent role in the in the 
regulation of NFB-dependent transcription, acts as an activator of NFB, but not a 
repressor.  Together, our data shows that NFB-dependent transcription is central for 
human cardiomyocytes to respond to TNFα, but that other factors, including PARP-1 
and likely many others, are also critical for this response.   
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4.2 Introduction 
 
Cardiovascular disease (CVD) is the leading cause of death in the United States 
(Mehra, 2007).  Understanding the regulatory processes that control the biology of 
cardiomyocytes in normal and disease states is a necessary step in developing better 
preventative and therapeutic approaches to CVD.  Key aspects of cardiomyocytes 
physiology are determined by the regulation of gene expression.  Numerous studies 
have demonstrated a clear role for sequence-specific DNA-binding transcription 
factors, such as GATA4, STATs and AP-1 in regulating gene expression outcomes in 
cardiomyocytes (Epstein and Parmacek, 2005, Fischer and Hilfiker-Kleiner, 2007, 
Henderson and Tyagi, 2006, Kim and Iwao, 1999).  But probably the most established 
and well-characterized pro-inflammatory transcription factor is the Nuclear Factor 
Kappa-light-chain-enhancer of activated B cells, or NFB (Epstein and Parmacek, 
2005).  NFB is a dimeric complex of two proteins, one from the Rel class and the 
other from the NFB class (Fig. 4.1).  Members of the NFB class are synthesized as 
precursors with a repression domain, which is cleaved during activation.  This allows 
for dimerization of one member of each of the classes, which then results in an active 
NFB complex (Lentsch and Ward, 1999, Lentsch and Ward, 2000).  Upon 
stimulation by various molecules (including Tumor Necrosis Factor Alpha, or TNFα), 
a signaling cascade is initiated, which ultimately results in the activation of the 
cytosolic kinase IKKα/β.  This kinase phosphorylates IB, the protein which 
sequesters NFB in the cytosol.  Upon phosphorylation, IB is degraded by the 
proteosome, NFB translocates into the nucleus, bind chromatin and regulate gene 
expression (Fig. 4.2) (Lentsch and Ward, 1999, Lentsch and Ward, 2000).   
The pathways that regulate NFB-dependent gene expression are relatively 
well established, and a number of factors have been implicated as co-regulators for 
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Figure 4.1. NFB Family of Proteins.  Schematic shown the domain structure of the 
proteins that comprise the NFB family.  RelA, RelB and cRel proteins (Rel class) can 
dimerize with NFB1 or NFB2 proteins (NFB class).  LZD = Leucine Zipper 
Domain; GRR = Glycine Rich Region.  Figure adapted from (Rangan, et al., 2009).   
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NFB-dependent transcription.  These include DNA-binding transcription factors such 
as E2F, AP-2, SP-1 and p53, as well as co-regulators including CBP/p300, HDACs, 
CARM1, and even IKKα, which until recently was not thought to be chromatin-bound 
(Chen, et al., 2001, Covic, et al., 2005, Hassa, et al., 2003, Hassa, et al., 2005, Hirano, 
et al., 1998, Katsel and Greenstein, 2001, Lim, et al., 2007, Meylan, et al., 2009, 
Yamamoto, et al., 2003, Yang, et al., 2000).  Thus, NFB is a versatile transcription 
factor that can regulate a variety of biological processes depending on the signaling 
pathways that are activated, and the co-regulators that are involved.   
 PARP-1 is involved in regulating the response to a number of stress factors 
leading to CVD (Molnar, et al., 2006, Pacher and Szabo, 2007, Pillai, et al., 2005, 
Szabo, et al., 2006).  It plays a role at multiple stages of CVD, including the initial 
acute-phase pro-inflammatory response, and the later apoptotic phase if the cells are 
damaged beyond recovery.  Regarding the latter, cardiomyocytes cultured from 
PARP-1 knockout mice have been shown to improve mitochondrial functions, and 
reduced NAD+ consumption (Pacher and Szabo, 2007, Pillai, et al., 2006).  Further 
supporting the involvement of PARP-1 in pro-inflammatory responses, PARP-
deficient Drosophila have immune defects, and are more susceptible to bacterial 
infection as their wild-type counterparts (Tulin and Spradling, 2003).  These results 
indicate that PARP-1 inhibitors may be useful as therapeutic tools against heart 
disease, leading to studies testing PARP inhibitors for this purpose (Pacher and Szabo, 
2007).  PARP-1 has also been shown to regulate pro-inflammatory transcription in 
cells that are exposed to stress during CVD.  Specifically, PARP-1 can regulate the 
expression of pro-inflammatory genes, including inducible nitric oxide synthase 
(iNOS), adhesion molecules (VCAM1, ICAM1) and class II MHCs (Pacher and Szabo, 
2007).  The mechanism of PARP-1 action at these genes is not fully understood, 
although recent work has begun to elucidate some of these pathways, 
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Figure 4.2.  NFB Signaling Pathway.  A simplified rendition of the activation 
pathway of NFB.  Translocation of NFB into the nucleus is dependent on external 
signals, resulting in a signaling cascade which activates IKKα/β.  Degradation of 
phosphorylated IB allows NFB to translocate into the nucleus, and regulate gene 
expression.  Figure adapted from (Li and Stark, 2002).   
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which include p300/CBP, and Mediator (Hassa, et al., 2005).   
I am interested in the role of PARP-1 and other transcription factors in 
regulating NFB-dependent transcription in human cardiomyocytes.  Recently, 
immortalized cardiac cell lines have been developed as a tool for studying the 
regulation of processes such as gene expression in cardiomyocytes.  One example of 
such a cell line is the immortalized human cardiomyocyte cell line, AC16 (Davidson, 
et al., 2005).  These cells have been immortalized using the SV40 antigen, but were 
shown to maintain the hallmarks of primary cardiomyocytes, thus making them a 
useful model system for the study of gene regulation in cardiomyocytes.  Using ChIP-
chip in AC16 cells, I found that TNFα can stimulate NFB translocation into the 
nucleus, as well as its global recruitment onto chromatin.  In addition, I found that by 
categorizing NFB-recruited genes using RNA Polymerase II ChIP-chip data, I could 
identify functional categories of genes, which I then show to be regulated by NFB.  I 
also see that, while up-regulated genes are enriched for NFB binding sites, the 
majority of regulated genes do not contain a canonical DNA motif, strongly 
suggesting cooperation with other transcription factors for recruitment and activity of 
NFB.  While investigating the mechanisms of NFB action at gene promoters, I 
found that PARP-1 is required at genes with a canonical NFB site that are up-
regulated, but not at down-regulated genes. In conclusion, NFB transcription is 
critical for stress responses in human cardiomyocytes, and regulation of gene 
expression via NFB involves other factors such as PARP-1.  Future studies will 
examine the roles of other transcription factors in regulating the various categories of 
NFB-dependent genes, as well as investigate whether PARP-1 affects up-regulated 
genes lacking a canonical NFB site.   
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4.3 Results 
AC16 cells are a relatively newly characterized cell line (Davidson, et al., 
2005), and although it is known that cardiomyocytes are responsive to stress signals 
such as TNFα  (Natoli, et al., 1998), I wanted to confirm that these immortalized cells 
had a similar response to primary cardiomyocytes.  To this end, I treated the cells with 
TNFα, and determined whether the prototypic pro-inflammatory transcription factor, 
NFB, translocated into the nucleus.  I used an antibody against the p65 subunit of 
NFB complex, which has previously been reported to be entirely sequestered in the 
cytosol prior to activation (Lentsch and Ward, 1999, Lentsch and Ward, 2000).  I 
found that at basal levels, there was no p65 in the nucleus, but that upon TNFα 
treatment, NFB levels in the nucleus increased drastically (Fig 4.3A).  I was also able 
to demonstrate that using an IKKα/β inhibitor, BAY 11-7085, I could block the 
translocation of NFB into the nucleus upon TNFα treatment (Fig. 4.3A).  Having 
established that NFB activity was as expected in this cell line, I examined the effect 
of TNFα on the expression of prototypic pro-inflammatory NFB targets.  I measured 
the change in mRNA levels of six genes upon treatment with TNFα for 30 min and 
180 min.  All six genes showed a significant increase in expression after 180 min, with 
two of the genes (TNFA and IL6) having increased expression even at 30 min (Fig. 
4.3B).  This can be explained by the fact that these two genes encode cytokines 
(TNFα [which upregulates itself], and Il6).  Not only are these genes shorter, but they 
are also more early-response genes in the pro- inflammatory process (Lentsch and 
Ward, 2000).  In addition, I also used BAY 11-7085 to show that these responses were 
dependent on NFB activation.  If the cells were pre-treated with the inhibitor, the 
response to TNFα was either abrogated or greatly reduced (Fig. 4.3B).  These data 
show that TNFα activates a pro-inflammatory response in AC16 cells, and that the 
transcription factor NFB plays an important role in this activation.  Interestingly,  
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Figure 4.3.  AC16 cells are responsive to TNFα treatment.  (A) Western blot of 
AC16 cytoplasmic and nuclear fractions blotted for NFB, TFIIB (nuclear marker) 
and GAPDH (cytoplasmic marker), in control and TNFα-treated cells.   In addition, 
one set of samples was also pre-treated with 10 µg/ml of the IKKα/β inhibitor, BAY-
11-7082, for 1 hr.  (B-G) Analysis of mRNA expression by RT-qPCR in TNFα-
treated AC16 cells relative to vehicle treated cells.  Cells were treated with 25 ng/ml 
TNFα for either 30 min or 180 min.  One set of samples was also pre-treated with 
(labeled Bay) 10 µg/ml of BAY-11-7082 for 1 hr Expression data is standardized to β-
actin transcripts.  All samples were done in Luciferase Knockdown cells, for 
comparison with data in Fig. 4.11.  Each data point is a mean of n = 3.  Error bar 
represents SEM.   
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when I searched for DNA sequence motifs under significant peaks of NFB in the 
TNFα treated cells, I found that the NFB site itself was not as enriched as a number 
of other sites (Table 4.1).  This result was further investigated, and will be discussed 
later in this study.   
Having established that NFB translocates to the nucleus upon TNFα as expected, I 
then wanted to investigate the genomic binding pattern of NFB in AC16 cells.  I used 
Chromatin Immunoprecipitation coupled with DNA microarrays (ChIP-chip) using a 
Nimblegen promoter array, to probe 23,551 RefSeq promoters, tiled from -3.2 KB to 
+3.2 KB from the transcription start site (Fig. 4.4A).  While I observed some 
background binding of NFB in the basal condition, upon TNFα treatment, there was 
a drastic global increase in chromatin-bound NFB (Fig. 4.4A).  This result suggested 
that there was a global response in these cells to treatment with TNFα, which involved 
NFB binding to chromatin.  I then counted the number of promoters with statistically 
significant peaks of NFB, both in the untreated and TNFα-treated condition.  There 
were almost three times as many genes with peaks in the TNFα-treated cells, again 
demonstrating the global recruitment of NFB to chromatin (Fig. 4.4B).  In fact, genes 
could be categorized as either “significantly recruited” or “not recruited” based on 
stringent statistical criteria (Fig. 4.4D and 4.4E).   
This was also confirmed by conventional ChIP coupled with quantitative PCR (ChIP-
qPCR) (Fig. 4.4C).   
As previously mentioned, NFB is a transcription factor that regulates 
transcription of numerous genes in various different contexts (Covic, et al., 2005, 
Hassa, et al., 2003, Lentsch and Ward, 2000, Meylan, et al., 2009).  Therefore, I was 
interested in the functional outcomes of NFB binding to gene promoters upon TNFα 
treatment in AC16 cells.  In order to address this question, I performed RNA 
Polymerase II (Pol II) ChIP-chip on the same Nimblegen arrays as were used for 
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Table 4.1.  Enrichment of transcription factor binding sites (based on Transfac®) 
under statistically significant NFkB peaks  
 
 
aSite bFold Enrichment 
NFY 6.8 
SP1 6.7 
AP2 6.6 
PAX4 6.3 
PAX5 6.0 
AHRARNT 5.7 
EGR1 5.6 
TAXCREB 5.5 
CREB 5.5 
ATF 5.5 
NFKB 2.7 
 
aSites within 200bp of statistically significant peaks of NFB 
bEnrichments all have pvalues of p<1x10-300 
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Figure 4.4.  NFB is recruited to chromatin upon TNFα treatment in AC16 cells.  
(A) Heat maps of NFB ChIP-chip data in control cells, or TNFα-treated cells (25 
ng/ml for 30 min), shown from -3 kb to +3 kb relative to the TSS.  The data are 
ordered based on the intensity of the NFB signal at the promoter in the TNFα-treated 
sample.  (B)  Venn diagram showing the number of promoters with statistically 
significant (p<0.016) peaks of NFB on the ChIP-chip array in control and TNFα-
treated cells.  (C) Scatter plot of gene-specific ChIP-qPCR analyses of NFB binding 
at regions of statistically significant (p<0.016) NFB recruitment upon TNFα 
treatment, and regions without NFB recruitment.  Each data point is a mean of n = 3.  
Bar represents median.  (D) Average Log2 ratios of ChIP-chip data minus and plus 
TNFα for promoters with statistically significant (p<0.016) NFB recruitment upon 
TNFα treatment.  (E) Same as (D) for promoters without NFB recruitment.   
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NFB.  As is demonstrated by the resulting heat maps (Fig. 4.5A), a considerable 
number of genes contained Pol II bound at the promoter in the untreated condition.  
Upon TNFα treatment, a large proportion of genes showed significant change in Pol II 
binding, which can also be seen by averaging all the data (Figs. 4.5A and 4.5B).  
Specifically, there was a small but significant overall decrease in promoter-proximal 
Pol II, accompained by an increase in Pol II in the body of the gene (defined as +1KB 
to +3KB for statistical analyses) (Fig. 4.5B).  This suggested that AC16 cells 
responded in a global manner to TNFα treatment by altering transcription of target 
genes.  The ChIP-chip data for Pol II was also confirmed by ChIP-qPCR (Fig. 4.5C).   
Pol II binding information serves as a direct measure of transcriptional activity 
(specifically Pol II in the body of the gene), but I wanted to ask whether changes in 
Pol II binding were likely to result in changes at the mRNA level.  I made use of three 
existing data sets for changes in gene expression after 1 hr of TNFα treatment.  These 
data sets are previously published, and use HeLa cells, HuVEC and epidermal 
keratinocytes (Banno, et al., 2005, Tian, et al., 2005, Wada, et al., 2009).  I used 
stringent fold-cutoff criteria to select the 80 most up-regulated and 80 most down-
regulated genes in each of the three data sets, and plotted our AC16 cell Pol II ChIP-
chip data for these 160 genes.  What I observed was that at the up-regulated genes the 
ChIP-chip signal in the body of the gene increased significantly, whereas as the down-
regulated genes, the peak of Pol II at the promoter virtually disappeared (Fig. 4.5 D, 
E).  This result supports the strength and the relevance of using Pol II ChIP-chip, both 
in terms of measuring a direct transcriptional response to TNFα, but at the same time, 
investigating genes that are likely regulated at the mRNA (and therefore protein) level 
as well.   
Having established that NFB is recruited to the genome upon TNFα 
treatment, and that Pol II binding is also regulated by TNFα, I wanted to find the 
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Figure 4.5.  RNA Polymerase II (Pol II) distribution on chromatin is altered upon 
TNFα treatment in AC16 cells.  (A) Heat maps of Pol II ChIP-chip data in control 
cells, or TNFα-treated cells (25 ng/ml for 30 min), shown from -3 kb to +3 kb relative 
to the TSS.  The data are ordered based on the total intensity of the Pol II in the 
TNFα-treated sample.  (B)  Average Log2 ratios of Pol II ChIP-chip data minus and 
plus TNFα for all promoters on the array.  (C) Scatter plot of gene-specific ChIP-
qPCR analyses of Pol II binding at regions of statistically significant (p<0.016) Pol II 
recruitment to the gene body upon TNFα treatment, regions without Pol II changes 
and regions of statistically significant (p<0.016) Pol II release from the gene body 
upon TNFα treatment.  Each data point is a mean of n = 3.  Bar represents median.  
(D) Average Log2 ratios of Pol II ChIP-chip data minus and plus TNFα for the top 80 
mRNA transcripts which are up-regulated in HeLa cells, HuVEC and epidermal 
keratinocytes upon 1 hr treatment with TNFα, based on published expression 
microarray data (refs).  All changes in mRNA transcript levels are 3 fold or greater 
(p<0.05).  (E) Same as (D), except for the 80 most down-regulated transcripts.   
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intersection between these data sets, or in other words, obtain a list of candidate genes 
whose transcription is regulated by NFB binding.  Using stringent statistical criteria 
(p<0.016, Fold>2, Wilcoxin sign-rank test), I divided the genes that showed changes 
in NFB into three functional categories based on changes in Pol II from +1KB to 
+3KB (i.e. in the body of the gene):  Pol II recruited, Pol II unchanged and Pol II 
released (these categories will henceforth be referred to as above) (Fig. 4.6 A-C).  The 
functional importance of these categories was determined using gene ontology (GO) 
analysis (Beissbarth and Speed, 2004).  While the Pol II unchanged category 
contained one non-relevant GO term, both the recruited and released categories 
yielded a significant number of terms (Fig. 4.6G).  When dissecting these terms, it was 
clear that while the up-regulated category consisted of genes involved in stress 
responses, such as nitric oxide synthesis and defense mechanism, the down-regulated 
category mostly comprised “housekeeping” functions, including transcription and 
metabolism (Fig. 4.6H, Tables 4.2, 4.3 and 4.4).  These results demonstrate that TNFα 
likely regulates a transition of the cell from a basal state to a stress-responsive state, 
and that this change at is orchestrated by NFB-dependent changes in transcription.   
For further proof that these categories contained genes that were ultimately relevant 
for the cellular response to TNFα, I went back to the mRNA data from HeLa cells, 
HuVEC and epidermal keratinocytes used in Fig. 4.4 (Banno, et al., 2005, Tian, et al., 
2005, Wada, et al., 2009).  In the Pol II recruited and released categories, a majority of 
the genes were up-regulated 1.2 fold or more at the mRNA level in at least 2 of the 
three above cell lines (Fig. 4.6I).  This again confirms that the genes regulated at the 
transcriptional level are also highly likely to be regulated at the protein level.   
Next, I performed motif searches underneath NFB peaks after TNFα treatment in the 
three Pol II-sorted categories of genes, and surprisingly, the categories revealed 
distinct binding behaviors of NFB.  In the Pol II recruited categories, the 
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Figure 4.6.  Categorization of NFB ChIP-chip data based on Pol II status.  
Average Log2 ratios of ChIP-chip data for NFB (A, C, E) and Pol II (B, D, F), minus 
and plus TNFα, for promoters where NFB is recruited.  Genes were sub-categorized 
based on Pol II binding, and will henceforth be referred to as such (recruited (A, B), 
unchanged (C, D) or released (E, F) upon TNFα).  Note: unchanged genes were 
selected based on p>0.9, to have similar numbers in each sub-category.  (G) Number 
of significant GO terms (p<0.1) obtained for Pol II recruited, unchanged and released 
genes using GOstat.  (H) Significant GO terms for Pol II recruited and released 
genes from (G) separated into functional categories.  (C) Percentage of genes in Pol II 
recruited and Pol II released categories that are regulated at least 1.2 fold at the mRNA 
level in two of the three cell lines in Fig. 4.5 (D,E).   
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most highly enriched binding sites were the reported canonical NFB sequences 
(Table 4.6).  On the other hand, in the unchanged and released categories, the NFB 
sequences were not significantly enriched, and instead, a number of other motifs were 
identified for a variety of transcription factors (Tables 4.8 and 4.9).  Interestingly 
however, even though the canonical binding site was enriched at Pol II recruited 
genes, a majority of them still do not contain a known NFB-binding sequence (Table 
4.5).  Additionally, when this analysis was performed on the Pol II recruited genes 
after removing all NFB canonical binding site-containing regions, a number of other 
transcription factor binding sites, including CREB, were still significantly enriched 
(Table 4.7).  This analysis reveled that although NFB can bind its canonical binding 
site, and does so specifically at up-regulated genes, there are a large number of 
promoters without a canonical site that are regulated and recruit NFB, strongly 
suggesting cooperation between NFB and other key transcription factors.   
Until now, I established that changes in NFB and Pol II binding can serve to 
separate regulated genes into functional categories.  The next question to address was 
whether NFB was in fact regulating the transcriptional changes that I observed in 
these categories.  I therefore selected 5 – 10 genes in each of the three Pol II 
categories, and examined gene-specific effects on factor binding at these promoters 
(Table 4.10).  I treated the cells with the IKKα/β inhibitor, BAY 11-7085, and 
discovered that inhibiting NFB translocation into the nucleus upon TNFα treatment 
had profound effects on Pol II binding (Fig. 4.7).  Specifically, Pol II increase and 
decrease upon TNFα treatment was abrogated by BAY 11-7085 (Fig. 4.7B) (as was 
recruitment of NFB, as expected (Fig. 4.7A)).  Therefore, not only is NFB and Pol 
II binding altered by exposure of AC16 cells to TNFα, but NFB is critical for the 
regulation of up- and down-regulated genes, even at genes that do not contain a 
canonical NFB binding site. 
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Table 4.2.  Gene ontology analysis showing enriched terms for genes where both 
NFB and RNA Polymerase II are recruited upon TNFα treatment. 
 
 
 
 
 
 
 
 
 
Go Term P value 
Cell Communication 0.00421  
Positive Regulation of Nitric Oxide Biosynthetic Process 0.00421  
Signal Transduction 0.00582  
Regulation of Nitric Oxide Biosynthetic Process 0.00582  
Nitric Oxide Biosynthetic Process 0.0449  
Nitric Oxide Metabolic Process 0.0449 
Nitric Oxide Synthase Regulator Activity 0.0499  
Positive Regulation of Binding 0.0723  
Negative Regulation of Biological Process 0.0905  
Positive Regulation of Biosynthetic Process 0.095  
Defense Response 0.095  
Regulation of Signal Transduction 0.095  
Regulation of Biological Process 0.095  
Small GTPase Regulator Activity 0.095  
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Table 4.3.  Gene ontology analysis showing enriched terms for genes where NFB 
is recruited and RNA Polymerase II is unchanged upon TNFα treatment. 
 
Go Term P value 
Embryonic Development 0.0809  
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Table 4.4.  Gene ontology analysis showing enriched terms for genes where NFB 
is recruited and RNA Polymerase II is released upon TNFα treatment. 
 
Go Term P value 
Transcription Factor Activity 3.6e-05  
Sequence-Specific DNA Binding 0.0185  
Regulation of Transcription 0.0356  
DNA Binding 0.0356  
Regulation of Transcription, DNA-Dependent 0.0356  
Regulation of Nucleic Acid Metabolic Process 0.0461  
Transcription, DNA-Dependent 0.0461  
RNA Biosynthetic Process 0.0461  
Regulation of Gene Expression 0.0502  
Transcription 0.0514  
Regulation of Cellular Metabolic Process 0.0613 
Aminopeptidase Activity 0.0681  
Regulation of Metabolic Process 0.091  
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PARP-1 is a known co-activator of NFB-dependent transcription, making it a prime 
candidate for the factors that cooperate with NFB at target genes in AC16 cells.  To 
test the role of PARP-1 in this cardiomyocyte cell line, I generated two separate 
shRNA-mediated PARP-1 knockdown cell lines (Fig. 4.8A) (Knockdown cell lines 
generated and tested with the help of Xin Luo).  In both  
knockdown cell lines, I tested the response of pro-inflammatory genes (same as in Fig. 
4.3) that are known to be regulated by PARP-1 in other cell types.  PARP-1 depletion 
caused a drastic reduction in induction of the mRNAs of these genes upon TNFα 
treatment compared with control cells, regardless of the time of maximal induction 
(Fig. 4.8 B –G).  Since both cell lines behaved identically, for future experiments I 
used P1-1 only.   Whether or not the catalytic activity of PARP-1 plays a role in 
NFB-dependent transcription has been somewhat controversial.  It appears to depend 
on the context and cell type, although more reports than not have suggested that it is 
not required (Hassa, et al., 2003, Hassa, et al., 2005).  In order to test the function of 
poly(ADP-ribosyl)ation (PARylation) in the response of AC16 cells to TNFα, I pre-
treated the cells a PARP catalytic inhibitor, PJ34 (Soriano, et al., 2001), and showed 
that PARylation was inhibited (Fig 4.9A).  I observed that in the PJ34-treated cells, the 
induction of pro-inflammatory genes was not affected (Fig. 4.9B), suggesting that in 
human cardiomyocytes, the NFB-dependent response to TNFα does not depend on 
PARP-1 catalytic activity alone.  Finally, to determine whether PARP-1 localization 
was significantly altered upon TNFα treatment, I performed a PARP-1 ChIP-chip 
(which was independently confirmed (Fig. 4.10C)), and saw that overall, there was no 
drastic change in PARP-1 binding before and after treatment (Fig. 4.10A and 4.10B).  
PARP-1 has been previously reported in the literature to be a co-activator of NFB, so 
to address whether these two proteins were co-localized on chromatin, I started by 
identifying the promoters that contained a statistically significant peak of PARP-1 and  
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Table 4.5.  Percentage of promoters with TNFα-dependent NFB recruitment 
that contain a canonical NFB binding site.  Due to the resolution of ChIP 
sonication, two different distances from the peak center are shown below.   
 
Category a1kb b400bp 
Pol II recruited 38 % 33 % 
Pol II unchanged 19 % 13 % 
Pol II released 17 % 13 % 
 
aNFB binding site in a 1 kb window surrounding the statistically significant NFB 
ChIP-chip peak 
bNFB binding site in a 400 bp window surrounding the statistically significant NFB 
ChIP-chip peak 
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Table 4.6.  Top 20 Transfac® binding site enrichment for genes where both 
NFB and RNA Polymerase II are recruited upon TNFα treatment. 
 
Transfac® Binding Site Ratio Site Count 
CREL_01 5.901452 30 
NFKAPPAB65_01 5.859398 15 
NFKAPPAB_01 5.60956 31 
EGR1_01 5.266389 33 
NGFIC_01 5.154057 34 
CREB_01 4.501922 11 
SP1_Q6 4.500055 18 
NFKB_C 4.490372 26 
MAX_01 4.474713 13 
STAT3_02 4.401539 10 
MAZR_01 4.223586 27 
ELK1_02 4.151735 23 
ARNT_01 4.147146 20 
IK3_01 4.124764 22 
SP1_01 4.002718 13 
E2F_03 3.963268 13 
PAX2_01 3.880892 32 
ATF_01 3.874284 23 
EGR2_01 3.845436 24 
USF_Q6 3.818203 21 
 
Sites are within 200bp on either side of the NFB peak center, all p values: p<1x10-300 
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Table 4.7.  Top 20 Transfac® binding site enrichment for genes where both 
NFB and RNA Polymerase II are recruited upon TNFα treatment, after 
removing all regions which contain a canonical NFB binding site. 
 
Transfac® Binding Site Ratio Site Count 
CREB_Q4 4.255078 4 
STAT3_02 4.206689 6 
NFE2_01 4.128633 14 
ELK1_02 4.025716 14 
ATF_01 4.025182 15 
NFY_Q6 3.940657 13 
CREB_01 3.911865 6 
NGFIC_01 3.863659 16 
EGR1_01 3.812069 15 
ARNT_01 3.633502 11 
E4BP4_01 3.622731 12 
CREBP1_Q2 3.59685 12 
NRF2_01 3.553173 12 
USF_Q6 3.475422 12 
AP1_Q4 3.397627 2 
E2F_01 3.222782 11 
AP1_01 3.186089 12 
SP1_Q6 3.185758 8 
PAX5_01 3.180876 20 
CEBPB_02 3.170474 10 
 
Sites are within 200bp on either side of the NFB peak center, all p values: p<1x10-300 
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Table 4.8.  Top 20 Transfac® binding site enrichment for genes where NFB is 
recruited and RNA Polymerase II is unchanged upon TNFα . 
 
Transfac® Binding Site Ratio Site Count 
USF_C 6.37998 27 
AP1_Q4 6.119471 8 
E2F_03 5.249472 24 
AHRARNT_01 4.893034 45 
MAZR_01 4.487834 40 
NMYC_01 4.270084 41 
SP1_01 4.196438 19 
E2F_02 4.120228 44 
USF_01 4.108155 16 
MYCMAX_03 4.037753 46 
CREB_02 4.024033 17 
AHRARNT_02 3.938088 37 
HMX1_01 3.861733 39 
HEN1_01 3.444987 28 
ARNT_01 3.420487 23 
ARNT_02 3.356281 30 
MYCMAX_01 3.347713 27 
MYCMAX_02 3.264825 19 
CREB_Q2 3.240882 7 
SP1_Q6 3.227477 18 
 
Sites are within 200bp on either side of the NFB peak center, all p values: p<1x10-300 
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Table 4.9.  Top 20 Transfac® binding site enrichment for genes where NFB is 
recruited and RNA Polymerase II is released upon TNFα treatment . 
 
Transfac® Binding Site Ratio Site Count 
AP2ALPHA_01 7.350379 9 
PAX4_01 4.397058 58 
HEN1_01 4.349422 47 
TAXCREB_02 4.30688 50 
AREB6_03 4.304521 50 
AP2_Q6 4.256468 53 
AHRARNT_02 4.242204 53 
NFY_01 4.207955 18 
SP1_01 4.152074 25 
EGR2_01 4.148384 48 
NF1_Q6 4.140876 35 
E2F_03 4.11141 25 
HOX13_01 4.049337 51 
AP2GAMMA_01 4.044471 15 
CREB_Q4 3.961824 11 
AHRARNT_01 3.923472 48 
PAX5_01 3.770719 70 
EGR3_01 3.732387 43 
MIF1_01 3.663757 46 
AREB6_02 3.662176 39 
 
Sites are within 200bp on either side of the NFB peak center, all p values: p<1x10-300 
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Figure 4.7.  At NFB recruited promoters, changes in Pol II upon TNFα 
treatment are dependent on NFB.  Box plots of gene-specific ChIP-qPCR analyses 
of Pol II and NFB binding at regions of statistically significant (p<0.016) NFB 
recruitment upon TNFα treatment (25 ng/ml for 30 min).  Eight promoters were 
selected from the Pol II recruited and Pol II released sub-categories, and five 
promoters were selected from the Pol II unchanged sub-category.  Of all the 
promoters, only six in the “Pol II recruited” sub-category have a consensus NFB 
binding site.  Box limits represent the 25th and 75th percentile, and error bar limits 
represent the outer-most data points.  Each data point is a mean of n = 3.  Asterisk 
denotes significance (p<0.01) in a Student’s T-test.  (A) ChIP-qPCR data for NFB in 
all three sub-categories, with amplicons spanning the peak of NFB binding according 
to the ChIP-chip.  (B) ChIP-qPCR data for Pol II in all three sub-categories, with 
amplicons spanning the body of the genes (>1kb into the gene).     
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Table 4.10.  Selected genes for qPCR analysis in Pol II recruited, Pol II unchanged 
and Pol II released gene categories. 
 
Pol II recruited (n=10) Pol II unchanged (n=5) Pol II released (n=9) 
ZC3H12A JHDM1D PARD6A 
NFKB2 NDUFS6 RASSF7 
BIRC3 P2RY11 HCCA2 
CADM1 CENPB FSCN1 
NEO1 SLBP C9orf167 
OXSR1  ADCYAP1R1 
MAPK6  SLC7A10 
CADM1  CALML3 
SMURF2  PPP2R5B 
TRIM33   
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Figure 4.8.  PARP-1 is an essential co-activator for the TNFα-dependent increase 
in key pro-inflammatory NFB target genes in AC16 cells.  (A)  Western blot of 
control and PARP-1 knockdown AC16 whole cell extract blotted for PARP-1 and β-
Actin (as a loading control).  Two separate PARP-1 knockdown constructs were used 
to show specificity.  (B-G) Analysis of mRNA expression by RT-qPCR in TNFα-
treated AC16 cells relative to vehicle treated cells, in control and PARP-1 knockdown 
cells.  Cells were treated with 25 ng/ml TNFα for either 30 min (dark blue) or 180 min 
(light blue).  Expression data is standardized to β-actin transcripts.  Each data point is 
a mean of n = 3.  Error bar represents SEM. 
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Figure 4.9.  PARP-1 catalytic activity is not required for TNFα-dependent 
activation of pro-inflammatory genes in AC16 cells.  (A)  Western blot of control 
and PARP-1 inhibitor (PJ34)-treated AC16 whole cell extract blotted for PARP-1, 
Poly(ADP-ribose) (PAR) and β-Actin (as a loading control).  Cells were pre-treated 
+/- 5 µM PJ34 for 1 hr, as well as +/- hydrogen peroxide (C – control, H – hydrogen 
peroxide treated) to increase the PAR signal.  (B-G) Analysis of mRNA expression by 
RT-qPCR in TNFα-treated (25 ng/ml for 30 min (dark blue) or 180 min (light blue)) 
AC16 cells relative to vehicle treated cells, in control and PJ34-treated (5 µM for 1 hr) 
cells.  Expression data is standardized to β-actin transcripts.  Each data point is a mean 
of n = 3.  Error bar represents SEM. 
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of NFB (Fig. 4.11C).  I found that 68% of the promoters that contained a peak of 
NFB after TNFα treatment also contained a peak of PARP-1, confirming that they 
were bound at the same promoters.  However, when I asked whether the peaks of 
PARP-1 and NFB were within 500 bp of each other, I saw that in the majority of 
cases, the peaks were not co-localized, supporting our data showing that PARP-1 and 
NFB do not affect each other’s recruitment to chromatin (Fig. 4.12A).  Additionally, 
we found that of all the TNFα-regulated genes (i.e. Pol II recruited or release), about 
three quarters did not show co-localization (i.e. peak of binding within 1kb) of PARP-
1 and NFB at their promoters (Fig. 4.12B).  Finally we see that at a vast majority of 
promoters that show recruitment of NFB upon TNFα treatment, the binding of 
PARP-1 is unchanged across a 3kb region around the TSS (Fig. 4.12C).  These data 
suggest that may be these proteins have a more complex interaction than a purely co-
activator – transcription factor relationship, and this hypothesis is further probed in the 
discussion section.   
Next, I wanted to determine the role of PARP-1 in NFB-dependent 
transcription.  I began by confirming that the depletion of PARP-1 translated into a 
significant decrease of PARP-1 on chromatin (Fig. 4.11D), and that BAY 11-7085 
does not affect PARP-1 localization at the genes in the three aforementioned Pol II 
categories (Fig. 4.11E).  Also, PARP-1 knockdown does not affect NFB 
translocation into the nucleus upon TNFα treatment (Fig 4.11F).  I next examined the 
role of PARP-1 as a co-regulator of the genes in the three categories.  I found that, 
while depleting PARP-1 abrogates the Pol II recruitment in the corresponding 
category, the binding of Pol II is unchanged at the genes in the released category, 
suggesting that PARP-1 specifically plays a role as an activator, and not a repressor, in 
NFB-dependent transcription (Fig. 4.11G).  Although PARP-1 has been shown to act 
both as an activator and a repressor of gene expression in various contexts (Hassa, et 
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al., 2003, Hassa, et al., 2005, Ju, et al., 2006, Ju, et al., 2004, Krishnakumar, et al., 
2008, Pavri, et al., 2005), it appears to be solely an activator in NFB-dependent 
transcription.   
My bioinformatic data (Tables 4.7 – 4.9) suggest the involvement of other 
transcription factors in regulating NFB-dependent transcription, so in order to 
follow-up on this result, I looked at the role of  the CREB/ATF family of proteins in 
this pathway.  I chose this family since it has previously been reported to play a role in 
NFB-dependent transcription (Spooren, et al., , Todorov, et al., 2005), and its 
members are significantly enriched in relevant classes of my bioinformatic analysis 
(Tables 4.7 – 4.9).  Initially, I confirmed the bioinformatic results experimentally by 
transient trasfections followed by luciferase reporter gene assays (Fig. 4.13A – 
Plasmids courtesy of Dr. Nina Heldring).  I found that using a plasmid with a CRE 
(CREB Response Element, the DNA motif bound by CREB/ATF transcription 
factors) enhance the TNFα-dependent activation of the reported in AC16 cells (Fig. 
4.13A).  Pre-treating the cells with the NFB inhibitor BAY 11-7085, or co-
transfecting a plasmid expressing a dominant-negative ATF protein (A-ATF) 
abrogated this response (Fig. 4.13A).   
In order to further investigate the role of these family members, I generated a 
cell line that stably overexpressed a dominant negative version of CREB (A-CREB) as 
well as another line stably overexpressing A-ATF. (Plasmids for overexpression 
courtesy of Dr. Nina Heldring).  Unfortunately, the overexpression of A-CREB was 
detrimental to the cells, causing them to die before cells could be collected for 
experiments.  The A-ATF cells, on the other hand, though somewhat slower-growing 
and less healthy, were able to survive and proliferate.  Confirmation of the expression 
of ATF factors (represented by ATF2) as well as the A-ATF were performed by 
western blot (Fig. 4.13B, C).  I therefore used these cells to  
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determine whether ATF cooperates with NFB to regulate tarvget genes.  More 
specifically, at NFB target genes that have no NFB consensus site, but have a CRE 
site, is ATF required for maximal expression of target genes?  As a representative of 
the ATF family, I looked for ATF2 at promoters, and found a subset of genes with 
ATF2 bound (Fig. 4.13D).  I chose to look at one TNFα-upregulated gene (MAPK6), 
one unregulated gene (JHDM1D), and two downregulated genes (PARD6A and 
PPP2R5B) that do not have an NFB consensus site (henceforth referred to as “non-
consensus regulated”).  I also used NFKB2, an upregulated gene that does have a 
NFB consensus site, as a control.  Upon expression of A-ATF, ATF2 binding was 
significantly reduced at these promoters, as expected (Fig. 4.13D).  I next looked at 
NFB binding at these target genes, and found that while at NFKB2 and JHDM1D 
(two controls) the recruitement of NFB was unaffected, at the non-consensus 
regulated genes, lack of ATF2 at the promoter inhibits NFB recruitment, consistent 
with a model in which NFB and ATF2 cooperate.  Also consistent with this model is 
the reduction of Pol II recruitment and mRNA production in the A-ATF cells (Fig. 
4.13F, G).  Taken together, these data reveal a role for ATF2 in tethering NFB p65 to 
target promoters for transcriptional regulation.   
 
4.4 Discussion 
 Cardiovascular disease (CVD) is the leading cause of death in the United 
States, and understanding the molecular mechanisms leading to CVD is key to finding 
sustainable therapies and taking preventative measures to these pathologies (Mehra, 
2007).  In this study, I examine the role of the nuclear transcription factor NFB in 
mediating the signaling events leading to CVD.  I use TNFα-treated human 
cardiomyocytes (it is known that TNFα is released by a number of cell types during 
conditions of stress, including cardiomyocytes) to determine a role for NFB in 
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regulating RNA Polymerase II (Pol II) in response to stress.  Using this system, I have 
shown herein that NFB is not only globally recruited to chromatin upon TNFα 
treatment, but that it is vital in mediating TNFα-dependent changes in gene expression 
by Pol II.  In addition, I have shown that, unexpectedly, the majority of NFB binding 
events occur independently of a canonical NFB binding site, suggesting intricate 
cooperation with a number of other transcription factors.  Finally, I have demonstrated 
a role for PARP-1 at NFB target genes that are up-regulated by TNFα, but not the 
down-regulated ones, suggesting different mechanisms at different target promoters. 
 
NFB is Recruited to the Genome upon TNFα Treatment.  Recruitment of NFB to 
the genome after various different stress stimuli is a well-documented phenomenon 
(Lim, et al., 2007, Schreiber, et al., 2006).  I expected to obtain a subset of genes 
showing NFB recruitment, but instead, I observed a genomic increase in NFB 
binding across many genes (Fig. 4.4).  This result was somewhat unexpected based on 
the rapid time-point at which I performed our experiments, as well as previous data on 
NFB binding to the genome (Lim, et al., 2007, Schreiber, et al., 2006).  However, to 
our knowledge, this is the first report of NFB binding sites at promoters in a human 
cardiomyocyte cell line, and it is possible that these cells are acutely responsive to 
stress signals.  In fact, based on what is known about the role of NFB in CVD, it is 
not entirely surprising to find such a global response (Lentsch and Ward, 1999, 
Lentsch and Ward, 2000, Valen, 2004).  In this study, I have used the p65 (or RelA) 
subunit as the representative member of the NFB protein family, but as was 
discussed previously (Fig. 4.1), there are multiple NFB proteins that mediate the 
signaling pathways (Lentsch and Ward, 2000, Vallabhapurapu and Karin, 2009).  In 
fact, a previous study has examined the recruitment of different subunits of NFB to 
the genome, and has found that depending on the subunit, they can be bound to the 
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Figure 4.10.  PARP-1 binding to promoters is relatively unaltered upon TNFα 
treatment in AC16 cells.  (A) Heat maps of PARP-1 ChIP-chip data in control cells, 
or TNFα-treated cells (25 ng/ml for 30 min), shown from -3 kb to +3 kb relative to the 
TSS.  The data are ordered based on the intensity of the PARP-1 at the promoter in the 
untreated sample.  (B)  Average Log2 ratios of PARP-1 ChIP-chip data minus and 
plus TNFα for all promoters on the array.  (C) Scatter plot of gene-specific ChIP-
qPCR analyses of PARP-1 binding at regions of statistically significant (p<0.016) 
peaks of PARP-1, as well as unbound regions.  Note: unbound regions were defined as 
having p>0.9.  Each data point is a mean of n = 3.  Bar represents median.   
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Figure 4.11.  PARP-1 is unaffected by inhibition of NFB, and depletion of 
PARP-1 does not alter NFB translocation into the nucleus.  Box plots of gene-
specific ChIP-qPCR analyses of PARP-1 were performed exactly as described in Fig.. 
4.7..  Each data point is a mean of n = 3.  Asterisk denotes significance (p<0.01) in a 
Student’s T-test.  (A)  Cells were treated with 25 ng/ml TNFα for 30 min (or left 
untreated).  ChIP-qPCR data shows knockdown of PARP-1 at the chromatin in all 
three sub-categories.  (B)  Cells were treated with 25 ng/ml TNFα for 30 min (or left 
untreated), either with or without pre-treatment with 10 µg/ml BAY-11-7082 for 1 hr.  
ChIP-qPCR data shows that PARP-1 binding is unchanged upon TNFα in all three 
sub-categories.  (C) Venn diagram showing overlap of genes with NFB and PARP-1 
peaks. (D) Western blot of AC16 cytoplasmic and nuclear fractions blotted for NFB, 
PARP-1, TFIIB (nuclear marker) and GAPDH (cytoplasmic marker), in control and 
TNFα-treated cells.   Data for control cells is duplicated from Fig. 4.1.  (E-G) ChIP-
qPCR data of PARP-1 (E),  NFB (F), and Pol II (G) binding in all three categories 
upon TNFα treatment in control (Luc) knockdown and PARP-1 knockdown cells. 
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chromatin prior to stimulation, pre-bound and further recruited, or unbound and 
recruited upon stimulation (Schreiber, et al., 2006).  Specifically, in monocytes, p50 
and p52 proteins appear to be pre-bound to chromatin, and there isn’t much change in 
their binding upon treatment with lipopolysaccharide (LPS).  On the other hand, p65 
(the subunit that I examined) appears to be completely absent in the untreated state, 
and significantly recruited upon LPS treatment.  I did, however, find some p65 
binding in the AC16 cells prior to TNFα treatment, but there are a number of possible 
explanations.  Firstly, monocytes are an entirely different cell line, and the differences 
in NFB could be cell-type specific.  Additionally, when I performed Gene Ontology 
analysis on the genes that contained a peak of p65 prior to TNFα treatment, I did not 
find any significantly enriched terms, meaning that while there was binding of the 
factor, it may not be functionally relevant (data not shown).  Finally, the stringency of  
binding site identification can vary from study to study, and despite the fact that our 
criteria were highly stringent, it is possible that this alternate study applied even 
greater stringency (which could also explain the differences in binding site numbers).  
Taken together however, our data as well as the literature suggest that while there may 
be nuances between cell types, NFB recruitement to promoters upon stress is a 
hallmark mechanism of regulating transcription.   
 
TNFα-Dependent Signaling Regulates RNA Polymerase II.  TNFα is a pro-
inflammatory cytokine which is known to initiate a large number of signaling cascades 
that result in changes in gene expression, and eventually changes in cell physiology 
(Kronke, et al., 1992, Schutze, et al., 1992).  A majority of cell types are highly 
responsive to stress signals such as TNFα, but certain cell types are much more likely 
to require a rapid inflammatory response as a result of TNFα exposure, and one such 
example is cardiomyocytes during the onset of CVD  (Schulz, et al., 2004).  It has also 
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Figure 4.12.  PARP-1 is not a classical NFB co-activator.  (A) Pie chart showing 
percentage of genes at which the PARP-1 peaks +/- TNFα are overlapping (i.e. very 
little lateral movement of the peak PARP-1 upon TNFα).  Also shown is a schematic 
to illustrate the two categories.  (B)  Pie charts showing percentage of genes where 
PARP-1 and NFB co-localize at promoters (defined as the peak of one factor being 
with 1kb of the peak of the other) in the Pol II recruited and released categories of 
genes as previously define Fig. 4.6).  Again, a schematic is shown to clarify the 
definition of co-localized.  (C)  Pie charts showing percentage of genes with a 
statistically significant difference in the amount of PARP-1 bound at promoters minus 
and plus TNFα (Wilcoxin test p 0.016).   
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Figure 4.13. ATF2 cooperates with NFB to regulate TNFα-dependent 
transcription.  (A) Luciferase reporter gene assays using pGL3 with a CRE at the 
promoter (a No CRE plasmid was used for the control condition).  Cells were also 
either treated with BAY 11-7085 or co-transfected with A-ATF.  All data was 
normalized to βgal.  Each data point is a mean of n = 3. Error bar represents SEM.  (B) 
Western blot of whole cell extract from AC16 overexpressing Flag tagged A-ATF (or 
empty vector control), blotted for FLAG and β-Actin (as a loading control) .  (C) 
Western blot of nuclear extract from AC16 plus or minus 25 ng/ml TNFα treatment 
for 1 hour, blotted for ATF2 and TBP (as a loading control) .  (D-F) ChIP-qPCR 
analyses of ATF2 (D), NFB (E), and Pol II (F) levels at the promoters of five NFB 
target genes (NFKB2 – upregulated, consensus NFB site; MAPK6 – upregulated, 
CRE; JHDM1D – unregulated, CRE; PARD6A and PPP2R5B – downregulated, CRE) 
in control (pQCXIP) and A-ATF overexpressing cells, plus and minus TNFα.  (G) 
Analysis of mRNA expression for the same genes in the same cell lines as (D-F) by 
RT-qPCR.  The data are normalized to the β-actin transcript and expressed relative to 
control (pQCXIP) cells.  Each bar represents the mean plus the SEM, n  3. 
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been shown that cardiomyocytes can up-regulate and secrete TNFα themselves when 
they are stressed ((Comstock, et al., 1998, Maass, et al., 2002), see Fig. 4.3), which 
means that the TNFα signaling pathways get rapidly propagated in the context of 
CVD.  In our study, I show that TNFα alters the genomic binding pattern of Pol II at 
gene promoters and into the gene bodies.  In fact, I used Pol II density in the gene 
body to identify transcription regulation, a method which has previously been used in 
the literature (Welboren, et al., 2009).  Furthermore, comparison of our Pol II ChIP-
chip with expression data sets from three un-related cell lines confirm the connection 
between immediate transcriptional responses by Pol II and stable mRNA 30 minutes 
later (Fig. 4.5 D, E).  While our heat maps and average log2 ratio analysis suggest that 
a large number of genes are up-regulated upon TNFα treatment (Fig. 4.5), I show that 
a significant number of genes are also down-regulated.  This suggests a general re-
arrangement of the transcriptional program in response to TNFα, as quickly as 30 
minutes after exposure.  Interestingly, a recent study used microarrays, ChIP and RNA 
FISH to show that TNFα causes a wave of Pol II to be released into the body of target 
genes, and that this wave correlates with the appearance of nascent RNAs (Wada, et 
al., 2009).  This further supports the use of Pol II density in the body of the gene as a 
measure of transcription.  In fact, the authors of this study show that the rate of Pol II 
movement can be altered by CTCF binding sites and cohesion binding (Wada, et al., 
2009).  Based on this and on our work shown here, I may be able to use AC16 cells in 
the future to determine the rate of Pol II travel along gene bodies, which I can 
correlate with many variables, including factor binding and local chromatin 
environment.  Such analyses should help shed light on what factors affect transcription 
by Pol II at a highly molecular level.   
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NFB Regulates Transcription of Genes that Alter the Physiological State of the 
Cells.  By sub-setting the genes that recruit NFB based on their Pol II status, I found 
that genes with NFB binding upon TNFα treatment revealed different characteristics.  
Specifically, genes that are up-regulated have a higher enrichment of canonical NFB 
binding sites than genes that are down-regulated.  This strongly suggests different 
mechanisms at these two categories of genes, which will be actively investigated in 
future studies.  The Gene Ontology analysis also reveals specific differences between 
up- and down-regulated genes.  Upon TNFα treatment, NFB up-regulated genes 
include proteins involved in nitric oxide synthesis (a hallmark of inflammation), 
signaling and defense mechanisms.  Conversely, down-regulated genes include 
proteins involved in transcription and metabolism.  The cells appear to be focusing 
their efforts on responding to the stress signal, and are down-regulating many of the 
“housekeeping” processes in order to conserve resources.  This is a known 
phenomenon for stress-response, specifically for heat-shock (Aufricht, 2005).  
Additionally, infection (which triggers many of the same pathways as treatment with 
TNFα) also causes massive down-regulation of genes that are used for host 
maintenance (Prosniak, et al., 2001).  Therefore, human cardiomyocytes respond to 
stress by TNFα by rapidly reprioritizing the transcription that occurs.   
 
NFB and PARP-1 Function Together to Up-Regulate Genes Upon TNFα 
Treatment.  PARP-1 has been previously shown to cooperate with NFB to regulate 
transcription of key pro-inflammatory genes (Hassa, et al., 2003, Hassa, et al., 2005, 
Pacher and Szabo, 2007, Pillai, et al., 2005, Szabo, et al., 2006, Tulin and Spradling, 
2003).  Here I confirm a role for PARP-1 in the regulation of NFB-dependent 
transcription in cardiomyocytes.  I see that while NFB can both up- and down-
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regulate gene expression, PARP-1 appears only to be an activator in this context.  This 
is consistent with what has been previously reported in the literature regarding a role  
 
for PARP-1 in NFB-dependent transcription.  However, PARP-1 has often been 
labeled as an “NFB co-activator”, which suggests that upon stimulation, PARP-1 is 
recruited to chromatin by NFB.  This study, on the other hand, suggests that the 
binding of PARP-1 is not dependent on NFB (treating with an IKK inhibitor does not 
affect PARP-1 binding, but blocks NFB recruitment), but that the activity of NFB at 
up-regulated promoters requires PARP-1.  Additionally, co-regulators would be 
expected to co-localize on chromatin, and I show that while PARP-1 and NFB  bind 
largely to the same promoters, they are not necessarily binding to the same sites, 
suggesting that the functional interacting between them occurs after they are bound to 
chromatin (for example, by recruiting other factors) (Fig. 4.12B).  Finally, PARP-1 is 
not recruited to chromatin upon TNFα treatment as you would expect for a co-
activator, but is bound prior so stimulation and NFB recruitment (Fig. 4.12A, C). Our 
results are not necessarily contradictory to the majority of the literature, but our 
interpretation takes into account the many different conclusions both from our study 
and from other studies.  For example, work done by another lab demonstrates that 
PARP-1 interacts with both the p50 and p65 subunits of NFB, and that the interaction 
with p50 is strengthened upon stimulation with LPS.  First of all, in vivo, PARP-1 
would only come into contact with p65 after stimulation, and secondly, interaction 
based on an immunoprecipitation assay with proteins in solution does not necessarily 
suggest co-localization on chromatin.  Additionally, this group shows that PARP-1 
acetylation by p300/CBP can increase association of PARP-1 with p50 (interestingly, 
not p65) and Mediator, and again, this is still consisitent with PARP-1 being pre-
bound at these promoters, and recruiting both p300/CBP and Mediator after 
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stimulation.  This may also explain why all the above proteins are found in a complex.  
Therefore, when I combine my data with the data from these studies, I am able provide 
an interpretation which explains all the results together, without necessarily requiring 
that PARP-1 be a classical co-activator of NFB.    
 
Transcriptional Regulation by NFB in Cardiomyocytes is Likely to Involve Other 
Transcription Factors, such as CREB.  Based on the motif finding analysis 
performed on the different classes of NFB-regulated genes, I concluded that the 
majority of NFB binding events did not require a canonical NFB binding site, 
suggesting cooperation of NFB with other DNA-binding transcription factors.  It is 
known that NFB requires a number of factors for many of its functions (Chen, et al., 
2001, Covic, et al., 2005, Hassa, et al., 2003, Hassa, et al., 2005, Katsel and 
Greenstein, 2001, Lim, et al., 2007, Meylan, et al., 2009, Yamamoto, et al., 2003, 
Yang, et al., 2000).  Although transcription factors are known to cooperate with NFB 
(e.g. AP2, SP1, p53), most published work focuses on genes that have both an NFB 
site and another site (Katsel and Greenstein, 2001, Lim, et al., 2007, Yang, et al., 
2000).  For instance, a recent study looked at NFB p65 binding upon LPS treatment 
in human monocytes, and found that many NFB sites were enriched for a flanking 
E2F1 site (Lim, et al., 2007).  They go on to show that NFB requires E2F1 to 
regulate target gene expression changes upon LPS treatment, although it was not 
required to recruit p65 to promoters.  This is likely because the targets they looked at 
also had an NFB canonical binding site.  Here, I have shown a requirement for other 
transcription factors such as ATF2 to recruit NFB to promoters which do not contain 
a canonical NFB site (Fig. 4.13).  Specifically, I can use a dominant negative form of 
ATF to prevent NFB binding to promoters upon TNFα treatment, and block 
transcription by Pol II, strongly suggesting cooperation between these factors.  Further 
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experiments are likely to identify more such factors that cooperate with NFB to 
regulate inflammation in cardiomyocytes. 
 
Future perspectives: Increasing Evidence Points to Roles for NFB in Diverse 
Physiological Processes.  Although the mechanism by which NFB is activated and 
regulates gene expression has been studied for decades, it has been considered 
primarily as a pro-inflammatory transcription factor (Lentsch and Ward, 1999, 
Lentsch and Ward, 2000, Vallabhapurapu and Karin, 2009).  Only recently are I 
beginning to understand the magnitude of physiological responses that involve, and 
require, NFB-dependent pathways.  NFB has recently been shown to be vital in the 
progression of lung carcinoma (Meylan, et al., 2009).  In the background of a p53 
mutation and Ras overexpression, NFB signaling is constitutively activated, 
promoting tumor formation in mice.  The authors briefly show that NFB target genes 
are altered in these mutant backgrounds, but mechanisms behind these changes are 
unclear.  It is tempting to speculate that perhaps some of the same factors that 
cooperate with NFB during inflammatory responses (PARP-1, CBP, CREB) may be 
playing a role in carcinogenesis, and this hypothesis warrants further study.  It would 
be too simplistic, however, to imagine that all the pathways would be completely 
conserved, even if the players are the same.  An interesting example of this comes 
from a study that looks at the cooperation between PARP-1 and NFB not in stress-
regulated transcription, but in the response to DNA damage.  In this work, the authors 
show the importance of PARP-1 catalytic activity in forming a critical DNA repair 
protein complex (while PARP-1 catalytic activity is not required for TNFα-dependent 
transcription regulated by NFB) (Stilmann, et al., 2009).  This shows us that 
understanding NFB-dependent pathways in one system cannot necessarily predict 
behaviors in other contexts, but can provide us with candidates to investigate in other 
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physiological responses.  NFB is also involved in ageing, and interestingly, it is 
found in the same pathway as another NAD+-dependent enzyme, the sirtuin SIRT6.  
But while PARP-1 is a co-activator of NFB, SIRT6 is an antagonist, and H3K9 
deacetylation by SIRT6 at NFB targets attenuates NFB signaling and reverses the 
effect of premature ageing and death seen in SIRT6 knockout mice (Kawahara, et al., 
2009).  Sirtuins and PARPs are known to compete for NAD+, which could set the 
stage for competition between the two enzymes.  It will be interesting to determine 
whether PARP-1 may be playing a role in the ageing phenotype caused by 
overactivation of NFB, and whether other transcription factors, including ones in the 
CREB family that I have already identified as cooperating with NFB, are also 
involved.  In conclusion, NFB-regulated pathways are as wide-spread as they are 
versatile, and understanding the molecular mechanisms that underlie these pathways in 
different physiological and pathological contexts could greatly increase the chances of 
developing novel therapies to a variety of diseases and disorders that plague the world 
today. 
 
4.5 Materials and Methods 
 
Cell lines.  AC16 human adult ventricular cardiomyocyte cells purchased from 
American Type Cell Culture (ATCC) (Davidson, et al., 2005).  The cells were 
maintained in DMEM F-12 supplemented with 12.5% fetal bovine serum.  TNFα was 
purchased at PeproTech (Cat# 300-01A), and the IKKα/β inhibitor BAY-11-7082 was 
purchased from Calbiochem (Cat# 196870).  For relevant experiments, PJ34 was 
purchased from Alexis Biochemicals (Cat# ALX-270-289).   For all TNFα treatments, 
medium was changed to serum-free DMEM F-12, 24 hrs after plating.  PARP-1-
depleted AC16 cells were generated by retroviral-mediated gene transfer of two short 
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hairpin RNA sequences specifically targeting the PARP-1 mRNA using the 
pSUPER.retro system (Oligoengine) (Frizzell, et al., 2009, Zhang, et al., 2009)].  
Control cells harboring a short hairpin RNA sequence directed against luciferase were 
generated in parallel.  A-ATF overexpressing cells were generated using the pQCXIP 
system (Clonetech), and an empty vector was used to generate a control cell line in 
parallel (plasmids courtesy of Dr. Nina Helding).  Selection for knockdown and 
overexpressing cells was performed in 0.5 µg/ml puromycin.   
 
Antibodies.  A previously characterized custom rabbit polyclonal anti-PARP-1 
antibody was used for ChIP and western blotting (Kim, et al., 2004).  NFB p65 ChIP 
grade antibody was purchased from Abcam (Cat# 7970)  All other antibodies were as 
follows: Pol II (Santa Cruz SC-899 and SC-900, mixed in a 1:4 ratio), TBP (Santa 
Cruz SC273X), Dynamin (Sigma-Aldrich D4038), PAR (Trevigen 4335-AMC-050) 
and β-ACTIN (Sigma-Aldrich, A5316). 
 
mRNA expression analyses.  Cells were seeded at ~1.5 x 105 cells per well in 6-well 
plates and grown for a day before being left in serum-free medium overnight.  The 
cells were then treated with TNFα, BAY-11-7082, or PJ34 as appropriate (see figure 
legends), and collected at about 80% confluence.  Total RNA was isolated using 
Trizol Reagent (Invitrogen) according to the manufacturer's protocols.  The total RNA 
was reverse transcribed using oligo(dT) and subjected to real-time quantitative PCR 
using gene-specific primers (see primer sequences listed below; Section 2).  All target 
gene transcripts were normalized to the β-actin transcript.  Each experiment was 
conducted a minimum of three times with independent isolates of total RNA to ensure 
reproducibility. 
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Transient transfection and reporter gene assays.  Cells were seeded at ~1.5 x 105 
cells per well in 6-well plates and grown for a day before changing the medium to 
serum-free, and transfecting the following plasmids using the GeneJuice system (EMD 
Biosciences): pCMV-βgal, pCMV empty or A-ATF,  pGL3 promoter only or 
promoter with CRE (plasmids courtesy of Dr. Nina Heldring).  The following day, 
cells were treated with TNFα for 4 hours, after which they were collected, lysed in 
ProMega 5X Lysis Buffer, and the supernatant was collected by centrifugation.  
Parallel luciferase and βgal assays were performed.  Control cells were left untreated.   
 
Primers 
ChIP primers 
ICAM1_TSS_Fwd 5'-CGGTGTAGACCGTGATTCAA-3' 
ICAM1_TSS_Rev 5'-TCCGGAATTTCCAAGCTAAA-3' 
INOS_TSS_Fwd 5'-TGGTTTCCAAAGGGAGTGTC-3' 
INOS_TSS_Rev 5'-TGAAGAGGCACCACACAGAG-3' 
VCAM1_TSS_Fwd 5'-ACACACAGGTGGGACACAAA-3' 
VCAM1_TSS_Rev 5'-CCAAGGATCACGACCATCTT-3' 
TNF_TSS_Fwd 5'-GCTTGTGTGTCCCCAACTTT-3' 
TNF_TSS_Rev 5'-AACCAGCGGAAAACTTCCTT-3' 
NFKBp50_TSS_Fwd 5'-CTCGACGTCAGTGGGAATTT-3' 
NFKBp50_TSS_Rev 5'-GCGAAACCTCCTCTTCCTG-3' 
IL6_TSS_Fwd 5'-TGCACTTTTCCCCCTAGTTG-3' 
IL6_TSS_Rev 5'-TCATGGGAAAATCCCACATT-3' 
ZC3H12A_TSS_Fwd 5'-CGTGCTTATCTTGCGCATAC-3' 
ZC3H12A_TSS_Rev 5'-CTTCCTGCTCCGCTCCTC-3' 
ZC3H12A_1kb_Fwd 5'-GTTTTGGGAGGGAGGTTAGG-3' 
 240 
ZC3H12A_1kb_Rev 5'-GACAGGCTTCTCTCCACAGG-3' 
NFKB2_-1kb_Fwd 5'-ACACACATGCACACGGAGAC-3' 
NFKB2_-1kb_Rev 5'-CGGGTGAGCGTATCTTGAGT-3' 
NFKB2_TSS_Fwd 5'-CCCTTGGTATTTTCGGGACT-3' 
NFKB2_TSS_Rev 5'-GGAAGGGGCAGGAAAGTTAG-3' 
NFKB2_2kb_Fwd 5'-AGCAAGAGGCCAAAGAACTG-3' 
NFKB2_2kb_Rev 5'-AGGGAGAAGGAGCCATCACT-3' 
BIRC3_-0.5kb_Fwd 5'-TGCAAAGGAGAACTGCATGA-3' 
BIRC3_-0.5kb_Rev 5'-AGCTGCAGAAGTCCAGCATT-3' 
BIRC3_1kb_Fwd 5'-AGGCAGAAAGAAAAGGCACA-3' 
BIRC3_1kb_Rev 5'-CATGCAGCACATCCATTTTT-3' 
CADM1_TSS_Fwd 5'-GGCTTCTGCTGTTGCTCTTC-3' 
CADM1_TSS_Rev 5'-ACACCTACCTGTGGGGATCA-3' 
CADM1_3kb_Fwd 5'-GGCTGACTTTTGCTTGCTTT-3' 
CADM1_3kb_Rev 5'-TGCGGCTATTCAATCTGATG-3' 
NEO1_TSS_Fwd 5'-TCACTCTCGGGGAAGAGATG-3' 
NEO1_TSS_Rev 5'-CAGGCAGTAGAGCCAGAAGG-3' 
NEO1_2kb_Fwd 5'-TGAGGAGTGGGTAGGAGTGG-3' 
NEO1_2kb_Rev 5'-GCAGAGCGGTTTACAGGAAG-3' 
MAPK6_TSS_Fwd 5'- GGAGACCTGAGCCGACACT-3' 
MAPK6_TSS_Rev 5'- CACACACACTCACGGGACTT-3' 
MAKP6_2kb_Fwd 5'- ACAGCCAACGTTTAGCAAGG-3' 
MAKP6_2kb_Rev 5'- CAGCCCCACTCTTAAACTGC-3' 
JHDM1D_TSS_Fwd 5'-TGCGATATCTGCAAGGACTG-3' 
JHDM1D_TSS_Rev 5'-GGCTGGAGGGGGTTTATTTA-3' 
JHDM1D_1.5kb_Fwd  5'-TATTTGGGTGTTGTGGCAAA-3' 
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JHDM1D_1.5kb_Rev 5'-GGAAACCGGCTTCAACTAAA-3' 
NDUFS6_TSS_Fwd 5'-AGAAGGTCACGCACACTGG-3' 
NDUFS6_TSS_Rev 5'-GGAGGAAGGTGCATCCTGTA-3' 
NDUFS6_2kb_Fwd 5'-TTCCAGAGCTACAGGGCATT-3' 
NDUFS6_2kb_Rev 5'-CCCATCAAACCACACAACAG-3' 
P2RY11_TSS_Fwd 5'-GGGATTCTGGAGCCATACAA-3' 
P2RY11_TSS_Rev 5'-TTCCAGGAAGAAACCAGGTG-3' 
P2RY11_2kb_Fwd 5'-CAATGCATAACCCTGGCTCT-3' 
P2RY11_2kb_Rev 5'-TCCCTGGACACGAGTTCTTT-3' 
CENPB_TSS_Fwd 5'-CTGACGTTCCGGGAGAAG-3' 
CENPB_TSS_Rev 5'-GGATTCTCCTCCACCTCCTG-3' 
CENPB_2kb_Fwd 5'-CTTTGCCATGGTCAAGAGGT-3' 
CENPB_2kb_Rev 5'-TGTCCAAGACCTCGAACTCC-3' 
SLBP_TSS_Fwd 5'-CCCACATAAAGGCGGTTG-3' 
SLBP_TSS_Rev 5'-GGCAGAGAGCGCAGAGTAGA-3' 
SLBP_2kb_Fwd 5'-ATGGGAAGTTGTGAGGCTTG-3' 
SLBP_2kb_Rev 5'-TGCCTCCCATGTAGACTCCT-3' 
PARD6A_TSS_Fwd 5'-TAGCATCGTCGAGGTGAAGA-3' 
PARD6A_TSS_Rev 5'-AGGGGAGAAAGAGGGAATTG-3' 
PARD6A_2kb_Fwd 5'-GGTCCTTGTGTGTCCCAGTT-3' 
PARD6A_2kb_Rev 5'-GGAAGTTCTCCCCAATGTCA-3' 
RASSF7_TSS_Fwd 5'-CGCCCACACCTGTAGTCT-3' 
RASSF7_TSS_Rev 5'-CATTGGCTGCCTCTGTCAC-3' 
RASSF7_2kb_Fwd 5'-CCCCTCACCTATGGCATCT-3' 
RASSF7_2kb_Rev 5'-GCTCCTGAACAGCCAGGTC-3' 
HCCA2_TSS_Fwd 5'-CGGTGAGGCCTGAGTCTCTA-3' 
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HCCA2_TSS_Rev 5'-TCCTCTACAGGGCTTCCAGA-3' 
HCCA2_2kb_Fwd 5'-AGGAGTGGGTTCACACCAAG-3' 
HCCA2_2kb_Rev 5'-AGATCGGGGTCCTGAGTTCT-3' 
FSCN1_TSS_Fwd 5'-CTCGTCTACTGCCACCATGA-3' 
FSCN1_TSS_Rev 5'-AGGTACTTGTTGCCGCAGTT-3' 
FSCN1_2kb_Fwd 5'-TACCCTCTGGTGAACCCATC-3' 
FSCN1_2kb_Rev 5'-TCGGGGAGAATCTGAGAAAG-3' 
C9orf167_-1.5kb_Fwd 5'-CACCCCTGTAGATGGGAGAA-3' 
C9orf167_-1.5kb_Rev 5'-CCCTATGGGTCAAAGGTGAA-3' 
C9orf167_TSS_Fwd 5'-ACCCCCTGACTCACTTCCTT-3' 
C9orf167_TSS_Rev 5'-CGGAGTAGAGGAAGCTCTGG-3' 
C9orf167_2kb_Fwd 5'-GTGAGGGCTTCTTTCCTGAC-3' 
C9orf167_2kb_Rev 5'-GCCTCCACTACAGGAGGTTC-3' 
ADCYAP1R1_TSS_Fwd 5'-CGTCCTTTGCGGAGTCTG-3' 
ADCYAP1R1_TSS_Rev 5'-GCGACCCTTACCTGCTCACT-3' 
ADCYAP1R1_2kb_Fwd 5'-AAGGATCCCTCTCCTGCACT-3' 
ADCYAP1R1_2kb_Rev 5'-GGTCCCAAAGTGTTTCTCCA-3' 
SLC7A10_TSS_Fwd 5'-AGATCTGCCCCAAGTCCTCT-3' 
SLC7A10_TSS_Rev 5'-CTCCCCCACCTCCCTTAAA-3' 
SLC7A10_2kb_Fwd 5'-CCTTCAGTTCCTTCCTGCTG-3' 
SLC7A10_2kb_Rev 5'-CCTGGCTCAGTGTTCAAGGT-3' 
CALML3_-0.8_Fwd 5'-AGCAGGAGGTCTGTCCTTGA-3' 
CALML3_-0.8_Rev 5'-TGATCGAGGAATGCAAACAA-3' 
CALML3_TSS_Fwd 5'-AGCTGACTGAGGAGCAGGTC-3' 
CALML3_TSS_Rev 5'-GTCCCCATCCTTGTCAAACA-3' 
CALML3_1.5_Fwd 5'-ATACGCTGGCAGCAAAGAGT-3' 
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CALML3_1.5_Rev 5'-ACTTCACAACCAGGGAGCAC-3' 
PPP2R5B_TSS_Fwd 5'-TGGTCTGGCAGCTCACTTTA-3' 
PPP2R5B_TSS_Rev 5'-GCTGCTCAGGATGACATCAA-3' 
PPP2R5B_2kb_Fwd 5'-AGGAGATGGCACAAGAGCAT-3' 
PPP2R5B_2kb_Rev 5'-GGCAGACCCTCCTAATCTCC-3' 
TRIM33_TSS_Fwd 5'-TTCGCTCTCTCGCTAGCTCT-3' 
TRIM33_TSS_Rev 5'-CTTTGTTTTCCGCCATGTTT-3' 
TRIM33_2.5kb_Fwd 5'-TGGGGTGTAGGGAGGATAAA-3' 
TRIM33_2.5kb_Rev 5'-GCTTCTCCAACAACCAAAGC-3' 
 
mRNA  primers 
ICAM1mRNA_Fwd 5'-AGCTTCTCCTGCTCTGCAAC-3' 
ICAM1mRNA_Rev 5'-AATCCCTCTCGTCCAGTCG-3' 
iNOSmRNA_Fwd 5'-TGGATGCAACCCCATTGTC-3' 
iNOSmRNA_Rev 5'-CCCGCTGCCCCAGTTT-3' 
VCAM1mRNA_Fwd 5'-CGAGACCACCCCAGAATCTA-3' 
VCAM1mRNA_Rev 5'-GGTGCTGCAAGTCAATGAGA-3' 
TNFmRNA_Fwd 5'-AACCTCCTCTCTGCCATCAA-3' 
TNFmRNA_Rev 5'-GGAAGACCCCTCCCAGATAG-3' 
NFKBp50mRNA_Fwd 5'-CTGGAAGCACGAATGACAGA-3' 
NFKBp50mRNA_Rev 5'-CCTTCTGCTTGCAAATAGGC-3' 
IL6_mRNA_Fwd 5'-GGTACATCCTCGACGGCATCT-3' 
IL6_mRNA_Rev 5'-GTGCCTCTTTGCTGCTTTCAC-3'  
NFKB2mRNA_Fwd 5'- AGGTCTACTGGAGGCCCTGT-3’ 
NFKB2mRNA_Rev 5'- CTTGTCTCGGGTTTCTGGAC-3’ 
JHDM1DmRNA_Fwd 5'- CGAGGGGACTGTTCTTCTTG -3’ 
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JHDM1DmRNA_Rev 5'- CTTCCGGACTGAAAGGACAC -3’ 
PARD6AmRNA_Fwd 5'- GTTGCCAACAGCCATAACCT -3’ 
PARD6AmRNA_Rev 5'- CAGGTCACTGCTGTCATCGT -3’ 
MAP6KmRNA_Fwd 5'- ATCTATTCCCCATCCCAAGG -3’ 
MAP6KmRNA_Rev 5'- AAGAGACTGCGATGCCACAT -3’ 
PPP2R5B_mRNA_Fwd 5'- CCAGAGTGGCTTCTGAGGAC -3' 
PPP2R5B_mRNA_Rev 5'- AGCATTCTGTTGCCAAGACC -3' 
 
Chromatin immunoprecipitation (ChIP).  ChIP was performed essentially as 
described previously (Kininis, et al., 2007, Krishnakumar, et al., 2008).  Briefly, cells 
were grown to ~70% confluence, and left in serum-free medium overnight.  Cells were 
then treated with relevant chemicals (eg. TNFα 25 ng/ml for 30 min., with or without 
pre-treatment with 10 µg/ml BAY-11-7082),  cross-linked with 1% paraformaldehyde 
in PBS for 10 min. at 37°C, and quenched in 125 mM glycine in PBS for 5 min. at 
4°C.  The cells were collected by centrifugation and sonicated in lysis buffer (1% 
SDS, 10 mM EDTA, 50 mM Tris•HCl, pH 7.9, 1x protease inhibitor cocktail) to 
generate chromatin fragments of ~500 bp in length.  The material was clarified by 
centrifugation, diluted 10-fold in dilution buffer (0.5% Triton X-100, 2 mM EDTA, 
150 mM NaCl, 20 mM Tris•HCl, pH 7.9, 1x protease inhibitor cocktail), and pre-
cleared with protein A-agarose beads.  The pre-cleared, chromatin-containing 
supernatant was used in immunoprecipitation reactions with antibodies against the 
factor of interest, or without antibodies as a control.  The immunoprecipitated genomic 
DNA was cleared of protein and residual RNA by digestion with proteinase K and  
RNase H, respectively.  The DNA was then extracted with phenol:chloroform:isoamyl 
alcohol and precipitated with ethanol.  Quantitative real-time PCR (qPCR) was used to 
determine the enrichment of immunoprecipitated material relative to the input material 
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using gene-specific primer sets to the specified regions.   Each ChIP experiment was 
conduced a minimum of three times with independent chromatin isolates to ensure 
reproducibility. 
 
ChIP-chip.  LM-PCR amplified genomic DNA samples were used to probe a custom 
human (HG18) oligonucleotide genomic array from Nimblegen.  The custom array 
contained ~2,100,000 features (tiling interval of 75 bp for the ~50-mer probes), 
including 23,551 promoter regions (approximately -3 kb to +7 kb relative to the 
transcription start site for most promoters).  The ChIP-chip analyses were run a 
minimum of two times to ensure reproducibility. 
 
Genomic data analyses.  Genomic data analyses were performed using the statistical 
programming language R (R Development Core Team) as previously described 
(Krishnakumar, et al., 2008, Team, 2006).   The log2 ratio data from each of the arrays 
was subjected to lowess normalization.  A single array error model was generated 
using a 800 bp moving window with 200 bp steps in which both the mean probe log2 
ratio and p-values were calculated for each window.  The p-values are from a 
nonparametric Wilcoxon signed-rank test.  Significant peaks were defined as the 
center of three consecutive windows with positive means, the center window with a 
mean greater than either adjacent window, all windows having p-values less than 
0.016, and the middle window having a signal intensity greater than 0.5.  Correlation 
analyses, averaging (metagene) analyses, and gene categorization were done as 
described in Chapter 2/3. 
 
Motif Finding Analysis.  Transcription factor binding sites (Transfac motifs) were 
identified in regions with statistically significant peaks of factor binding (as defined in 
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each specific analysis, usually 400 bp around the peak) using the UCSC Genome 
Browser feature Galaxy.  Following this, the enrichment of each binding site over the 
background regions (defined as all the regions on our ChIP-chip promoter array) was 
obtained, and the significance of this enrichment was calculated using a Fisher-exact 
test.    
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 247 
REFERENCES 
Aufricht, C. 2005. Heat-shock protein 70: molecular supertool? Pediatr Nephrol 
20:707-13. 
 
Banno, T., A. Gazel, and M. Blumenberg. 2005. Pathway-specific profiling identifies 
the NF-kappa B-dependent tumor necrosis factor alpha-regulated genes in 
epidermal keratinocytes. J Biol Chem 280:18973-80. 
 
Beissbarth, T., and T. P. Speed. 2004. GOstat: find statistically overrepresented Gene 
Ontologies within a group of genes. Bioinformatics 20:1464-5. 
 
Chen, L., W. Fischle, E. Verdin, and W. C. Greene. 2001. Duration of nuclear NF-
kappaB action regulated by reversible acetylation. Science 293:1653-7. 
 
Comstock, K. L., K. A. Krown, M. T. Page, D. Martin, P. Ho, M. Pedraza, E. N. 
Castro, N. Nakajima, C. C. Glembotski, P. J. Quintana, and R. A. Sabbadini. 
1998. LPS-induced TNF-alpha release from and apoptosis in rat 
cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J 
Mol Cell Cardiol 30:2761-75. 
 
Covic, M., P. O. Hassa, S. Saccani, C. Buerki, N. I. Meier, C. Lombardi, R. Imhof, M. 
T. Bedford, G. Natoli, and M. O. Hottiger. 2005. Arginine methyltransferase 
CARM1 is a promoter-specific regulator of NF-kappaB-dependent gene 
expression. EMBO J 24:85-96. 
 
Davidson, M. M., C. Nesti, L. Palenzuela, W. F. Walker, E. Hernandez, L. Protas, M. 
Hirano, and N. D. Isaac. 2005. Novel cell lines derived from adult human 
ventricular cardiomyocytes. J Mol Cell Cardiol 39:133-47. 
 
Epstein, J. A., and M. S. Parmacek. 2005. Recent advances in cardiac development 
with therapeutic implications for adult cardiovascular disease. Circulation 
112:592-7. 
 
Fischer, P., and D. Hilfiker-Kleiner. 2007. Survival pathways in hypertrophy and heart 
failure: the gp130-STAT axis. Basic Res Cardiol 102:393-411. 
 
Frizzell, K. M., M. J. Gamble, J. G. Berrocal, T. Zhang, R. Krishnakumar, Y. Cen, A. 
A. Sauve, and W. L. Kraus. 2009. Global analysis of transcriptional regulation 
by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in 
MCF-7 human breast cancer cells. J Biol Chem. 
 
Hassa, P. O., C. Buerki, C. Lombardi, R. Imhof, and M. O. Hottiger. 2003. 
Transcriptional coactivation of nuclear factor-kappaB-dependent gene 
 248 
expression by p300 is regulated by poly(ADP)-ribose polymerase-1. J Biol 
Chem 278:45145-53. 
 
Hassa, P. O., S. S. Haenni, C. Buerki, N. I. Meier, W. S. Lane, H. Owen, M. Gersbach, 
R. Imhof, and M. O. Hottiger. 2005. Acetylation of poly(ADP-ribose) 
polymerase-1 by p300/CREB-binding protein regulates coactivation of NF-
kappaB-dependent transcription. J Biol Chem 280:40450-64. 
 
Henderson, B. C., and S. C. Tyagi. 2006. Oxidative mechanism and homeostasis of 
proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol 
41:959-62. 
 
Hirano, F., H. Tanaka, Y. Hirano, M. Hiramoto, H. Handa, I. Makino, and C. 
Scheidereit. 1998. Functional interference of Sp1 and NF-kappaB through the 
same DNA binding site. Mol Cell Biol 18:1266-74. 
 
Ju, B. G., V. V. Lunyak, V. Perissi, I. Garcia-Bassets, D. W. Rose, C. K. Glass, and 
M. G. Rosenfeld. 2006. A topoisomerase IIbeta-mediated dsDNA break 
required for regulated transcription. Science 312:1798-802. 
 
Ju, B. G., D. Solum, E. J. Song, K. J. Lee, D. W. Rose, C. K. Glass, and M. G. 
Rosenfeld. 2004. Activating the PARP-1 sensor component of the groucho/ 
TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent 
neurogenic gene activation pathway. Cell 119:815-29. 
 
Katsel, P. L., and R. J. Greenstein. 2001. Identification of overlapping AP-2/NF-kappa 
B-responsive elements on the rat cholecystokinin gene promoter. J Biol Chem 
276:752-8. 
 
Kawahara, T. L., E. Michishita, A. S. Adler, M. Damian, E. Berber, M. Lin, R. A. 
McCord, K. C. Ongaigui, L. D. Boxer, H. Y. Chang, and K. F. Chua. 2009. 
SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene 
expression and organismal life span. Cell 136:62-74. 
 
Kim, M. Y., S. Mauro, N. Gevry, J. T. Lis, and W. L. Kraus. 2004. NAD+-dependent 
modulation of chromatin structure and transcription by nucleosome binding 
properties of PARP-1. Cell 119:803-14. 
 
Kim, S., and H. Iwao. 1999. Activation of mitogen-activated protein kinases in 
cardiovascular hypertrophy and remodeling. Jpn J Pharmacol 80:97-102. 
 
Kininis, M., B. S. Chen, A. G. Diehl, G. D. Isaacs, T. Zhang, A. C. Siepel, A. G. 
Clark, and W. L. Kraus. 2007. Genomic analyses of transcription factor 
binding, histone acetylation, and gene expression reveal mechanistically 
distinct classes of estrogen-regulated promoters. Mol Cell Biol 27:5090-104. 
 249 
 
Krishnakumar, R., M. J. Gamble, K. M. Frizzell, J. G. Berrocal, M. Kininis, and W. L. 
Kraus. 2008. Reciprocal binding of PARP-1 and histone H1 at promoters 
specifies transcriptional outcomes. Science 319:819-21. 
 
Kronke, M., S. Schutze, P. Scheurich, and K. Pfizenmaier. 1992. TNF signal 
transduction and TNF-responsive genes. Immunol Ser 56:189-216. 
 
Lentsch, A. B., and P. A. Ward. 1999. Activation and regulation of NFkappaB during 
acute inflammation. Clin Chem Lab Med 37:205-8. 
 
Lentsch, A. B., and P. A. Ward. 2000. The NFkappaBb/IkappaB system in acute 
inflammation. Arch Immunol Ther Exp (Warsz) 48:59-63. 
 
Li, X., and G. R. Stark. 2002. NFkappaB-dependent signaling pathways. Exp Hematol 
30:285-96. 
 
Lim, C. A., F. Yao, J. J. Wong, J. George, H. Xu, K. P. Chiu, W. K. Sung, L. 
Lipovich, V. B. Vega, J. Chen, A. Shahab, X. D. Zhao, M. Hibberd, C. L. Wei, 
B. Lim, H. H. Ng, Y. Ruan, and K. C. Chin. 2007. Genome-wide mapping of 
RELA(p65) binding identifies E2F1 as a transcriptional activator recruited by 
NF-kappaB upon TLR4 activation. Mol Cell 27:622-35. 
 
Maass, D. L., D. P. Hybki, J. White, and J. W. Horton. 2002. The time course of 
cardiac NF-kappaB activation and TNF-alpha secretion by cardiac myocytes 
after burn injury: contribution to burn-related cardiac contractile dysfunction. 
Shock 17:293-9. 
 
Mehra, R. 2007. Global public health problem of sudden cardiac death. J 
Electrocardiol 40:S118-22. 
 
Meylan, E., A. L. Dooley, D. M. Feldser, L. Shen, E. Turk, C. Ouyang, and T. Jacks. 
2009. Requirement for NF-kappaB signalling in a mouse model of lung 
adenocarcinoma. Nature 462:104-7. 
 
Molnar, A., A. Toth, Z. Bagi, Z. Papp, I. Edes, M. Vaszily, Z. Galajda, J. G. Papp, A. 
Varro, V. Szuts, Z. Lacza, D. Gero, and C. Szabo. 2006. Activation of the 
poly(ADP-ribose) polymerase pathway in human heart failure. Mol Med 
12:143-52. 
 
Natoli, G., A. Costanzo, F. Guido, F. Moretti, and M. Levrero. 1998. Apoptotic, non-
apoptotic, and anti-apoptotic pathways of tumor necrosis factor signalling. 
Biochem Pharmacol 56:915-20. 
 
 250 
Pacher, P., and C. Szabo. 2007. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in 
cardiovascular diseases: the therapeutic potential of PARP inhibitors. 
Cardiovasc Drug Rev 25:235-60. 
 
Pavri, R., B. Lewis, T. K. Kim, F. J. Dilworth, H. Erdjument-Bromage, P. Tempst, G. 
de Murcia, R. Evans, P. Chambon, and D. Reinberg. 2005. PARP-1 determines 
specificity in a retinoid signaling pathway via direct modulation of mediator. 
Mol Cell 18:83-96. 
 
Pillai, J. B., M. Gupta, S. B. Rajamohan, R. Lang, J. Raman, and M. P. Gupta. 2006. 
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin 
II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol 291:H1545-
53. 
 
Pillai, J. B., A. Isbatan, S. Imai, and M. P. Gupta. 2005. Poly(ADP-ribose) 
polymerase-1-dependent cardiac myocyte cell death during heart failure is 
mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity. J 
Biol Chem 280:43121-30. 
 
Prosniak, M., D. C. Hooper, B. Dietzschold, and H. Koprowski. 2001. Effect of rabies 
virus infection on gene expression in mouse brain. Proc Natl Acad Sci U S A 
98:2758-63. 
 
Rangan, G., Y. Wang, and D. Harris. 2009. NF-kappaB signalling in chronic kidney 
disease. Front Biosci 14:3496-522. 
 
Schreiber, J., R. G. Jenner, H. L. Murray, G. K. Gerber, D. K. Gifford, and R. A. 
Young. 2006. Coordinated binding of NF-kappaB family members in the 
response of human cells to lipopolysaccharide. Proc Natl Acad Sci U S A 
103:5899-904. 
 
Schulz, R., S. Aker, S. Belosjorow, and G. Heusch. 2004. TNFalpha in 
ischemia/reperfusion injury and heart failure. Basic Res Cardiol 99:8-11. 
Schutze, S., T. Machleidt, and M. Kronke. 1992. Mechanisms of tumor necrosis factor 
action. Semin Oncol 19:16-24. 
 
Soriano, F. G., L. Virag, and C. Szabo. 2001. Diabetic endothelial dysfunction: role of 
reactive oxygen and nitrogen species production and poly(ADP-ribose) 
polymerase activation. J Mol Med 79:437-48. 
 
Spooren, A., R. Kooijman, B. Lintermans, K. Van Craenenbroeck, L. Vermeulen, G. 
Haegeman, and S. Gerlo. Cooperation of NFkappaB and CREB to induce 
synergistic IL-6 expression in astrocytes. Cell Signal 22:871-81. 
 
 251 
Stilmann, M., M. Hinz, S. C. Arslan, A. Zimmer, V. Schreiber, and C. Scheidereit. 
2009. A nuclear poly(ADP-ribose)-dependent signalosome confers DNA 
damage-induced IkappaB kinase activation. Mol Cell 36:365-78. 
 
Szabo, C., P. Pacher, and R. A. Swanson. 2006. Novel modulators of poly(ADP-
ribose) polymerase. Trends Pharmacol Sci 27:626-30. 
 
Team, R. D. C. 2006. R: A language and environment for statistical computing, R 
Foundation for Statistical Computing, Vienna, Austria. 
 
Tian, B., D. E. Nowak, M. Jamaluddin, S. Wang, and A. R. Brasier. 2005. 
Identification of direct genomic targets downstream of the nuclear factor-
kappaB transcription factor mediating tumor necrosis factor signaling. J Biol 
Chem 280:17435-48. 
 
Todorov, V. T., S. Volkl, J. Friedrich, L. A. Kunz-Schughart, T. Hehlgans, L. 
Vermeulen, G. Haegeman, M. L. Schmitz, and A. Kurtz. 2005. Role of CREB1 
and NF{kappa}B-p65 in the down-regulation of renin gene expression by 
tumor necrosis factor {alpha}. J Biol Chem 280:24356-62. 
 
Tulin, A., and A. Spradling. 2003. Chromatin loosening by poly(ADP)-ribose 
polymerase (PARP) at Drosophila puff loci. Science 299:560-2. 
 
Valen, G. 2004. Signal transduction through nuclear factor kappa B in ischemia-
reperfusion and heart failure. Basic Res Cardiol 99:1-7. 
 
Vallabhapurapu, S., and M. Karin. 2009. Regulation and function of NF-kappaB 
transcription factors in the immune system. Annu Rev Immunol 27:693-733. 
 
Wada, Y., Y. Ohta, M. Xu, S. Tsutsumi, T. Minami, K. Inoue, D. Komura, J. 
Kitakami, N. Oshida, A. Papantonis, A. Izumi, M. Kobayashi, H. Meguro, Y. 
Kanki, I. Mimura, K. Yamamoto, C. Mataki, T. Hamakubo, K. Shirahige, H. 
Aburatani, H. Kimura, T. Kodama, P. R. Cook, and S. Ihara. 2009. A wave of 
nascent transcription on activated human genes. Proc Natl Acad Sci U S A 
106:18357-61. 
 
Welboren, W. J., M. A. van Driel, E. M. Janssen-Megens, S. J. van Heeringen, F. C. 
Sweep, P. N. Span, and H. G. Stunnenberg. 2009. ChIP-Seq of ERalpha and 
RNA polymerase II defines genes differentially responding to ligands. EMBO 
J 28:1418-28. 
 
Yamamoto, Y., U. N. Verma, S. Prajapati, Y. T. Kwak, and R. B. Gaynor. 2003. 
Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene 
expression. Nature 423:655-9. 
 
 252 
Yang, C. R., C. Wilson-Van Patten, S. M. Planchon, S. M. Wuerzberger-Davis, T. W. 
Davis, S. Cuthill, S. Miyamoto, and D. A. Boothman. 2000. Coordinate 
modulation of Sp1, NF-kappa B, and p53 in confluent human malignant 
melanoma cells after ionizing radiation. FASEB J 14:379-90. 
 
Zhang, T., J. G. Berrocal, K. M. Frizzell, M. J. Gamble, M. E. DuMond, R. 
Krishnakumar, T. Yang, A. A. Sauve, and W. L. Kraus. 2009. Enzymes in the 
NAD+ salvage pathway regulate SIRT1 activity at target gene promoters. J 
Biol Chem 284:20408-17. 
 
 
253 
Concluding Remarks 
 
 Although PARP-1 has been studied for a number of years, only recently are we 
beginning to understand the physiological roles that PARP-1 plays in vivo (Kraus, 
2008).  Specifically, recent studies have unveiled a prominent role for PARP-1 as a 
modulator of chromatin structure and transcription, and in this work, we have 
identified novel mechanisms by which PARP-1 achieves this regulation, in two 
different biological systems (Caiafa, et al., 2009, Hassa and Hottiger, 2002, Ju, et al., 
2006, Krishnakumar, et al., 2008, Pavri, et al., 2005).  Based on our data, we have 
formed a model of how we think PARP-1 acts at target promoters (Fig. 5).  We show 
in breast cancer cells that PARP-1 binds to the promoters of active genes and excludes 
the binding of repressor proteins from the promoter, including linker histone H1 and 
the histone demethylase KDM5B (Krishnakumar, et al., 2008).  Work from other labs 
has shown that PARP-1 can also recruit activator proteins, which fits with our model 
of PARP-1’s role at promoters (Hassa and Hottiger, 2002, Ju, et al., 2006, Pavri, et 
al., 2005)  For some of these proteins, PARP-1 catalytic activity is vital for regulating 
their localization, as is the case for KDM5B.  By coordinating repressor and activator 
protein binding at target promoters, PARP-1 is able to create a favorable chromatin 
environment (i.e. suitable positioning of nucleosomes) to promote the binding of Pol II 
and associated basal transcription machinery, which results in increased transcription.   
 In addition to maintaining basal transcription, PARP-1 is also involved in 
organizing the transcriptional response to a number of different signaling pathways, 
and cooperates with DNA-binding transcription factors to this end, one of which is 
NFB (Hassa and Hottiger, 2002, Ju, et al., 2006, Pavri, et al., 2005).  NFB is a 
major transcription factor involved in regulating the inflammatory pathways that are  
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Figure 5. Model of PARP-1-dependent regulation of chromatin structure and 
transcription at target promoters.  Schematic of a prototypic target gene.  TSS 
(Transcription start site) of the gene is depicted by a bent arrow.  TF = Transcription 
factor.  Black bar = Transcription factor binding site.   
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triggered as a result of CVD.  Here, I looked at how TNFα-stimulated NFB-
dependent transcription is regulated in human cardiomyocytes, and I confirm a role for 
PARP-1 as an activator.  Interestingly, I see that while PARP-1 and NFB are found 
primarily at an overlapping set of promoters, they do not directly co-localize, as may 
be the case if PARP-1 were a classical co-activator of NFB.  Furthermore, PARP-1 is 
pre-bound at target genes, and preventing NFB recruitment by inhibiting IKKα/β 
does not affect PARP-1 binding, suggesting that PARP-1 may be playing a more 
chromatin-based role in this system, in a manner similar to what I observed in breast 
cancer cells.  In addition, the lack of NFB canonical binding sites under a majority of 
the NFB peaks at promoters suggests cooperation with additional transcription 
factors, and I will be focusing on how NFB, PARP-1 and these other factors all 
coordinate the intricate response to TNFα that I observe in these cells.  In conclusion, 
PARP-1 is involved in variety of signaling and transcriptional pathways and is able to 
coordinate responses to a number of different stimuli.  It will be interesting to 
determine the level of conservation of the PARP-1-dependent pathways I have 
observed in this study, and how we can expand on these roles by investigating 
additional biological systems.  We are, however, only seeing the tip of the iceberg, and 
it is very likely that in the years to come, the common themes that connect all the 
different functions of PARP-1 in various systems will become much more evident.  
Identifying these commonalities is going to be critical to be able to capitalize on the 
therapeutic potential of PARP-1, and other PARP family members.  As we are slowly 
realizing, they are a poorly-tapped but very rich resource for the future of medicine.    
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